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The Influence of Micronutrients on Placental Development and 
Pregnancy Outcome 
Rebecca L. WILSON 
 
Appropriate placental development and function is intricately associated with 
pregnancy success. Indeed, placental function is essential for adequate fetal 
development in utero, as well as orchestrating maternal physiological adaptations 
to pregnancy. However, the incidence of pregnancy complications that are 
characterised by placental dysfunction is increasing. Whilst a significant amount 
is understood about the down-stream effects of placental dysfunction, the causes 
are poorly understood. Inadequate maternal micronutrient status has been 
identified as a risk factor for adverse pregnancy outcome; even small 
perturbations in micronutrient homeostasis can have significant consequences 
for cellular and physiological pathways. The overall goal of this research was to 
further the understanding of how maternal micronutrient status during 
pregnancy influences placental development and pregnancy outcome with a 
focus on trace elements: zinc, copper and selenium, as well as calcium and 
vitamin D. 
Initially, a systematic review of the literature identified possible 
associations between maternal zinc deficiency and hypertensive disorders of 
pregnancy, as well as the delivery of small-for-gestational age or low birthweight 
infants. Based on these results, an in-depth analysis of the effects of zinc 
deficiency on placental morphogenesis and maternal haemodynamic changes 
during pregnancy was conducted in a mouse model. This study confirmed 
maternal zinc status to be a key determinant of fetal growth, the effects of limited 
iv 
 
zinc on fetal growth restriction were likely to be mediated through adverse 
placental development and that altered placental function was associated with 
improper maternal cardiovascular adaptations to pregnancy. 
Next, a large-scale human epidemiological study was undertaken 
focusing on maternal trace elements, calcium and vitamin D status and risk of 
pregnancy complications in the SCreening fOr Pregnancy Endpoints (SCOPE) 
study. Of particular interest, this research showed a clear association between 
plasma copper in early pregnancy and the risk of developing any pregnancy 
complication with the data suggesting a possible mechanistic role for elevated 
free copper and inflammatory responses within the placenta. Furthermore, 
markers of calcium status were associated with inappropriate placental function 
and reduced fetal growth. This highlighted the importance of calcium in 
pregnancy and offered a hypothesis for the disparate published findings on the 
association between vitamin D deficiency and adverse pregnancy outcomes. 
Finally, one possible mechanism by which micronutrient deficiencies may 
impact placental morphogenesis is through altered epigenetic programming. 
Optimisation of visualisation techniques: immunohistochemistry and immuno-
fluorescence, to study DNA methylation in different cell types offers a unique 
avenue in which to study how micronutrients influence the epigenome. The 
research presented confirmed that DNA methylation markers differed between 
different placenta cell types and that these patterns of localization are dynamic 
across gestation. These changes are likely to impact placental function and offer 
some insight into possible changes found in the epigenome in pregnancies 
complicated by placental dysfunction. 
In summary, this PhD research offers a unique perspective on the 
importance of adequate nutrition during pregnancy and a platform for future 
endeavours seeking to understand how micronutrients support placental 
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1.1 The placenta is a key regulator of pregnancy success 
Pregnancy is a dynamic state characterised by major changes to maternal 
physiology and anatomy in order to accommodate the growth of the fetus and 
placenta. Adjustments in nutrient metabolism are key to supporting not only the 
fetus but also the mother and deficiencies in certain micronutrients, either 
through reduced dietary intakes or intestinal absorption, can have dire 
consequences on pregnancy outcome [1]. Pregnancy complications including 
preeclampsia, gestational hypertension, intrauterine growth restriction (IUGR) 
and preterm birth affect one in five first pregnancies. These pregnancy 
complications are strongly associated with pathology of the placenta and predict 
lifelong morbidity and mortality for both mother and child [2]. Although a lot is 
understood about the down-stream effects of placental dysfunction, the causes 
of improper placental development are poorly understood.  
The placenta is a transient organ, unique to pregnancy. It functions as an 
interface involved in the exchange of gases, nutrients and wastes between the 
fetus and mother [3], an endocrine organ responsible for producing numerous 
hormones [4] and as a barrier to protect the semi-allogeneic fetus from the 
maternal immune system [5]. Correct placental development is essential to 
placental function and pregnancy outcome. Through a combination of apoptosis 
[6-8], destruction of the extracellular matrix and smooth muscle de-
differentiation, the maternal spiral arteries are remodelled from normally small, 
high-resistance, low-flow muscular arteries in the decidua into flaccid, low 
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resistance, high flow distended vessels capable of supplying adequate blood flow 
to the rapidly growing fetus (Figure 1.1). However, in pregnancies complicated 
by placental dysfunction, defective placentation sees absent or incomplete 
remodelling of the maternal spiral arteries [9]. 
 
FIGURE 1.1. Adapted from Karumanchi et al., [10]. Schematic representation of spiral 
artery remodelling and maternal blood flow during early placentation. (A) In normal 
placental development, fetal cytotrophoblast cells invade the maternal spiral arteries 
transforming them into flaccid high-flow vessels. (B) Shallow invasion of the maternal 
spiral arteries by fetal cytotrophoblasts leads to defective transformation of the spiral 
arteries and placental ischemia which is often a characteristic of pregnancies complicated 
by preeclampsia and IUGR. 
Abnormal, shallow placentation results in inadequate uteroplacental 
blood flow [11] and the onset of placental ischemia. This not only reduces the 
delivery of oxygen and nutrients to the fetus and hence reduces fetal growth, but 
also results in increased cellular and oxidative stress [12]. Excessive placental 
oxidative stress has since been shown to be associated with the secretion of 
factors into maternal circulation resulting in wide spread endothelial dysfunction 
and many of the pathophysiological characteristics of preeclampsia [10]. More 
recently, it has been hypothesised that increased syncytiotrophoblast stress may 
also contribute to the development of preeclampsia [13]. Syncytiotrophoblasts 
form the surface epithelium of the fetal placental villi and coordinate nutrient 
and oxygen transfer to fetal circulation as well as hormone synthesis and 
secretion into maternal circulation to orchestrate maternal adaptations to 
pregnancy. While the causes of syncytiotrophoblast stress, as well as defective 
placentation remain to be elucidated, it is likely to be due to a combination of 
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genetic and environmental stimuli in which maternal nutrition is likely to play a 
major role [14].   
1.2 The role of micronutrients in successful pregnancies 
It is important that pregnant women retain adequate levels of essential vitamins 
and minerals in order to support the rapid growth of the fetus. Collectively 
known as micronutrients, these dietary components support virtually all aspects 
of cellular and metabolic activity including cell proliferation, apoptosis and 
differentiation, as well as tissue growth and homeostasis [15]. In terms of 
pregnancy, there is an exhaustive amount of literature looking at associations 
between deficiencies in vitamin D, folate, vitamin B12, iodine, iron, zinc and 
selenium and pregnancy complications [15]. Consequently, many of these 
vitamins and minerals are included in pregnancy supplements and increased 
dietary consumption is recommended for pregnant women [16, 17]. 
 Severe micronutrient deficiencies are relatively uncommon in the 
developed world [18]. However, suboptimal micronutrient status may alter the 
risk of chronic disease [19] and adverse pregnancy outcomes. This is because 
many physiological pathways can be disrupted by even the smallest 
perturbations in micronutrient homeostasis which can then have more significant 
consequences on health. For example, the one-carbon metabolic pathway, is 
integral to the production of methyl-donors which are then utilised in numerous 
biosynthetic reactions including DNA synthesis and epigenetic modifications of 
the genome (Figure 1.2) [20]. 
 The cyclic nature of the one-carbon metabolic pathway relies heavily on a 
number of micronutrients including folate, vitamin B12 and B6, as well as choline 
as cofactors [20]. Furthermore, there are micronutrients like zinc which are 
structurally integral for enzymes active in the pathway. For example, betaine-
homocysteine methyl transferse (BHMT), which catalyses the conversion of 
homocysteine to methionine, is a zinc metalloenzyme and activates 
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homocysteine using a zinc ion [21]. Deficiencies in folate [22, 23], vitamin B12 [24, 
25] and zinc [26] have all been associated with disruption to the one-carbon 
network and consequently the production of methyl-donors which has knock-on 
consequences for growth and development in pregnancy. Indeed reduced 
availability of methyl-donors has been hypothesised to be a mechanism behind 
inadequate placental development, placental insufficiency and ultimately IUGR 
[27]. 
 
FIGURE 1.2. Adapted from Furness et al., [28]. Schematic representation of the one-
carbon metabolism pathway with nutrients highlighted in orange. Vitamin B6 is a 
cofactor in the conversion of tetrahydrofolate to 5,10-methylene tetrahydrofolate (5,10-
MeTHF) and vitamin B2 is a precursor for another cofactor which is involved in the 
conversion of 5,10-MeTHF to 5-methyl tetrahydrofolate (5-MeTHF). 5-MeTHF donates 
its methyl group to homocysteine with the aid of vitamin B12 and betaine-homocysteine 
methyl transferse (BHMT), a zinc metalloprotein, producing methionine which then is 
converted to s-adenosylmethionine (SAM), the universal methyl-donor. De-methylation 
of SAM forms s-adenyosylhomocysteine (SAH) and acceptance of the methyl group by 
DNA causes DNA methylation and epigenetic modifications. Betaine is another nutrient 
which serves as a methyl donor to homocysteine for the conversion to methionine. 
 Having identified the possible consequences of reduced zinc availability 
in the production of methyl-donors, I first undertook a systematic review of the 
literature on studies which aimed to assess the association between maternal zinc 
deficiency in pregnancy and placenta-related pregnancy complications. The 
results are presented in Chapter 2 of this thesis and indicated a possible 
relationship between zinc deficiency in pregnancy and the development of 
hypertensive disorders of pregnancy, as well as the delivery of small-for-
gestational age or low birthweight infants. Given that both preeclampsia and 
C h a p t e r  1   P a g e  |  5  
 
 
IUGR are associated with pathologies of the placenta, we hypothesised a 
mechanistic connection between reduced zinc availability, placental 
morphogenesis, fetal growth and the maternal adaptation to pregnancy. 
 Animal models of zinc deficiency have shown that zinc is a key nutrient 
in all facets of pregnancy from embryogenesis right through to lactation. Severe 
zinc restriction modelled by almost completely removing zinc from the diet (˂1 
mg/kg feed) 3-5 days prior to ovulation causes epigenetic defects in the oocytes 
and ultimately leads to decreased in vitro fertilisation potential [29] and reduced 
implantation rates [30]. The teratogenic nature of zinc deficiency is also 
highlighted by affects to skeletal and brain development of the offspring in utero 
[31-33], as well as to significantly higher rates of fetal loss and a reduction in fetal 
and placental weights [30]. However, the effects on placental development and 
function are largely unknown. With this in mind, I developed a mouse model to 
characterise the effects of marginal maternal zinc deficiency on the placenta with 
a predominant focus on placental morphogenesis and oxidative stress (Chapter 
3). This was in combination with analysis of the effects of zinc deficiency on 
changes in maternal blood pressure across pregnancy. 
1.3 Interactions between zinc and other plasma minerals 
and adverse pregnancy outcomes 
Given the diverse range of biological functions for which zinc is required, it is 
not surprising that inadequate intake of zinc in the maternal diet is associated 
with adverse pregnancy outcomes and poor infant development. Although 
severe zinc deficiency is relatively rare, mild to moderate zinc deficiency is 
estimated to be common throughout the world [34] and overlaps with 
deficiencies in a number of other micronutrients. Multiple micronutrient 
deficiencies exist because of interactions which can affect both absorption and 
bioavailability and are highly dependent on the relative concentrations of the 
nutrients [35]. Micronutrient interactions can be synergistic for example vitamin 
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C and iron [36], or antagonistic as in the case of vitamin A and zinc [37]. 
Therefore, in situations where dietary nutritional intakes are poor and in 
combination with micronutrient interactions, multiple micronutrient deficiencies 
exist. 
Minerals and trace elements like zinc, copper, iron and calcium share 
similar chemical properties and therefore can compete for similar uptake 
mechanisms and proteins [35]. Indeed, there is accumulating evidence which 
shows a clear connection between zinc, iron, copper and calcium metabolism. For 
example, severe copper deficiency results in anaemia due to changes in iron 
metabolism [38]. This is thought to be driven by the multi-copper protein 
ceruloplasmin which is capable of stimulating iron efflux from the liver [39]. Iron 
supplementation has been shown to reduce circulating zinc concentrations and 
vice-versa [40] while there is some evidence to suggest calcium supplementation 
also has a negative effect on both zinc and iron absorption [41, 42].  
In terms of placental transfer of nutrients to the fetus, McArdle et al., 
showed in a series of publications, the essential interactions between copper and 
iron in the placenta [43]. Furthermore, my own research using our mouse model 
also showed a possible effect of maternal zinc deficiency on iron transport to the 
fetus. Yet, there are very few human population studies which have undertaken 
an assessment of multiple micronutrient deficiencies in pregnancy and their 
effects on pregnancy outcome [44-47]. With this in mind, I utilised the extensive 
SCreening fOr Pregnancy Endpoints (SCOPE) database and biobank to look at 
circulating plasma trace elements in early pregnancy and the associations with 
adverse pregnancy outcomes with particular focus on: zinc, selenium, iron and 
copper (Chapter 4). A very clear association between high plasma copper in early 
pregnancy and the risk of developing any pregnancy complication was found 
with the data suggesting a possible mechanistic role for elevated free copper and 
inflammatory responses within the placenta. Associations between plasma zinc 
and selenium and an increased risk of any pregnancy complication were also 
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observed and has now provided the basis for on-going laboratory experiments 
into how these mineral profiles affect placental cell function. 
1.4 The synergistic relationship between vitamin D and 
calcium in pregnancy 
The inorganic nature of minerals means they retain their chemical structure and 
can passively move throughout the body and into cells. Vitamins on the other 
hand are organic compounds, harder to absorb from the diet and are often 
utilised in metabolic pathways to inhibit or promote cell function [48]. 
Furthermore, these metabolic pathways can also interact with one another. For 
example, the one-carbon metabolic pathway which utilises folate, creates the 
methyl-donors which are required for vitamin D metabolism [27]. Deficiencies in 
folate can therefore affect vitamin D metabolism resulting in functional vitamin 
D deficiency. Classically, vitamin D has been associated with calcium 
homeostasis and bone mineralisation. However, vitamin D plays important roles 
in other important cellular functions such as regulating immune function, 
modulating cell proliferation and differentiation and disease prevention [49]. 
Furthermore, vitamin D has the ability to regulate placental physiology. By the 
third trimester, serum levels of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the 
active form of the vitamin,  increase as much as two-fold when compared to non-
pregnant or post-partum levels [50-52]. Indicating the importance of high levels 
of vitamin D within the mother particularly in late gestation. 
 The consequences of vitamin D deficiency in pregnancy have been 
extensively studied and numerous investigations have been conducted on 
whether vitamin D supplementation can prevent pregnancy complications [53]. 
However, a recent Cochrane review of vitamin D supplementation and the 
prevention of a number of adverse pregnancy outcomes, including preeclampsia 
and fetal growth restriction, concluded that there was no significant reduction in 
the rates of these complications with vitamin D supplementation [54]. My own 
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study found higher levels of vitamin D at 15±1 weeks’ gestation were associated 
with a protective effect on developing gestational diabetes mellitus and is 
presented in Chapter 5. However, there was no significant associations between 
vitamin D deficiency and other pregnancy complications including preeclampsia 
and preterm birth. Given the heterogeneous nature of the literature that reports 
associations with vitamin D deficiency and pregnancy outcome [55], this was not 
overly surprising. 
Vitamin D is necessary to maintain calcium homeostasis and along with 
parathyroid hormone functions to increase plasma calcium levels [56] through 
increasing intestinal absorption of calcium, increasing kidney reabsorption and 
mobilising calcium from bone [57]. Calcium availability during pregnancy is 
extremely important for fetal bone growth and vitamin D deficiency sees 
increased demineralisation of maternal bone in order to maintain adequate 
transfer of calcium to the fetus [58]. Yet many studies on vitamin D in pregnancy 
have failed to consider calcium status and may explain the inconsistencies in the 
literature regarding vitamin D deficiency and adverse pregnancy outcomes. 
Indeed, Chapter 6 of this thesis shows that while vitamin D deficiency was not 
associated with reduced fetal growth, higher urinary excretion of calcium, a 
marker for higher calcium status, was protective against uteroplacental dys-
function and SGA. However, while there is a vast amount of literature showing 
associations between micronutrients and pregnancy complications, the 
mechanisms are poorly understood. Environmental factors such as maternal diet 
are known to impact the epigenome and in particular, DNA methylation, has 
often been shown to be associated with environmental exposures. Thus, it is 
possible that mechanistically, micronutrient deficiencies may result in altered 
epigenetic programming of organs like the placenta during pregnancy that affect 
pregnancy outcome.  
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1.5 Methylation status of the placenta – the next frontier 
Epigenetics refers to the study of molecular modifications to chromatin structure 
and accessibility which alters gene expression without altering the underlying 
DNA sequence. Such modifications provide a mechanistic link between nutrition 
and disease [20]. The most widely studied modification is DNA methylation 
which as previously described, relies on the one-carbon metabolic pathway in 
order to generate 5-methylcytosine and maintain methylation status. 
Micronutrient intake is imperative to this process in order to maintain the cyclical 
pattern of one-carbon metabolism and the study of nutri-epigenomics is 
emerging as a new field of biological research, particularly in the context of the 
developmental origins of health and disease (DoHAD) hypothesis [59]. This is 
because DNA methylation patterns are prone to change, particularly during 
reprogramming events like gametogenesis and early embryonic development 
[60].  
 Key to determining the importance of epigenetics in placental dysfunction 
is first understanding how modifications influence normal placental 
development. In terms of placental development, the placental genome is 
hypomethylated compared to other healthy tissues [61, 62]. It is unclear as to why 
this is however, given the placenta comprises numerous different cell types, 
studying DNA methylation in this organ is complicated [63]. To address this, I 
aimed to characterise global DNA methylation patterns in placental tissue across 
gestation using immunohistochemistry and immunofluorescence (Chapter 7). 
This was in order to visually determine if DNA methylation differed depending 
on the cell type within the placenta. Furthermore, I wanted to characterise how 
levels of 5-hydroxy-methylcytosine, a derivative of 5-methylcytosine which is 
produced during demethylation [64] differed in the different placenta cell types. 
The findings in this study showed levels of both 5-methylcytosine and 5-
hydroxymethylcytosine changed across gestation as well as between different 
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trophoblast cell types, providing solid evidence that epigenetic profiles can differ 
significantly between difference cell types within a complex tissue. Such 
information and optimised protocols can now be used in future experiments 
determining how these different methylation modifications may be altered in 
response to environmental exposures like maternal diet and what are the 
consequences for placenta cell function. 
1.6 Summary 
The research presented in this PhD focuses on a number of key micronutrients, 
their interactions and pregnancy outcome offering a unique perspective into the 
importance of adequate nutrition in pregnancy. Through the combination of an 
animal model and ex vivo and in vitro human analyses, it provides novel insights 
into both the mechanistic effects of micronutrient deficiencies to fetal growth in 
utero, as well as a translational perspective. Furthermore, it provides a platform 
for future nutritional research to broaden endeavours from a focus on one 
specific nutrient to multiple micronutrients which, although increasing the 
complexity, ultimately enhances our understanding for future recommendations 
for pregnant women.  
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ABSTRACT 
Adequate zinc stores in the body are extremely important during 
periods of accelerated growth. However, zinc deficiency is common in 
developing countries and low maternal circulating zinc 
concentrations have previously been associated with pregnancy 
complications. We reviewed current literature assessing circulating 
zinc and dietary zinc intake during pregnancy and the associations 
with preeclampsia (PE); spontaneous preterm birth (sPTB); low 
birthweight (LBW); and gestational diabetes (GDM). Searches of 
MEDLINE; CINAHL and Scopus databases identified 639 articles and 
64 studies were reviewed. In 10 out of 16 studies a difference was 
reported with respect to circulating zinc between women who gave 
birth to a LBW infant (≤2500 g) and those who gave birth to an infant 
of adequate weight (>2500 g), particularly in populations where 
inadequate zinc intake is prevalent. In 16 of our 33 studies an 
association was found between hypertensive disorders of pregnancy 
and circulating zinc; particularly in women with severe PE (blood 
pressure ≥160/110 mmHg). No association between maternal zinc 
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status and sPTB or GDM was seen; however; direct comparisons 
between the studies was difficult. Furthermore; only a small number 
of studies were based on women from populations where there is a 
high risk of zinc deficiency. Therefore; the link between maternal zinc 
status and pregnancy success in these populations cannot be 
established. Future studies should focus on those vulnerable to zinc 
deficiency and include dietary zinc intake as a measure of zinc status. 
 
2.1 Introduction 
Adequate maternal nutrition, particularly before and during pregnancy, is 
imperative to the health of both the mother and child [1,2]. Poor nutrition in 
pregnancy may lead to inappropriate nutrient partitioning between the mother 
and fetus, which can be deleterious to the health of both [3]. Each year, 3.5 million 
deaths in women and children are attributed to undernutrition [4]. Zinc 
deficiency is predicted to be responsible for 1% of all deaths globally and 4.4% of 
deaths in children aged 6 months to 5 years [5]. The World Health Organization 
(WHO) prioritized minimizing zinc deficiency in developing nations as part of 
the Millennium Development Goal 1: to eradicate extreme poverty and hunger 
[6]. Therefore, understanding the effects of zinc deficiency on pregnancy and fetal 
growth is very important. 
Zinc is an essential component of over 1000 proteins including antioxidant 
enzymes, metalloenzymes, zinc-binding factors and zinc transporters. These are 
required for a variety of biological processes including carbohydrate and protein 
metabolism, DNA and RNA synthesis, cellular replication and differentiation, 
and hormone regulation [7–10]. The importance of zinc to the growth of the fetus 
is demonstrated by the active transport of zinc across the placenta into the fetal 
circulation resulting in higher cord blood concentrations compared to those in 
the maternal circulation [11–14]. Rodent models of severe maternal zinc 
deficiency show increased rates of fetal loss and congenital malformations in the 
surviving fetuses [15] as well as reduced fetal growth [16–18], lower implantation 
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rates and impaired placental growth [19], all highlighting the teratogenic effects 
of zinc deficiency in pregnancy. 
Diet is the main factor that determines zinc status [20]. In the United States 
and Australia, an additional 2–4 mg zinc per day is recommended for pregnant 
women compared to non-pregnant women [21,22]. It is widely acknowledged 
that many pregnant women do not meet this recommendation [23–25], 
particularly in developing countries where diets are often plant-based. Grains 
and legumes contain a significant amount of phytic acid and phytate binding of 
zinc limits its absorption in the small intestine, contributing to zinc deficiency 
[22]. Estimates based on bioavailability of zinc, physiological requirements and 
predicted zinc absorption suggest the prevalence of zinc deficiency to range from 
4% (European countries including the United Kingdom, Sweden, Germany and 
France) to 73% in Bangladesh, India and Nepal [26]. A more recent evaluation, 
based on similar estimates, also predicted inadequate zinc intakes in over 25% in 
populations in Southeast Asia and Africa [27]. 
A recent Cochrane review assessed the effects of zinc supplementation 
versus no supplementation (with or without placebo) on the success of 
pregnancy in 21 randomized controlled trials (RCTs) [28]. It was concluded that 
zinc supplementation reduced the risk of spontaneous preterm birth (sPTB) by 
14% (RR: 0.86, 95% CI: 0.76–0.97; 16 RCTs) but there was no effect on other 
outcomes such as stillbirth/neonatal death, birthweight and pregnancy-induced 
hypertension [28]. However, this review did not include the effects of zinc 
supplementation on reducing the risk of gestational diabetes (GDM) and analysis 
of maternal circulating zinc concentrations provides evidence that low maternal 
zinc may be associated with GDM, as well as preeclampsia (PE), gestational 
hypertension (GH), sPTB and infant birthweight [24,29]. The association between 
serum zinc and PE has been reviewed recently [30] but there has been no 
extensive review that has assessed maternal zinc concentrations with respect to 
a range of pregnancy complications. Here, we review the current literature based 
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on observational studies assessing the association between maternal zinc status 
and a number of pregnancy complications in order to determine whether 
maternal circulating zinc or dietary zinc intake are important factors associated 
with pregnancy outcome. 
2.2 Methods 
2.2.1 Eligibility Criteria 
Studies included human prospective cohorts, case-control, longitudinal and 
cross-sectional studies assessing maternal circulating zinc concentrations and 
pregnancy complications including PE, eclampsia, GH, GDM, small for 
gestational age (SGA), intrauterine growth restriction (IUGR; ˂10th percentile), 
low-birthweight (LBW; ≤2500 g) and sPTB. Only studies that measured maternal 
circulating zinc during pregnancy or at delivery and/or dietary zinc intake at 
these times were included. Studies that assessed zinc concentrations in placenta, 
amniotic fluid, in offspring (post-natally), cord blood only and breast milk were 
excluded. There were no restrictions imposed on age of women included in the 
studies or on any other population characteristic such as race or body mass index 
(BMI). Given the heterogeneity of the observational strategies, a meta-analysis 
was not possible. 
 
2.2.2 Information Sources and Search 
The search strategy and procedure was guided by the PRISMA statement [31]. 
Potential studies were located through electronic databases [Ovid Medline 
(1946–present), CINAHL (1937–present) and Scopus (1995–present)], as well as 
manual searches of references in review articles and relevant articles known by 
the authors. Limits included full text articles written in English and published in 
academic journals. The last search was performed on August 25, 2016. Search 
terms and MeSH headings in the title, abstract, and index terms, were initially 
identified in Medline and subsequent key words were used for the remaining 
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databases (Appendix A). Briefly, the search included the following: zinc; dietary 
zinc; zinc intake; plasma zinc; serum zinc; preeclampsia; eclampsia; gestational 
hypertension; gestational diabetes mellitus; fetal macrosomia; small for 
gestational age; intrauterine growth restriction; low birthweight; preterm birth. 
 
2.2.3 Data Collection 
An independent search of the literature was performed in April 2015 and again 
in August 2016. Titles and abstracts were examined independently by two of the 
authors who documented reasons for excluding full text articles. Any differences 
between the two reviewers were clarified; a third reviewer resolved any 
disagreements. If an article appeared in duplicate from two or three of the 
databases, only the search containing the most relevant and useful information 
was included. For each eligible study, the following data was extracted: author, 
year and country of publication; inclusion/exclusion criteria; sample size; zinc 
measure including sample type, collection time during pregnancy and method 
of analysis and pregnancy outcome. Most studies did not report on 
exclusion/inclusion criteria; these were therefore not included in the results table. 
Values determining zinc status were all converted to μg/L for easier comparisons 
between studies (Appendix B). 
2.3 Results 
Figure 2.1 outlines the literature search and selection of studies. We identified 
635 citations after searching Medline (OVID), CINAHL and Scopus databases. A 
further seven were added by the authors. After screening the title and abstract, 
116 full text papers were read. Of these, 67 studies met the inclusion criteria, 
including 29 on SGA/LBW (Table 2.1), 34 on hypertensive disorders of pregnancy 
(Table 2.2), 11 on sPTB (Table 2.3) and 9 on GDM (Table 2.4). Eleven studies 
assessed multiple pregnancy outcomes and are included in the relevant 
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pregnancy outcome tables. Table 2.5 summarizes all included studies and 
whether there was a positive, negative or no association between zinc status and 
the pregnancy complication. The included studies were tabulated based on those 
that measured dietary zinc intake, then those that measured serum/plasma zinc. 
Globally, the average percentage of people affected by inadequate zinc intake is 
estimated to be 17.3% [27]. As dietary consumption of zinc is most influential on 
zinc status, studies that measured circulating zinc were further categorized based 
on whether they sampled from countries where inadequate zinc intake has been 
predicted to affect <17% or ≥17% of the population. We did not limit the studies 
to a specific period during gestation when zinc was measured and this 
FIGURE 2.3. Flow diagram of the search strategy used in this review including the 
relevant number of papers at each point. 
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information was not provided in eight studies [32–39]. However, zinc 
concentrations decline across gestation due to a combination of factors including 
hemodilution and increased fetal demand [40,41] and this made direct 
comparison of the studies difficult. 
 
2.3.1 Infant Birthweight 
There were four studies that assessed dietary zinc intake and birthweight with 
three based on women from countries where the estimated prevalence of low 
dietary zinc intake is <17% (Table 2.1) [42–45]. Lower zinc intake was reported in 
women from the United Kingdom (UK) who gave birth to an SGA infant 
compared to those who gave birth to an appropriate-for-gestational-age (AGA) 
infant (SGA: mean (SEM) 11.3 (0.5) vs. AGA 13.0 (0.6) mg/day, p ˂ 0.05) [45]. This 
was similar to another study of Indian women that reported lower zinc intakes 
in women who delivered an infant weighing <2500 g compared to those who 
delivered an infant that was ≥2500 g [42]. Logistic regression analysis in one study 
from the United States reported daily zinc intake ˂6 mg/day to be associated with 
a 2-fold increase in the risk of delivering a LBW infant (aOR: 2.01, 95% CI: 1.11–
3.66) [44] although dietary zinc intakes <median were not found to be associated 
with LBW in another study of American women (OR: 1.4, 95% CI: 0.9–2.1) [43]. 
While both studies used a 24 h recall questionnaire to determine zinc intakes, 
there were differences in ethnicity of the women studied as Neggers et al., [43] 
predominantly studied African-American women as opposed to Scholl et al. who 
studied Caucasian women [44]. 
Twelve studies were identified that measured maternal circulating zinc in 
countries where inadequate zinc intake is predicted to be <17%, and looked at the 
association with birthweight (Table 2.1) [38,46–56]. Only one study, based on 
3817 women in China, reported a 3.4-fold increase in the risk of delivering a LBW 
infant with serum zinc <560 µg/L (adjusted RR: 3.41, 95% CI: 1.97, 5.91) [56]. This 
is in contrary to two studies that reported significantly higher zinc concentrations 
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in women with an SGA infant in the third trimester [47,55]. However, these 
findings were based on a relatively small number of women: 40–51 pregnant 
women including 10–16 women with SGA. Conversely, another study, which 
followed 476 women of whom 39 gave birth to an SGA infant, found the 
incidence of LBW to be 8 times higher in women with serum zinc in the lowest 
quartile (457.5–797.4 µg/L) compared to the highest (1039.2–1660.1 µg/L) (8.2, 
95% CI: 2.4–27.5) [52]. The remaining eight studies found no differences in 
maternal zinc concentrations between women with a SGA infant and those with 
an uncomplicated pregnancy. However, one study found a positive correlation 
between maternal zinc status and birthweight (r = 0.632, p ˂ 0.001) [50]. 
The association between maternal circulating zinc and birthweight was 
assessed in 14 studies based on women where inadequate dietary zinc intake was 
predicted to affect ≥17% of the population [57–69], of which 7 reported a 
significant association (Table 2.1) [57,59–61,66–68]. All three of the studies based 
on women from Africa reported serum/plasma zinc on average 72–333 µg/L 
lower in women who gave birth to a LBW infant compared to those who gave 
birth to an appropriate weight infant [57,59,67]. In another study, the risk of 
delivering a LBW infant was also reported to be 3-fold greater in women with 
serum zinc levels ≤392.2 μg/L compared to those with levels above this figure 
(3.07, 95% CI: 1.07–8.97) [67]. Conversely, two other studies reported serum zinc 
to be 40–172 µg/L higher in women who gave birth to a LBW infant compared to 
those who gave birth to an appropriate weight infant [66,60]. A further four 
studies, also based on women from India, reported no association between 
circulating zinc levels and birthweight [62–64,69] and this was also reported in 
two studies of Turkish women [58,65]. However, univariate analysis and small 
sample size in these studies may not provide an accurate assessment of the effects 




























TABLE 2.1. Included studies assessing maternal zinc status and birthweight. 
Author, Country Sample Size 
Zinc Measure 
Outcome of the Study 
(1) Sample Type 
(2) Time at Which Gestation Diet 
was Assessed or Sample Collected 
(3) Method of Analysis 
[42] Simmer,  
United Kingdom a 
28 SGA  
29 uncomplicated 
Dietary zinc intake 
Third trimester of pregnancy  
7 day dietary recall 
↓ mean (SEM) dietary intake in the SGA mothers compared to the 
women with uncomplicated pregnancies.  
SGA: 11.3 (0.5) vs. uncomplicated: 13.0 (0.6) mg/day, p < 0.05 
[43] Negandhi,  
India b 
144 LBW  
240 uncomplicated 
Dietary zinc intake 
26–30 weeks 
24 h dietary recall 
↓ mean dietary zinc intake in women with a LBW infant compared 
to those with an uncomplicated pregnancy.  
LBW: 5.39 mg/day vs. uncomplicated 6.77 mg/day, p < 0.001 
[44] Scholl,  
United States c 
115 with zinc intake ≤6 
mg/day  
699 with zinc intake ˃6 
mg/day 
Dietary zinc intake 
28 and 36 weeks 
24 h dietary recall 
2-fold ↓ risk of delivering a LBW infant with dietary zinc intake ˃6 
mg/day. 
OR: 2.01, 95% CI: 1.11–3.66 
[45] Neggers,  
United States d 
180 LBW  
1218 uncomplicated 
Dietary zinc intake 
18 and 30 weeks 
24 h dietary recall using the 
nutrient data base developed by 
the University of Minnesota 
NS association between low dietary zinc intake (less than median) 
and risk of LBW. 
OR: 1.4, 95% CI: 0.9–2.1 
Inadequate dietary zinc intake estimated to affect <17% of the studied population 
[46] Wang,  
China b 
247 with serum zinc 
<560 µg/L 
2940 with serum zinc 
≥560 μg/L 
Fasting serum zinc 
Across gestation 
Flame AAS 
↑ incidence of LBW in the mothers with serum zinc <560 µg/L 
compared to those with serum zinc ≥560 μg/L. 
Adjusted RR: 3.41, 95% CI: 1.97, 5.91 
[47] Voss Jepsen,  
Denmark a 
10 SGA  
30 uncomplicated 
Heparin plasma zinc 
Collected at 35–41 weeks 
AAS 
↑ mean (SD) plasma zinc between SGA mothers and those with 
uncomplicated pregnancies. 




























[48] Borella,  
Italy a 
16 SGA  
35 uncomplicated 
Heparin plasma zinc 
Collected in the third trimester 
Flame AAS 
↑ mean (SD) plasma zinc in SGA women compared to women with 
uncomplicated pregnancies. 
SGA: 685.6 (119.6) vs. uncomplicated: 627.5 (150) µg/L, p < 0.001 
[49] Neggers,  
USA e 
39 LBW  
437 uncomplicated 
Serum zinc 
Collected across gestation 
Flame AAS 
8-fold ↑ prevalence of LBW with serum zinc in the lowest quartile 
(457.5–797.4 µg/L) compared to the highest (1039.2–1660.1 µg/L). 
OR: 8.2, 95% CI:2.4–27.5 
[50] Bro,  
Denmark a 
47 SGA and 34 preterm  
220 uncomplicated 
Serum zinc 
Collected at delivery 
Flame AAS 
NS mean (SD) serum zinc levels between SGA and women with  
uncomplicated pregnancies. 
SGA: 764.7 (119.6) vs. uncomplicated: 679.7 (98) µg/L 
[38] Hyvonen-
Dabek, Finland f 
4 SGA  
10 uncomplicated 
Serum zinc 
Collection time not specified 
Particle induced X-ray emission 
NS mean (SD) serum zinc in SGA women compared to those with  
uncomplicated pregnancies. 
SGA: 1270 (320) vs. uncomplicated: 1150 (220) µg/L 
[51] Mistry,  
UK a* 
19 SGA  
107 uncomplicated 
Heparin plasma zinc 
Collected at 28–32 weeks 
Inductively coupled plasma mass 
spectrometry 
NS in mean (95% CI) plasma zinc between SGA women and those 
with  
uncomplicated pregnancies. 
SGA: 708.1 (510.4–905.8) vs. uncomplicated: 634.4 (580.5–688.2) 
μg/L 
[52] Tamura,  
USA g 
80 SGA  
80 uncomplicated 
Serum zinc 
Collected at 18 weeks and 30 weeks 
Flame AAS 
NS in mean (SD) plasma zinc between SGA and women with 
uncomplicated pregnancies at 18 weeks. 
SGA: 627 (118) vs. uncomplicated: 667 (98) µg/L 
NS in mean (SD) plasma zinc between SGA and women with 
uncomplicated pregnancies at 30 weeks. 
SGA: 562 (92) vs. uncomplicated: 575 (92) µg/L 




Non-fasting heparin plasma zinc 
Collected at first prenatal visit (6 to 
34 weeks) 
Flame AAS 
NS in the prevalence (n (%)) of SGA measured between the lowest 
quartile and upper 3 quartiles of zinc. 
Highest: 103 (4.4) vs. lowest: 36 (4.8) 





Collected within 24 h of delivery 
AAS 
NS in mean (SD) serum zinc levels between SGA and women with 
uncomplicated pregnancies. 
































Heparin plasma zinc 
Collected across gestation 
AAS 
NS mean (SEM) plasma zinc in mothers with a LBW infant 
compared to mothers with uncomplicated pregnancies. 
LBW: 604.9 (22.4) vs. uncomplicated: 577.2 (7.7) μg/L 




EDTA plasma zinc 
Collected at delivery 
Flame AAS 
NS mean (SEM) plasma zinc in women with a LBW infant 
compared to women with uncomplicated pregnancies. 
LBW: 640 (20) vs. uncomplicated: 620 (20) µg/L 
Inadequate dietary zinc intake estimated to affect ≥17% of the studied population 
[57] Atinmo,  
Nigeria h 
20 LBW  
30 uncomplicated 
Heparin plasma zinc 
Collected at delivery 
AAS 
↓ mean (SD) serum zinc in women with a LBW infant compared to 
those with uncomplicated pregnancies. 
LBW: 663.1 (144.6) vs. uncomplicated: 731.5 (235.6) µg/L, p < 0.05 
[58] Abass,  
Sudan b 




Atomic absorption spectrometry 
↓ median (IQR) serum zinc in women with a LBW infant compared 
to those with uncomplicated pregnancies. 




81 LBW  
84 uncomplicated 
EDTA plasma zinc 
Collected at delivery 
Flame AAS 
3-fold ↓ risk of delivering a LBW infant with serum zinc ≥ 392.2 μg/L 
OR: 3.07, 95% CI: 1.07–8.97 
[60] Bahl,  
India c 
19 LBW  
56 uncomplicated 
Serum zinc 
Collected at delivery 
Flame AAS 
↓ mean (SD) serum zinc in women with a LBW infant compared to 
those with uncomplicated pregnancies. 
LBW: 553 (43) vs. 692 (95) µg/L, p < 0.001 
[61] Singh,  
India e 
47 LBW  
45 uncomplicated 
Serum zinc 
Collected at delivery 
AAS 
↓ mean (SD) serum zinc in women with a LBW infant compared to 
those with uncomplicated pregnancies. 
LBW: 623 (330) vs. uncomplicated: 895 (514) μg/L, p < 0.001 
[62] Prema,  
India e 
23 LBW  
208 uncomplicated 
Serum zinc 
Collected at delivery between 9–
11.30 a.m. 
Flame AAS 
↑ mean (SD) serum zinc in mothers with a LBW infant compared to 
mothers with an uncomplicated pregnancy. 
LBW: 660 (162) vs. uncomplicated: 620 (146) µg/L, p <  0.01 
[63] Badakhsh,  
Iran b 
30 LBW  
110 uncomplicated 
Serum zinc 
Collected at delivery 
AAS 
↑ mean (SD) serum zinc in mothers with a LBW infant compared to 
mothers with an uncomplicated pregnancy. 




























[64] Goel,  
India a 
20 LBW  
25 uncomplicated 
Heparin plasma zinc 
Collected at delivery 
AAS 
NS mean (SD) plasma zinc in women with a LBW infant compared 
to those with an uncomplicated pregnancy. 
LBW: 726 (61) vs. uncomplicated: 763 (56) μg/L 
[65] Srivastava,  
India b 
26 LBW  
25 uncomplicated 
Heparin plasma zinc 
Collected at delivery 
Flame AAS 
NS mean (SD) plasma zinc between mothers with a LBW infant and 
mothers with uncomplicated pregnancies. 
LBW: 6470 (4860) vs. uncomplicated: 5670 (2490) µg/L 
[66] Jeswani,  
India a 
10 SGA  
25 uncomplicated 
Serum zinc 
Collected at 28–40 weeks 
AAS 
NS mean (SD) serum zinc in SGA women compared to those with 
uncomplicated pregnancies. 
SGA: 938 (76.2) vs. uncomplicated: 962.8 (194.8) µg/L 
[67] George,  
India a 
65 SGA  
51 uncomplicated 
Heparin plasma zinc 
Collected before labor between 8–
10 a.m. 
AAS 
NS in mean (SD) plasma zinc between SGA and women with 
uncomplicated pregnancies. 
SGA: 675 (90) vs. uncomplicated: 706.7 (139) µg/L 
[68] Akman,  
Turkey f 
22 SGA  
34 uncomplicated 
Serum zinc 
Collected at delivery 
AAS 
NS mean (SD) serum zinc between SGA women and women with 
uncomplicated pregnancies. 
SGA: 1218 (543) vs. uncomplicated 1038 (343) µg/L 
[69] Ozdemir,  
Turkey b 
16 LBW  
59 uncomplicated 
Serum zinc 
Collected at 38–42 weeks  
Flame AAS 
NS mean (SD) serum zinc between mothers with a LBW infant and 
mothers with uncomplicated pregnancies. 
Data represented on graphs 
a SGA defined as ˂10th percentile, b LBW defined as ˂2500 g, c LBW defined as ≤2000 g, d LBW defined as ˂2750 g, e LBW defined as ˂2000, f SGA not defined, a* 
SGA defined as ˂10th percentile based on customised centiles, g SGA defined as ˂15th percentile, h LBW defined as ≤2500 g. Bold print signifies results that 
were significantly different. Abbreviations: AAS: atomic absorption spectrometry; CI: confidence interval; IQR: interquartile range; LBW: low birth weight; 
NS: non-significant; OR: odds ratio; SD: standard deviation; SEM: standard error of the mean; SGA: small for gestational age. 
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2.3.2 Hypertensive Disorders of Pregnancy 
Only one study assessed dietary zinc intake and the association with hypertensive 
disorders (Table 2.2) and found no significant differences in dietary zinc intake 
between 13 women who developed a hypertensive disorder in pregnancy and 44 
whose pregnancies remained uncomplicated [70]. 
Thirteen studies analyzed serum/plasma zinc in women who developed a 
hypertensive disorder of pregnancy in women residing in countries where 
inadequate zinc intake is estimated to be low (<17%) (Table 2.2). Three studies 
reported mean serum/plasma zinc to be on average 120–1200 µg/L lower in 
women who developed PE compared to women whose pregnancies remained 
uncomplicated [49,71,72] and included one study that reported a reduction in 
risk of PE with serum levels above 1360 µg/L after adjusting for maternal age, 
height and weight before pregnancy (aOR: 0.005, 95% CI: 0.001–0.07) [71]. A 
further two studies reported circulating zinc to be lower in women who 
developed severe PE (blood pressure BP ≥ 160/110) compared to women whose 
pregnancies remained uncomplicated [73,74]. The remaining eight studies, whose 
sample sizes ranged from 10–271 women with PE/GH and 10–2038 women with 
an uncomplicated pregnancy, reported no difference in maternal zinc status 
between women with a hypertensive disorder of pregnancy and those without 
[38,47,54,75–79]. 
There were twenty studies that analyzed circulating zinc in women with a 
hypertensive disorder of pregnancy in populations where inadequate zinc intake 
is estimated to be ≥17% (Table 2.2) [32–34,36,37,39,80–93]. Ten studies reported 
mean serum/plasma zinc to be significantly lower in women who developed PE 
and/or GH [33,34,36,37,39,80–83,93] however, one reported plasma zinc to be 
higher in women with PE compared to those whose pregnancies remained 
uncomplicated when measured during the latent phase of labor; with (PE mean 
(SD): 15.53 (4.92) vs. uncomplicated: 11.93 (3.11) μg/g protein, p = 0.003) [89]. These 
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studies also included three which found circulating zinc to be 80–260 μg/L lower in 
women who developed severe PE when compared to women whose pregnancies 
remained uncomplicated [39,37,83]. A further nine studies reported no difference 
in circulating zinc between women with PE/GH and those whose pregnancies 
remained uncomplicated. 
2.3.3 Spontaneous Preterm Birth 
The literature search identified four studies which measured dietary zinc 
intakes during pregnancy and sPTB with varying conclusions (Table 2.3) 
[94,95,43,44]. Two of these studies, which analyzed 5738 and 818 women 
respectively, determined that low zinc intake (≤6 mg/day which is ≤54% of the 
recommended 11 mg/day [21]) was associated with a more than 2-fold increase 
in the risk of delivering preterm (aOR: 2.3, 95% CI: 1.2–4.5 and aOR: 1.85 95% CI: 
1.09–3.12, respectively), after adjusting for factors such as ethnicity, pre-pregnancy 
BMI, smoking, alcohol and multivitamin consumption [102,44]. If delivery date 
was calculated by last menstrual period (LMP), zinc intake below 9 mg/day was 
associated with a 2.75-fold increased risk in delivering <32 weeks gestation (aOR: 
2.75, 95% CI 1.31–5.77) [44]. However, another study reported no association 
between low dietary zinc intake (less than the median) and the risk of sPTB (OR: 
1.1, 95% CI: 0.7–1.7) [43] but mean zinc intake of the women in this study was 14 
mg/day, higher than the recommended 11 mg/day, indicating that low zinc intake 
was not prevalent within this studied population. 
When separated based on estimates of inadequate zinc intake, there were three 
studies which assessed whether there was an association between circulating zinc 
and sPTB in low-risk populations (Table 2.3). While two showed no significant 
difference between serum/plasma zinc levels during gestation in women who 
gave birth preterm and those who gave birth at term [48,54], one study which 
recruited 3081 women in China found a 2.4-fold increase risk of PTB with serum 




























TABLE 2.2. Included studies assessing maternal zinc status and hypertensive disorders of pregnancy. 
Author, Country Sample Size 
Zinc Measure 
Outcome of the Study 
(1) Sample Type 
(2) Time at Which Gestation Diet 
was Assessed or Sample Collected 
(3) Method of Analysis 
[70] Tande,  
United States a,b 
13 hypertensive (11 PE 
+ 2 GH) 
44 uncomplicated 
Dietary and supplement intake 
First 3 months of pregnancy 
Harvard food frequency 
questionnaire 
NS in mean (SEM) dietary zinc intake between those with and 
without gestational hypertension. 
Hypertensive: 16.9 (1.56) vs. uncomplicated: 15.4 (1.03) mg/day 
Inadequate dietary zinc intake estimated to affect <17% of the studied population 
[71] Lazebnik,  
United States a,b 




Collected within 1 h of delivery 
AAS 
↓ mean (SD) serum zinc in women with PE when compared to 
women with uncomplicated pregnancies. 
PE: 420 (100) vs. uncomplicated: 520 (130) µg/L, p < 0.05 
NS mean (SD) plasma zinc in hypertensive women compared to 
those whose pregnancies remained uncomplicated. 
Hypertensive: 530 (110) vs. uncomplicated: 520 (110) µg/L 
[55] Cherry,  




Heparin plasma zinc 
Collected across gestation 
AAS 
↓ mean (SEM) plasma zinc in women with toxemia/ 
hypertension compared to women with uncomplicated 
pregnancies. 
Toxemic: 541.5 (16.8) vs. uncomplicated: 590.7 (8) μg/L, p <0.009 





Collected at delivery 
Instrumental neutron activation 
analysis 
↓ mean (SEM) serum zinc in mothers with PE compared to 
women with uncomplicated pregnancies. 
PE: 700 (200) vs. uncomplicated: 1900 (500) μg/L, p < 0.0001 
[73] Kiilholma, 
Finland c,d 




Collected at delivery 
Particle induced X-ray emission 
↓ mean (SD) serum zinc in women with mild and severe PE 
compared to women with uncomplicated pregnancies.  
Mild PE: 510 (70) and severe PE: 370 (10) vs. uncomplicated: 




























↓ mean (SD) serum zinc in women with severe PE compared to 
those with mild PE.  
Severe PE: 370 (10) vs. mild PE: 510 (70) μg//L, p < 0.005 
[74] Araujo Brito,  
Brazil e 
20 mild PE and 24 
severe PE  
50 uncomplicated 
Fasting sodium citrate plasma zinc 
Collected before delivery 
Flame AAS 
↓ mean (SD) plasma zinc in mothers with severe PE compared to 
mothers with uncomplicated pregnancies. 
Severe PE: 388 (82) vs. uncomplicated: (483 (83) µg/L, p < 0.05 
NS mean (SD) plasma zinc in women with mild PE compared to 
women with uncomplicated pregnancies. 
Mild PE: 500 (94) vs. uncomplicated: (483 (83) µg/L 
[75] Magri,  
Malta b 
33 GH  
110 uncomplicated 
Serum zinc  
Collected in third trimester 
Electro-thermal AAS 
NS in mean (SD) serum zinc between women with GH and 
women with uncomplicated pregnancies. 
PE: 606 (80) vs. uncomplicated: 636 (100) μg/L 
[76] Fenzl,  
Croatia a,b 
30 PE and 30 GH  
37 uncomplicated 
Fasting serum zinc 
Collected at the time of diagnosis 
Flame AAS 
NS in mean (SD) serum zinc between both women with PE or 
GH women and women with uncomplicated pregnancies. 
PE: 603 (93) and GH: 599 (83) vs. uncomplicated: 578 (93) μg/L 
[77] Katz,  
Israel d 
43 severe PE  
80 uncomplicated 
Plasma zinc 
Collected immediately after 
delivery 
Inductively coupled plasma mass 
spectrometry 
NS mean (SD) plasma zinc in mothers with severe PE vs 
mothers with uncomplicated pregnancies.  
Severe PE: 685 (875) vs. uncomplicated: 534 (139) µg/L 
[38] Hyvonen-Dabek,  
Finland f 
10 hypertensive  
10 uncomplicated 
Serum zinc 
Collection time not specified 
Particle induced X-ray emission 
NS mean (SD) serum zinc in women with PE compared to 
women with an uncomplicated pregnancy.  
PE: 1070 (320) and hypertensive: 1090 (170) vs. uncomplicated: 
1150 (220) 




Heparin plasma zinc 
Collected in the third trimester 
Flame AAS 
NS mean (SD) plasma zinc in the hypertensive women 
compared to those who remained uncomplicated.  
Hypertensive: 685.6 (149) vs. uncomplicated: 627.5 (150) µg/L 
[78] Mistry,  
United Kingdom a 
244 PE  
472 uncomplicated 
Non-fasting heparin plasma zinc 
Collected at 15 weeks gestation 
Inductively coupled plasma mass 
spectrometry 
NS median (interquartile range) plasma zinc in women with PE 
women compared to those with uncomplicated pregnancies.  





























[53] Tamura,  
United States a 
271 hypertensive  
2038 uncomplicated 
Non-fasting heparin plasma zinc 
Collected at first prenatal visit (6 to 
34 weeks) 
Flame AAS 
NS in the prevalence (n (%)) of hypertension measured between 
the lowest quartile and upper 3 quartiles of zinc. 
Highest: 205 (7.9) vs. Lowest: 66 (7.7) 
[79] Lao TT,  
China a 
28 PE  
28 uncomplicated 
Heparin plasma zinc 
Collected after diagnosis, before 
delivery 
Flame AAS 
NS mean (SD) plasma zinc in women with PE compared to 
women with uncomplicated pregnancies. 
PE: 641 (163) vs. uncomplicated: 647 (111) µg/L 
Inadequate dietary zinc intake estimated to affect ≥17% of the studied population 
[80] Sarwar,  
Bangladesh a 
50 PE  
58 uncomplicated 
Fasting serum zinc 
Collected ˃20 weeks gestation 
Flame AAS 
↓ mean (SEM) serum zinc in mothers with PE compared to 
mothers with uncomplicated pregnancies. 
PE: 770 (50) vs. uncomplicated: 980 (30) µg/L, p < 0.001 
[34] Kumru,  
Turkey a 
30 PE  
30 uncomplicated 
Serum zinc 
Collection time not specified 
AAS 
↓ mean serum zinc in women with PE when compared to 
women with uncomplicated pregnancies. 
Data represented on graphs, p < 0.001 
[81] IIhan,  
Turkey a 
21 PE  
20 uncomplicated 
Serum zinc 
Collected at 31–38 weeks  
Flame AAS 
↓ mean (SD) serum zinc in women with PE when compared to 
those with an uncomplicated pregnancy. 
PE: 829.4 (289.3) vs. uncomplicated: 1251.9 (242.3) μg/L, p <0.001 




Fasting serum zinc 
32–38 weeks 
Flame AAS 
↓ median (max-min) serum zinc in women with PE when 
compared to those with an uncomplicated pregnancy. 
PE: 812.4 (1106.5–624) vs. uncomplicated: 1084.5 (1385.5–881.2) 





Fasting heparin plasma zinc 
Collection time not specified 
Flame AAS 
↓ mean (SEM) serum zinc in mothers with PE compared to 
mothers with uncomplicated pregnancies. 
PE: 764.9 (176.2) vs. uncomplicated: 1006.1 (201.2) µg/L, p < 
0.001 
[83] Al-Jameil,  
Saudi Arabia a 
40 PE  
40 uncomplicated 
Serum zinc 
Collected in the third trimester 
Inductively coupled plasma optical 
emission spectrometry 
↓ mean (SD) serum zinc in mothers with PE compared to 
mothers with uncomplicated pregnancies. 




























[33] Akinloye,  
Nigeria a 
49 PE  
40 uncomplicated 
Serum zinc 
Collection time not specified 
Flame AAS 
↓ mean (SD) serum zinc between women with PE and women 
with uncomplicated pregnancies. 
PE: 562 (92) vs. uncomplicated: 614 (52) μg/L, p < 0.05 
[39] Jain,  
India e 
25 mild PE and 25 
severe PE  
50 uncomplicated 
Serum zinc 
Collection time not specified 
AAS 
↓ mean (SD) serum zinc between women with mild PE and those 
with uncomplicated pregnancies. 
Mild PE: 831 (111) vs. uncomplicated: 1022 (157) μg/L, p < 0.05 
↓ mean (SD) serum zinc between women with severe PE and 
women with uncomplicated pregnancies. 
Severe PE: 787 (92) vs. uncomplicated: 1022 (157) μg/L, p < 0.05 
[37] Gupta, 
India b,e 
47 mild PE and. 18 
severe PE and 10 
eclamptic 
74 uncomplicated 
Non-fasting heparin plasma zinc 
Collection time not specified 
AAS 
↓ mean (SD) serum zinc in mothers with severe PE and 
eclampsia compared to mothers with uncomplicated 
pregnancies. 
Severe PE: 607 (107) and eclampsia: 607 (171) vs. 
uncomplicated: 695 (119) μg/L, p < 0.01 
NS in mean (SD) serum zinc between women with mild PE and 
women with uncomplicated pregnancies. 
Mild PE: 684 (134) vs. uncomplicated: 695 (119) μg/L 
[84] Bassiouni,  
Egypt g,d 
52 PE (28 mild and 24 
severe) 
20 uncomplicated 
Heparin plasma zinc 
Collected at delivery 
AAS 
NS in mean (SD) plasma zinc in women with mild PE compared 
to women with uncomplicated pregnancies.  
Mild PE: 604.2 (162.7) vs. uncomplicated: 646 (173.7) μg/L 
↓ mean (SD) plasma zinc in women with severe PE compared to 
the women with uncomplicated pregnancies. 
Severe PE: 410.8 (116.5) vs. uncomplicated: 646.0 (173.7 μg/L, p 
< 0.001 
[85] Harma,  
Turkey a 
24 PE  
44 uncomplicated 
Heparin plasma zinc 
Collected just during the latent 
phase of labor 
AAS 
↑ mean (SD) plasma zinc levels in women with PE when 
compared to women with uncomplicated pregnancies.  
PE: 15.53 (4.92) vs. uncomplicated: 11.93 (3.11) μg/g protein, p = 
0.003 
[86] Rafeeinia,  
Iran h 
35 PE and 15 severe PE  
50 uncomplicated 
Fasting serum zinc 
Collected in the third trimester 
AAS 





























Mild PE: 690 (40) and severe PE: 780 (80) vs. uncomplicated: 720 
(40) µg/L 
[87] Vafaei,  
Iran e 




Collected at 28-40 weeks 
Auto-analyser 
NS mean (SD) serum zinc in either the mild or severe PE women 
compared to women with uncomplicated pregnancies.  
Data represented on graphs 
[88] Ahsan,  
Bangladesh a,i 
44 PE and 33 eclampsia 
27 uncomplicated 
Serum zinc 
Collected at 28–42 weeks 
Flame AAS 
NS mean (SD) serum zinc in PE or eclamptic women compared 
to women with uncomplicated pregnancies. PE: 1045.8 (131) and 
eclampsia: 915 (131) vs. uncomplicated: 980.4 (131) µg/L 
[89] Rathore,  
India a 
14 PE  
47 uncomplicated 
Serum zinc 
Collected at delivery 
Flame AAS 
NS mean (SD) serum zinc between women with PE and those 
with uncomplicated pregnancies. 
PE: 492 (178) vs. uncomplicated: 575 (216) μg/L 





Collected between 29-38 weeks 
AAS 
NS mean (SD) serum zinc between women with PE women and 
those with uncomplicated pregnancies. 
PE: 10.6 (4.4) vs. uncomplicated: 12.7 (4.1) µg/L 




Fasting serum zinc 
Collected at 28-29 weeks 
Flame AAS 
NS in mean (SD) serum zinc between women with PE and 
women with uncomplicated pregnancies. 
PE: 792 (180) vs. uncomplicated: 1086 (199) μg/L 





Collected before the onset of labor 
Flame AAS 
NS mean (SD) plasma zinc in women with PE compared to 
women with an uncomplicated pregnancy.  
PE: 313 (47) vs. uncomplicated: 341 (44) µg/L 




Heparin plasma zinc 
Collected at delivery 
Inductively coupled plasma mass 
spectrometry 
NS mean (SD) plasma zinc between women with PE women and 
women with uncomplicated pregnancies.  
PE: 5200 (1444) vs. uncomplicated: 5561 (1057) µg/L 
[32] Adeniyi,  
Nigeria a 
55 pregnant women 
Plasma zinc 
Collection time not specified 
AAS 
NS mean (SD) plasma zinc in women with PE compared to 
women with uncomplicated pregnancies. 
PE: 940 (270) vs. uncomplicated: 970 (230) μg/L 
a PE defined as high blood pressure (≤140/90 mmHg) after 20 weeks gestation and proteinuria (≥300 mg/24 h), b GH defined as high blood pressure 
(≤140/90 mmHg) after 20 weeks gestation without proteinuria, c PE not defined, d Severe PE not defined, e Mild PE defined as blood pressure ≥140/90 
but less than 160/110 mmHg and severe PE defined as ≥160/110 mmHg, f PE defined as blood pressure ˃130/85 and proteinuria ≥1 by dipstick, severe 




























as blood pressure ˃ 130/85 and proteinuria ≥1 by dipstick, severe PE defined as blood pressure ˃160/110, i eclampsia defined as women diagnosed 
with PE whom also suffer seizures that cannot be attributed to other causes. Bold print signifies results that were significantly different. 
Abbreviations: AAS: atomic absorption spectrometry; GH: gestational hypertension; PE: preeclampsia; SD: standard deviation; SEM: standard error 
of the mean. 





Outcome of the Study 
(1) Sample Type 
(2) Time at Which Gestation Diet 
was Assessed or Sample Collected 
(3) Method of Analysis 
[44] Scholl, 
United States a 
115 with zinc intake ≤6 
mg/day  
699 with zinc intake ˃6 
mg/day 
Dietary zinc intake 
28 and 36 weeks 
24 h dietary recall 
2-fold ↓ risk of delivering a preterm infant with dietary zinc intake ˃6 
mg/day. 
OR (LMP): 1.85, 95% CI: 1.09–3.12, OR (OE): 2.13, 95% CI: 1.20–3.79 
2.75 to 3.44-fold ↓ risk of delivering a very preterm infant with dietary 
zinc intake ˃9 mg/day. 





413 preterm and  
58 early preterm  
5267 term 
Dietary zinc intake  
Harvard food frequency 
questionnaires 
2-fold ↓ for preterm birth <32 weeks with zinc intake ˃ 8.0 mg/day 
compared to 8.0–14.2 mg/day. 
OR: 2.3, 95% CI: 1.2–4.5 
[45] Neggers, 
United States a 
238 preterm 
1160 term 
Dietary zinc intake 
18 and 30 weeks 
24 h dietary recall using the nutrient 
database developed by the 
University of Minnesota 
NS association between low dietary zinc intake (less than median) 
and risk of PTB. 





Dietary zinc intake 
Each trimester  
24 h dietary recall 
NS in dietary zinc intake between each of the trimesters and in those 
who delivered preterm versus term. 





























Inadequate dietary zinc intake estimated to affect <17% of the studied population 




Fasting serum zinc 
First and second trimester 
Flame AAS 
↑ risk of preterm birth with serum zinc <767 μg/L and serum zinc 
between 767-996 μg/L.  
aOR: 2.41, 95% CI: 1.57, 3.70; aOR: 1.97, 95% CI: 1.27, 3.05, p < 0.001 
for both, respectively 





Collected at delivery 
Flame AAS 
NS mean (SD) serum zinc levels in women who delivered preterm 
compared to term women. 
Preterm: 666.7 (104.6) vs. term: 679.7 (98) μg/L 
[54] Tamura,  
United States c 
505 preterm and 136 
early preterm 
2038 uncomplicated 
Non-fasting heparin plasma zinc 
Collected at first prenatal visit (6 to 
34 weeks) 
Flame AAS 
NS in the prevalence or n(%)of PTB measured between the lowest 
quartile and upper three quartiles of zinc.  
Highest: 373 (14.5) vs. lowest: 132 (15.3) 
NS in the prevalence (n (%)) of early PTB measured between the 
lowest quartile and upper three quartiles of zinc. 
Highest: 107 (4.2) vs. lowest: 29 (3.4) 
Inadequate dietary zinc intake estimated to affect ≥17% of the studied population 





Collected at 28–40 weeks 
AAS 
↑ mean (SD) serum zinc in women who delivered preterm women 
compared to term.  
Preterm: 1154.4 (154.1) vs. uncomplicated: 962.8 (194.8) µg/L, p ˂0.01 




Heparin plasma zinc 
Collected at delivery 
AAS 
↑ mean (SD) plasma zinc in mothers who delivered preterm 
compared to term mothers.  
Preterm: 842 (43) vs. term: 744 (51) μg/L, p ˂ 0.001 





Collected at delivery 
Flame AAS 
NS mean (SD) in women who delivered Preterm that were an 
appropriate weight for date compared to uncomplicated. Preterm: 






Heparin plasma zinc 
Collected at delivery 
Flame AAS 
NS mean (SD) plasma zinc between preterm and term mothers. 
Preterm: 6350 (2640) vs. term: 6310 (5090) μg/L 
a PTB defined as ˂37 weeks gestation, b Early PTB defined as ˂32 weeks gestation, c PTB defined as ≤37 weeks gestation, d PTB not defined. Bold print 
signifies results that were significantly different. Abbreviations: AAS: atomic absorption spectrometry; aOR: adjusted odds ratio; CI: confidence interval; 
LMP: last menstrual period; OE: obstetric estimate; PTB: preterm birth; SD: standard deviation. 
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The association between maternal circulating zinc and sPTB was determined 
in four studies on populations with inadequate zinc intake ≥17%, all of which 
sampled women in India (Table 2.3) [61,63,64,69]. Two of the studies reported 
serum/plasma zinc to be higher in women who delivered preterm compared to 
those who delivered at term (average 98–1991 µg/L increase) [63,64]. However, no 
difference in circulating zinc measured at delivery was reported in the remaining 
two studies [61,69]. 
 
2.3.4. Gestational Diabetes Mellitus 
Two studies looked at the association between dietary zinc intake and GDM 
(Table 2.4) [98,97]. One collected data at 24–28 weeks gestation, and found an 11% 
reduction in the risk of gestational hyperglycaemia with every 1 mg/day increase 
in dietary zinc intake (aOR: 0.89, 95% CI: 0.82–0.96) [97]. The second, which 
sampled women at 14–20 weeks’ gestation, found no association between 
maternal dietary zinc intakes below 50% of the recommended daily allowance 
and GDM (OR: 1.4, 95% CI: 0.6–2.9) [98]. Differences between the studies 
included when dietary zinc was measured (early versus late second trimester) as 
well as ethnicity (Italian versus Iranian in which, genetic and cultural differences 
are likely). 
Of the five studies which assessed the association between circulating zinc 
and GDM in countries where inadequate zinc intake is estimated to be <17%, two, 
both studying Italian women, reported a significant difference in serum/plasma 
zinc in women who developed GDM compared to women whose pregnancies 
remained uncomplicated (Table 2.4) [97,47]. However, while one study reported 
that serum zinc was negatively associated with the risk of hyperglycemia in 
pregnancy (aOR: 0.94, 95% CI: 0.91–0.96) [97], the other found that there was in 
increase in serum zinc in women with GDM compared to women whose 
pregnancy remained uncomplicated (GDM mean (SD): 766.6 (117.6) vs. 
uncomplicated: 627.5 (150) µg/L, p ˂ 0.001) [47]. Both studies sampled women at 
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similar times during pregnancy and used atomic absorption spectrometry to 
quantitate zinc. The remaining three studies found no difference in circulating 
zinc [35,38,99] however, given the small sample size of women with GDM in 
these studies (n = 5–46), it is likely they were underpowered and not suitable for 
the chosen statistical tests. 
There were two studies that sampled women from countries where 
inadequate zinc intake was estimated to be ≥17% and assessed the association 
between maternal circulating zinc and GDM (Table 2.4) [98,100]. Neither study 
reported a difference in serum zinc in early pregnancy or at delivery in women 
with GDM compared to those whose pregnancies remained uncomplicated. 
2.4 Discussion 
This systematic review assessed whether maternal circulating zinc levels and/or 
dietary zinc intake were associated with a number of pregnancy complications. 
Overall, the evidence regarding the association between maternal zinc status and 
PE/GH, LBW/SGA, sPTB and GDM is weak and heterogeneity between the 
studies made comparisons difficult. However, systematic analysis of the 
available literature indicated some trends between maternal zinc status and 
infant birthweight as well as the development of severe PE (BP ≥160/110 mmHg).  
There is consistent evidence in animal models that maternal dietary zinc 
deficiency during pregnancy reduces fetal growth [16–19]. From the studies that 
measured maternal zinc intake during pregnancy reviewed here, a possible 
relationship between low zinc intake (≤54% of the recommended 11 mg/day) and 
decreased infant birthweight may exist in human populations. Both food 
frequency questionnaires and 24 h recalls are limited by the preparedness of the 
participants to accurately record their diets, the food composition tables used and 
their ability to capture variations within diets [103]. This may explain the 
conflicting results between studies which assessed dietary zinc intake and the 





























TABLE 2.4. Included studies assessing maternal zinc status and GDM. 
Author, Country Sample Size 
Zinc Measure 
Outcome of the Study 
(1) Sample Type 
(2) Time at Which Gestation Diet 
was Assessed or Sample Collected 
(3) Method of Analysis 
[97] Bo, 
Italy a,b 
126 GDM and 84 
aOGTT  
294 uncomplicated 
Dietary zinc intake 
24–28 weeks 
Food frequency questionnaire 
↓ mean (SD) daily zinc intake between GDM and aOGTT women 
and women with uncomplicated pregnancies. 
GDM: 8.5 (2.4) and aOGTT: 8.7 (2.5) vs. uncomplicated: 9.4 (2.8) 
mg/day, p = 0.007 
[98] Behboudi-
Gandevani S,  
Iran a 
72 with GDM 
961 uncomplicated 
Dietary zinc intake 
14–20 weeks 
Semi-quantitative food frequency 
questionnaire 
NS in mean (SD) daily zinc intake between GDM and those with  
uncomplicated pregnancies. 
GDM: 6.91 (3.42) vs. uncomplicated: 10.1 (7.45) mg/day 
Inadequate dietary zinc intake estimated to affect <17% of the studied population 




Heparin plasma zinc 
Collected in the third trimester 
Flame AAS 
↑ mean (SD) plasma zinc in GDM women compared to women 
with uncomplicated pregnancies. 
GDM: 766.6 (117.6) vs. uncomplicated: 627.5 (150) µg/L, p ˂0.001 
[35] Wang,  
China a,c 




Collection time not specified 
Inductively coupled plasma atomic 
emission spectroscopy 
NS in mean (SD) plasma zinc between women with IGT and 
women with uncomplicated pregnancies.  
IGT: 1080 (270) vs. uncomplicated: 1130 (330) μg/L 
NS mean (SD) plasma zinc between women with GDM and those 
with  
uncomplicated pregnancies.  






Collection time not specified 
Particle induced X-ray emission 
NS mean (SD) serum zinc in women with GDM compared to 
women with uncomplicated pregnancies.  


































Collected across gestation 
AAS 
NS mean (SD) serum zinc between women with GDM and those 
with  
uncomplicated pregnancies.  
GDM: 700 (100) vs. uncomplicated: 700 (80) μg/L 
Inadequate dietary zinc intake estimated to affect ≥17% of the studied population 
[98] Behboudi-
Gandevani, Iran a 
72 with GDM 
961 uncomplicated 
Serum zinc 
Collected 14–20 weeks 
Flame AAS 
NS mean serum zinc between GDM and women with 
uncomplicated pregnancies. 
GDM: 844 (440) vs. uncomplicated: 835 (444) μg/L 





Collected at delivery 
Furnace AAS 
NS mean (SEM) serum zinc in women with GDM compared to 
women with uncomplicated pregnancies. 
GDM: 610.3 (60.1) vs. uncomplicated: 656.2 (241.4) µg/L 
a GDM defined as high blood glucose levels in pregnant women who have not previously been diagnosed with diabetes which over a 3 h oral glucose 
tolerance test provided at least two values over the criteria of Carpenter and Coustan, b aOGTT defined as high blood glucose levels in pregnant 
women who have not previously been diagnosed with diabetes which over a 3 h oral glucose tolerance test provided one abnormal value over the 
criteria of Carpenter and Coustan, c IGT defined as women with blood glucose consistently higher than 7.8 mmol/L, d GDM diagnosed with an 
intravenous glucose tolerance test at 30 weeks gestation. Bold print signifies results that were significantly different. Abbreviations AAS: atomic 
absorption spectrometry; aOGTT: abnormal oral glucose tolerance test; BMI: body mass index; GDM: gestational diabetes mellitus; IGT: impaired 
glucose tolerance; OGTT: oral glucose tolerance test; SD: standard deviation.














TABLE 2.5. Summary of all the studies reviewed and whether zinc status was 
positively, negatively or not associated with the studied pregnancy complication. 








9 4 1 4 2 
 





2 reported a 
negative 
association [44,93] 
1 reported a 
negative 
association [96] 
 1 reported no 
association [45] 
 
2 reported no 
association [45,94] 
1 reported no 
association [97] 








58 26 33 7 6 
No. where inadequate zinc intake affects <17% of the population 
 12 13 3 4 
 




5 reported a 
negative 
association [55,71−74] 
1 reported a 
positive 
association [95] 




2 reported a 
positive 
association [47,48] 
8 reported no 
association 
[38,48,53,75−79] 
2 reported no 
association [50,53] 
3 reported no 
association 
[35,38,98] 
 8 reported no 
association [38,50-56] 
   
No. where inadequate zinc intake affects ≥17% of the population 
 14 20 4 2 
 
5 reported a 
negative 
association [57-61] 




2 reported a 
positive 
association [64,66] 
2 reported no 
association [97,99] 
 




1 reported a 
positive 
association [84] 
2 reported no 
association [60,65] 
 
 6 reported no 
association [64-69] 
9 reported no 
association [32,85-92] 
  
Abbreviations: GDM: gestational diabetes mellitus; LBW: low birth weight; SGA: small for 
gestational age; sPTB: spontaneous preterm birth. 
 
studies that measured dietary zinc intake in pregnancy and recorded infant 
birthweight reported a significant reduction in maternal zinc status in those who 
delivered a LBW/SGA infant [42,44,45]. The relationship between infant 














birthweight and maternal serum/plasma zinc is less clear. Plasma measures of 
zinc are considered preferable over serum as erythrocytes can be a source of zinc 
contamination within serum samples [22]. However, plasma zinc only accounts 
for approximately 0.1% of total body zinc [104], is heavily influenced by 
confounding factors like stress, infection and hormones [105–108,101] and does 
not directly correlate with dietary zinc intake [109]. This limits how useful 
measuring circulating zinc is as a biomarker for health and disease. When studies 
on LBW/SGA that measured maternal circulating zinc were separated based on 
populations where inadequate zinc intake is predicted to be ≥17%, 7 of the 13 
studies reported a difference in serum/plasma zinc between women who 
delivered LBW/SGA infant and those whose infants were of an appropriate 
weight. Given the lack of suitable alternatives, particularly in studies of pregnant 
women, determining zinc status by measuring serum/plasma zinc can still be 
informative about the importance of zinc to pregnancy, especially if measured in 
conjunction with dietary zinc intakes. 
Other maternal factors such as age, BMI, smoking status and alcohol 
consumption in pregnancy not only influence pregnancy outcome but also 
circulating zinc [110,111]. BMI is a significant factor in influencing the risk for 
developing PE and GH [112,113]. However, only 11 of the 32 studies on PE/GH 
[33,36,54,75,71,79,80,82,84,88,92] reported on BMI, making it difficult to comment 
on whether differences in BMI may be influencing the outcomes of the studies 
included in this review. Despite this, there may be a relationship between 
maternal circulating zinc levels and the severity of PE. Mean maternal zinc 
concentrations in women with severe PE (ranging from 388–410 μg/L) [73,74,83] 
were well below 562.1 μg/L, which is the defined zinc deficiency cut-off [26,114]. 
In women with mild PE and those with uncomplicated pregnancies, mean 
maternal zinc concentrations ranged between 684–831 µg/L [37,39,83] and 630–
1022 µg/L [37,39,74,83] respectively. A current leading hypothesis relating to the 
development of PE is increased placental oxidative stress [115]. Zinc itself has 














antioxidant capabilities and is an integral structural component of superoxide 
dismutase, a first line defense antioxidant [116] which has reduced activity in cell 
lines, animal models and human studies of zinc deficiency [117–121]. Hence, it is 
possible in pregnancies complicated by PE, that low maternal zinc concentration 
(˂562.1 µg/L) may reduce the potential to combat rises in free radical production 
and increase the severity of the complication. 
Zinc levels in maternal circulation decrease across gestation; this is 
thought to be due to a combination of increased maternal blood volume and fetal 
demands [40,122–124], and therefore comparisons between studies which 
measured zinc in maternal serum or plasma early in pregnancy versus late 
should be interpreted with caution. Overall, regardless of pregnancy outcome, 
the majority (31 out of 59 studies which measured maternal circulating zinc) 
collected samples during labor or at delivery. Physiologically, parturition results 
in huge changes to maternal hormonal profile with rises in estrogen, oxytocin 
and prostaglandin required to initiate labor [125]. Furthermore, there is an 
increase in the production of inflammatory cytokines and a withdrawal of anti-
inflammatory cytokines within the gestational tissues [126]. Infection and 
inflammation decrease plasma zinc [105] and use of the contraceptive pill, which 
raises estrogen and progesterone levels, also decreases circulating zinc [106,101]. 
Given that pregnancy itself is likely to confound zinc status, this has implications 
for interpreting studies that have measured serum/plasma zinc at delivery. In 
addition, how zinc may be associated with a pregnancy outcome needs to be 
measured before the pregnancy complication has manifested. Only five studies 
of 6795 pregnant women in total measured either circulating zinc or dietary zinc 
intake prior to 20 weeks gestation [44,53,54,79,98]. All found no significant 
difference in maternal zinc status during this time period between women who 
developed a pregnancy complication and those who did not, indicating that zinc 
status in early pregnancy may not be associated with adverse pregnancy 
outcomes. 














Due to the additional demands associated with pregnancy and fetal 
growth, pregnant women are more vulnerable to multiple nutrient deficiencies 
[127] and this is potentially another cofounding factor when assessing the 
association between maternal zinc status and pregnancy outcome. This is because 
nutrients can interact with each other in both a positive (e.g., vitamin A and zinc 
[128]) and negative manner (e.g., calcium or iron and zinc [129,130]). A number 
of studies reviewed here measured serum/plasma concentrations of other 
nutrients as well as zinc, including copper [35,97], iron [75,98], selenium [51,88], 
magnesium [95,99] and lead [78]. While circulating zinc levels were not different 
for the pregnancy outcomes studied in these articles, those of other 
micronutrients were. Serum copper concentrations were found to be higher in 
women with GDM or those who delivered an SGA infant when compared to 
women with an uncomplicated pregnancy in two studies [97,35]. Furthermore, 
serum iron was higher in women with PE and GDM compared to women whose 
pregnancies were uncomplicated [75,98]. Two other studies found selenium to be 
lower in the serum of women with PE or those who delivered an SGA infant 
compared to women with an uncomplicated pregnancy [88,51]. Therefore, it is 
important to consider other nutritional factors that may influence pregnancy 
outcome as well as micronutrient ratios in order to fully understand the 
importance of micronutrient status on pregnancy success. 
Finally, the lack of studies identified in this review analyzing truly zinc 
deficient women, nor those in populations at high risk of zinc deficiency, is a 
major limitation in determining the effects of zinc on pregnancy outcome. Only 
8 of the 64 studies reported mean circulating zinc below 562.1 μg/L 
[49,50,74,72,60,83,87,91] and there were very few studies based on women in 
countries where inadequate zinc intake is predicted to be prevalent like South-
East Asia and parts of Africa [26,27]. The majority of studies were based on 
populations in the United States and Europe where zinc deficiency is estimated 
to only affect 3.9%–12.7% of the population [26]. Therefore, there is the potential 














that the results from this review may be skewed given the lack of evidence based 
on women living in areas predicted to be at high risk of zinc deficiency. 
2.5 Conclusions 
The current review has explored the connection between maternal zinc status 
and pregnancy complications including hypertensive disorders of pregnancy, 
infant birthweight, spontaneous preterm birth (sPTB) and gestational diabetes 
mellitus (GDM). While it appears that there may be a relationship between 
maternal dietary zinc intake and infant birthweight and the development of severe 
PE, there is little evidence to suggest an association between zinc and sPTB or 
GDM. However, heterogeneity in the studies identified in this review reflects real 
uncertainty in the evidence linking zinc deficiency and pregnancy complications 
and therefore this warrants further study, particularly in developing countries 
whose populations are at increased risk of zinc deficiency. If we are to continue to 
reduce preventable deaths of newborns and children under the age of five [6], 
understanding the importance of micronutrients like zinc in child development, 
particularly in utero, will greatly increase the likelihood of success. Future 
studies need to focus on women more vulnerable to zinc deficiency in pregnancy 
in order to fully determine the effects of zinc status on pregnancy outcome. 
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2.6.1 Appendix A 
Outline of the search terms and MeSH headings identified in the Medline search and used for 
the remaining database searches. 
Search strategy: MEDLINE (OVID). 
 Searches Results 
1 exp Zinc/ or zinc.mp. 108695 
2 plasma zinc.mp. 1365 
3 zinc intake.mp. 679 
4 dietary zinc.mp. 1158 
5 serum zinc.mp. 2083 
6 1 or 2 or 3 or 4 or 5 108695 
7 preterm birth.mp. or exp Premature Birth/ 14642 
8 premature birth.mp. or Premature Birth/ 11131 
9 small for gestational age.mp. 9255 
10 exp Infant, Small for Gestational Age/ 5977 
11 
gestational hypertension.mp. or exp Hypertension, Pregnancy‐
Induced/ 
32078 
12 pre?eclampsia.mp. or exp Pre‐Eclampsia/ 30863 
13 exp Pre‐Eclampsia/ or exp Eclampsia/ or eclampsia.mp. 32471 
14 exp HELLP Syndrome/ or HELPP syndrome.mp. 1613 
15 gestational diabetes.mp. or exp Diabetes, Gestational/ 11382 
16 fetal macrosomia.mp. or exp Fetal Macrosomia/ 2369 
17 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 69148 
18 infant, low birth weight.mp. or Infant, Low Birth Weight/ 16571 
19 
infant, very low birth weight.mp. or exp Infant, Very Low Birth 
Weight/ 
8491 
20 17 or 18 or 19 89771 
21 6 and 20 380 
22 limit 21 to (english language and full text and humans) 165 
 
 
2.6.2 Appendix B 
List of conversion factors used to convert all measures of zinc to μg/L. 
Units Conversion  
μg/100 mL or μg/dL Multiply 10 
μmol/L or μM Divide 0.153 
mg/L Multiply 1000 
μg/mL Multiply 1000 
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ABSTRACT 
Zinc is an essential micronutrient in pregnancy and zinc deficiency 
impairs fetal growth. We used a mouse model of moderate zinc 
deficiency to investigate the physiological mechanisms by which zinc 
is important to placental morphogenesis and the maternal blood 
pressure changes during pregnancy. A 26% reduction in circulating 
zinc (P=0.005) was exhibited in mice fed a moderately zinc-deficient 
diet. Zinc deficiency in pregnancy resulted in an 8% reduction in both 
near term fetal and placental weights (both P<0.0001) indicative of 
disrupted placental development and function. Detailed 
morphological analysis confirmed changes to the placental labyrinth 
microstructure. Continuous monitoring of maternal mean arterial 
pressure (MAP) revealed a late gestation decrease in the zinc-deficient 
dams. Differential expression of a number of regulatory genes within 
maternal kidneys supported observations on MAP changes in 














gestation. Increased MAP late in gestation is required to maintain 
perfusion of multiple placentas within rodent pregnancies. Decreased 
MAP within the zinc-deficient dams implies reduced blood flow and 
nutrient delivery to the placenta. These findings show that adequate 
zinc status is required for correct placental morphogenesis and 
appropriate maternal blood pressure adaptations to pregnancy. We 
conclude that insufficient maternal zinc intake from before and during 
pregnancy is likely to impact in utero programming of offspring 
growth and development largely through effects to the placenta and 
maternal cardiovascular system. 
 
3.1 Introduction 
During pregnancy, the placental vasculature provides the interface 
between the fetus and the mother for exchange of nutrients and wastes.  
Adequate placental function underpins normal fetal development [1]. Defects in 
placental development and function are implicated in a number of clinical 
pregnancy complications. These include preeclampsia (PE) [2], a common 
hypertensive disorder of pregnancy [3] and fetal growth restriction (FGR) [4-7], 
defined as birth weight, adjusted for gestational age, of  ≤5th percentile [3]. 
Together these conditions pose a lifelong risk of morbidity and mortality for both 
the mother and infant. Increased placental oxidative stress is hypothesised to be 
an underlying cause of pathogenesis in pregnancies complicated by PE and FGR 
[8]. While the precise mechanisms remain unclear, it is highly likely that 
micronutrient deficiencies play a pivotal role.  
Zinc is extremely important during the accelerated fetal growth phase 
characteristic of late gestation. It is an essential element in more than 1000 
proteins required for biological functions including antioxidant defence, cell 
signalling and gene expression [9-12]. In development, zinc is not only important 
for the action of transcription factors and the enzymes which catalyse the 
synthesis of DNA and RNA, but also as a component of the accessory proteins 














that regulate the activation of key development genes [13]. Increased fetal loss 
and high rates of congenital malformation in several organs of surviving fetuses 
are characteristics of severe zinc deficiency in pregnancy [14,15].  Compromised 
DNA integrity and increased oxidative stress are likely drivers of impaired tissue 
and physiological function when zinc intake is insufficient, since zinc is an 
essential component of copper-zinc superoxide dismutase (Cu/Zn-SOD) [16], 
and DNA-repair mechanisms such as p53 [17,18].  
In rodents, maternal zinc deficiency consistently causes reduced fetal 
growth evident from mid-gestation to near term [19-23]. The mechanisms by 
which placental development and function contributes to impaired fetal growth 
in these models is largely unknown. Maternal hemodynamic adaptations to 
pregnancy are essential for optimal placental development and function, since 
adequate blood flow to the placenta underpins normal fetal growth [24]. Reduced 
uterine blood flow to the placenta not only constrains delivery of nutrients to the 
fetus and increases fetal hypoxia but also has implications for production of 
factors which modulate placental vascular growth [25]. We hypothesised that 
reduced fetal growth associated with maternal zinc deficiency is modulated by 
altered placental development and function and aimed to characterise the effect 
of moderate maternal zinc deficiency on placental morphogenesis and maternal 
cardiovascular adaptations to pregnancy, in particular maternal blood pressure. 
3.2 Results  
3.2.1  Moderate Dietary Zinc Restriction Reduces Circulating Zinc 
and Liver Metallothionein Concentrations 
To confirm that moderate dietary zinc restriction reduced maternal zinc status in 
C57BL/6J female mice fed a zinc-deficient diet (containing 10 mg/kg zinc) 
compared to a zinc-replete diet (containing 40 mg/kg zinc), we analysed maternal 
plasma zinc concentrations, liver metallothionein expression and placental and 














fetal zinc content. At gestational day (GD) 18.5, there was a 26% decrease in 
circulating zinc in the zinc-deficient dams when compared to the zinc-replete 
dams (Fig. 3.1a; P = 0.005) and long term zinc status, as measured by liver 
metallothionein, was also reduced by 19% (Fig. 3.1b; P<0.0001). There was no 
difference in maternal food consumption across the experimental period (mean 
7 day food consumption per cage containing 4 mice (SEM) deficient: 92.4 (1.29) 
vs. replete: 90.6 (1.86) g; P = 0.45), confirming reduced zinc status was not a 
consequence of anorexia. Placental zinc concentrations remained similar between 
the two diet groups (Fig. 3.1c; P = 0.59) and there was a trend for an increase in 
FIGURE 3.1. Lower zinc in the diets of the zinc-deficient mice reduced both short-
term and long-term zinc stores. At GD18.5, a reduction in circulating zinc levels 
(a) as well as liver metallothionein (b) was observed in the zinc-deficient dams. 
Placental tissue zinc however remained similar between the two diet groups (c) 
and there was a trend for an increase in zinc content of fetuses from zinc-deficient 
dams (d). Data are median and interquartile range (n = 10 zinc-replete and 7 zinc-
deficient [a & b] and n = 19 zinc-replete and 13 zinc-deficient [c & d]). Statistical 
significance was determined using Mann-Whitney Test on data based on an 
average litter size of 7.00. *P˂0.05, #P=0.08. 














zinc concentrations in fetuses from the zinc-deficient dams (Fig. 3.1d; P = 0.08), 
suggesting active mechanisms for sequestering zinc into gestational tissues. 
Circulating levels of phosphorus, sulphur and potassium were slightly higher in 
the zinc-deficient dams (Supplementary Table S3.1) but was likely due to minor 
differences in the diet compositions (Supplementary Table S3.2) and these 
nutrients did not differ in placental or fetal tissues (Supplementary Table S3.1). 
 
3.2.2 Moderate Maternal Zinc Deficiency Impairs Fetal Growth 
To investigate the impact of zinc deficiency during pregnancy on placental 
development, we first compared reproductive outcomes in zinc-deficient and 
zinc-replete dams. At GD0.5 the zinc-deficient dams did not differ in weight 
compared to the zinc-replete dams (Fig. 3.2a; P = 0.24). However, at GD18.5 (24 
hours before birth) they were 3% lighter compared to the zinc-replete (Fig. 3.2b; 
P = 0.044). The proportion of mated mice exhibiting viable pregnancies in late 
gestation was not different (data not shown) and litter size was not significantly 
different between the two diet groups (median [IQR] zinc-deficient: 7 [5, 8] vs. 
zinc-replete: 8 [6, 8.75]; P = 0.36), indicating no impact on fertility or fecundity. 
The lighter maternal body weight in the zinc-deficient dams was largely 
accounted for by an 8% reduction in both fetal and placental weights (Fig. 3.2c-
d; both P < 0.0001) as maternal carcass weight (maternal weight minus fetal and 
placental weights combined) did not differ between the two diet groups (Fig. 
3.2e; P = 0.24). The fetal-placental weight ratio did not significantly differ (Fig. 
3.2f; P = 0.21), indicating similar nutrient transport efficiencies between the 
placentas. The importance of zinc to growth and development was highlighted 
in the postnatal phase, with pups from the zinc-deficient mothers 32% lighter at 
weaning compared to pups born to control dams (Supplementary Fig. S3.1). 
Survival rates to weaning were similar regardless of zinc status (survival at 
weaning; zinc-deficient: 30 out of 40 (75%) vs. zinc-replete: 20 out of 27 (74%); χ2 
analysis; P = 1). 















FIGURE 3.2. Maternal zinc deficiency altered reproductive outcome, 
measured at GD18.5. No significant difference in maternal weight was 
observed between the zinc-replete and zinc-deficient dams at mating (a). At 
GD18.5, maternal weight of the zinc-deficient dams was reduced compared 
to the replete (b). This was largely due to a decrease in both fetal (c) and 
placental (d) weight as maternal carcass weight (e) was not significantly 
different. Placental efficiency, measured by the fetal-placental weight ratio 
was not different between the two diet groups (f). Data are median and 
interquartile range (n = 12 zinc-replete and 11 zinc-deficient). Statistical 
significance was determined using Mann-Whitney Test on data based on an 
average litter size of 7.00. *P˂0.05, ***P˂0.001.














3.2.3 Effect of Maternal Zinc Deficiency on Placental Morphology 
Having confirmed that moderate zinc deficiency in pregnancy resulted in 
reduced placental weight, we analysed placental morphology at GD18.5 as FGR 
is often associated with poor placental morphogenesis, and underpins future 
placental function [26]. Total placental mid-sagittal cross sectional area was not 
significantly different between the two diet groups despite a reduction in 
placental weight (median [IQR], deficient: 7.17 [5.88, 7.35] vs. replete: 6.71 [6.18, 
7.01] mm2; P = 0.21). Furthermore, there was no difference in the mid-sagittal 
cross sectional area of the labyrinth zone; the region responsible for nutrient and 
waste exchange (Fig. 3.3a; P = 0.69), despite an 8% reduction in labyrinth zone 
weight in placentas from zinc-deficient dams (Fig. 3.3b, P = 0.012). This implied 
a disproportionate shift in placental architecture, as commonly occurs in an 
adaptive response to nutritional perturbation [27], and was supported by 
detailed immunohistochemical (IHC) analysis. There are three main 
compartments which comprise the labyrinth zone; the fetal capillaries (FC: fetal 
circulation), maternal blood space (MBS: maternal circulation) and the 
trophoblasts which act as a barrier between the FC and MBS, to coordinate 
nutrient and waste exchange (Fig. 3.3c). In the placentas of zinc-deficient dams, 
both trophoblast volume and trophoblast barrier thickness were reduced by 16% 
(Fig. 3.3d-e; P = 0.007 and P = 0.016, respectively), there was a 17% increase in the 
volume density of FC (Figure 3.3f; P = 0.02) and 10% increase in surface area 
density (Figure 3.3g; P = 0.028) compared to placentas from zinc-replete dams. 
Together these results indicate a compensatory mechanism in the zinc-deficient 
placentas that nevertheless was unable to rescue fetal growth.















FIGURE 3.3. Maternal zinc deficiency during pregnancy resulted in 
changes to the placental architecture likely to affect fetal growth. Despite no 
significant different in the labyrinth zone mid-sagittal cross sectional area 
(a), labyrinth zone weight was reduced in the zinc-deficient placentas at 
GD18.5 (b). Double labelling immunohistochemistry was used to identify 
the fetal capillaries (FC) trophoblasts (TB) and maternal blood space (MBS) 
within the labyrinth zone (c). Analysis revealed decreases in the trophoblast 
volume (d) as well as trophoblast barrier thickness (e) in the placentas from 
zinc-deficient dams. An increase in fetal capillary volume density (f) and 
surface volume (g) was also found. Data are median and interquartile range 
(n = 23 and 21 placentas from 12 zinc-replete and 11 zinc-deficient dams, 
respectively). Statistical significance was determined using Mann-Whitney 
Test on data based on an average litter size of 7.00. *P˂0.05, **P˂0.01. GTB: 
giant trophoblast cells.














3.2.4 Placental Iron Transport is Reduced by Zinc Deficiency 
Zinc is extremely important in regulating the expression of a number of 
development genes crucial for fetal growth [13]. Conservation of zinc within the 
placentas and fetuses of the zinc-deficient dams suggested reduced zinc in the 
gestational tissues was not driving the reduction in fetal growth. A microarray 
analysis was used to identify pathways within the placenta that may be disrupted 
by maternal zinc deficiency however, only eight genes were identified to be 
potentially differentially expressed (Supplementary Table S3.3). An 8.5-fold 
increase in the expression of Transferrin Receptor (Tfrc) in placentas from zinc-
deficient dams was identified (Fig. 3.4a and Supplementary Table S3.3) and qPCR 
validation in an independent cohort of placentas confirmed an increase in gene 
expression (Fig. 3.4b; P<0.0001). Furthermore, there was a 36% increase in the 
expression of Tfrc in maternal kidney tissue from the same cohort of mice (Fig. 
3.4c; P = 0.019). IHC staining showed Tfrc protein localised to the apical surface 
of the trophoblast cells within the placental labyrinth (Fig. 4d) and Western blot 
analysis confirmed a 32% increase in protein expression in zinc-deficient 
placentas compared to zinc-replete (Fig. 3.4e and 3.4f; P = 0.022). Increased Tfrc 
expression was most likely a response to decreased placental and fetal iron 
concentration in the tissues from zinc-deficient dams (Supplementary Table 
S3.1). A 24% (P = 0.048) and 20% (P = 0.001) decrease in the zinc-deficient dams 
in placental and fetal iron, respectively, indicated disruption to placental iron 
transport despite maternal circulating iron remaining similar between the two 
diet groups (Table S3.1; P = 0.42). These data suggest a possible perturbation in 
the expression of Transferrin (Trf) protein which binds Tfrc to move 
predominantly iron into cells. However, using qPCR, we did not observe 
differential expression of Trf in either placentas or kidneys between the two diet 
groups (Fig. 3.4g and 3.4h; P = 0.12 and P = 0.82, respectively).















FIGURE 3.4. Microarray analysis revealed an 8.5-fold increase in gene 
expression of transferrin receptor (Tfrc) in the placentas of the zinc-deficient 
dams (a). This increase was validated and confirmed in an independent 
cohort of placental samples using qPCR (b). qPCR was also used to measure 
Tfrc expression within kidney tissue at GD18.5 and was also increased in 
tissue collected from zinc-deficient dams (c). Immunohistochemical 
analysis of Tfrc protein showed localisation to the apical surface of the 
trophoblast cells within the labyrinth zone (LZ) of the placenta (d). Tfrc 
protein expression was analysed using Western blot and compared to β-
actin expression (e); Tfrc band at ~100kD and β-actin at ~42kD, (full image 
in supplementary information). This revealed an increased expression of 
Tfrc protein in placentas from zinc-deficient dams (f). Transferrin (Trf) gene 
expression within the placenta and kidney was also quantified by qPCR but 
did not differ between the two diet groups (g and h). Data are median and 
interquartile range (n = 19 and 12 placentas [a]; 50 and 32 placentas [b and 
g]; 12 and 11 kidneys [c and h] and 12 and 10 placentas [e and f] from 12 
zinc-replete and 11 zinc-deficient dams, respectively). Statistical 
significance was determined using Mann-Whitney Test. *P˂0.05, 
***P˂0.001. JZ: junctional zone.














3.2.5 DNA Damage Caused by Oxidative Stress is Elevated by Zinc 
Deficiency 
In vitro and in vivo models of both zinc and iron deficiency reveal increased 
oxidative stress and DNA damage [28-32] as well as increased oxidative stress 
within the placenta in pregnancies complicated by FGR [33,34]. We investigated 
whether disrupted placental function in this model of zinc deficiency was 
associated with increased oxidative stress. Placental expression of 4-
hydroxynonenal (4HNE; a product of lipid peroxidation and marker of oxidative 
stress) was largely localized to the giant trophoblasts within the labyrinth zone 
(Fig. 3.5a) however, Western blot quantification of 4HNE expression revealed no 
difference in relative protein expression between placentas from zinc-deficient 
and zinc-replete dams (Fig. 3.5b; P = 0.72). There was also no difference in the 
expression of Cu/Zn-SOD between placentas from the two diet groups (Figure 
3.5c-d; P = 0.28). This indicates that neither increased lipid peroxidation nor 
reduced SOD expression was a characteristic of placental dysfunction in this 
model. However, increased DNA damage within the placental labyrinth zone in 
the placentas from the zinc-deficient dams as indicated by increased nuclei 
stained positively for 8-hydroxy-2’-deoxyguanosine (8-OHdG) (Fig. 3.5e-f; 
P<0.0001) suggests a reduction in cellular integrity mediated by increased 
oxidative stress which would contribute to placental dysfunction. 8-OHdG 
staining was localised predominantly within giant trophoblasts as well as within 
glycogen cells present in the junctional zone.















FIGURE 3.5. Maternal zinc deficiency resulted in increased DNA damage 
caused by oxidative stress within the placenta at GD18.5. 4-hydoxynoneal 
(4HNE) expression was localisation to the glycogen cells (GC) present in the 
junctional zone (JZ) and giant trophoblast cells (GTB) within the labyrinth 
zone (LZ) of the placenta (a). Western blot analysis showed no difference in 
4HNE expression between the two diet groups (b). Expression of Cu/Zn-
Superoxide Dismutase (SOD) was found throughout the placenta (c) but 
expression was not different between placentas collected from a zinc-
deficient or zinc-replete dams (d).  8-hydroxy-deoxyguanosine (8OHdG) 
was also expressed by the GTB cells and GC within the junctional zone (e). 
There was a statistically significant increase in the percentage of positive 
cells in the labyrinth zone of the placentas from zinc-deficient dams 
indicating an increase in DNA damage caused by oxidative stress (f). Data 
are median and interquartile range (n = 12 and 10 placentas [b] and 23 and 
21 placentas [d & f] from 12 zinc-replete and 11 zinc-deficient dams, 
respectively). Statistical significance was determined using Mann-Whitney 
Test. *P˂0.05. 














3.2.6 Maternal Zinc Deficiency Alters Maternal Blood Pressure 
Profile During Pregnancy and Lactation 
Adequate blood flow to the placenta is crucial for the maintenance of fetal growth 
and an exponential increase in placental blood flow is necessary for transport of 
oxygen, water and nutrients in late gestation [25]. Maternal cardiovascular 
adaptations to pregnancy are crucial in maintaining appropriate placental blood 
flow so we sought to investigate whether zinc deficiency in pregnancy altered 
maternal blood pressure. Continuous measurements of mean arterial pressure 
(MAP), systolic blood pressure (SBP) and diastolic blood pressure (DBP) prior to 
pregnancy, within pregnancy and across lactation revealed that blood pressure 
was disturbed without adequate zinc intake (Fig. 3.6a and Supplementary Figure 
S3.2a). Across the five days prior to mating, average 24 h MAP was elevated in 
the zinc-deficient dams compared to zinc-replete dams (Fig. 3.6a), driven by 
increased DBP during this period (Supplementary Fig. 3.2a). 24 h MAP, SPB and 
DBP were also elevated in the zinc-deficient dams during lactation. Within 
pregnancy, regardless of diet, MAP was different between days 11-19 of 
pregnancy compared to days 1-5. Between days 6-10 of pregnancy, 24 h MAP 
was elevated in the zinc-replete dams but decreased in deficient dams. This 
resulted in lower 24 h MAP between days 11-19 of pregnancy in the zinc-deficient 
dams compared to zinc-replete dams (Fig. 3.6a).Further analysis of diurnal MAP 
pattern during the day (0700 h – 1850 h) and night (1900 h – 0650 h) revealed 
differences in MAP during pregnancy were driven by differences in MAP during 
the day when mice are at rest and not during the night when mice are active 
(Supplementary Fig. S3.2b). Average 24 h pulse pressure; the difference between 
SBP and DBP, was lower in the zinc-deficient dams across the whole 
experimental period when compared to the zinc-replete dams (Fig. 3.6b). This 
along with the fact that 24 h heart rate (HR) was also decreased in the zinc-














deficient dams (Supplementary Fig. S3.2c) indicates a potential reduction in 
cardiac output and reduced organ perfusion. 
 
 
FIGURE 3.6. Maternal zinc deficiency changed the blood and pulse 
pressure profile of dams before pregnancy, during pregnancy and in 
lactation. Prior to pregnancy and during lactation, 24 hour mean arterial 
pressure (MAP) was significantly elevated in the zinc-deficient dams. (a) 
During pregnancy, from days GD0 to GD5, MAP was significantly elevated 
in the zinc-deficient dams. However, across GD6 to GD10, MAP began to 
decrease in the zinc-deficient dams while an increase was observed in the 
zinc-replete dams. This resulted in significantly lower MAP in the zinc-
deficient dams between GD11 to GD19 of pregnancy. (b) Pulse pressure, 
which is the difference between systolic and diastolic blood pressures, was 
significantly lower in the zinc deficient animals across the whole 
experimental period. Each data point represents the average 24 h MAP or 
pulse pressure for each diet grouP ± SEM. n = 4 zinc-replete and 4 zinc-
deficient dams. Statistical differences were determined using a general 
additive model.














3.2.7 Maternal Zinc Deficiency Effects Renal Gene Expression and 
Structure 
To investigate whether changes in maternal blood pressure late in gestation may 
be influenced by effects on aspects relating to renal function, we analysed kidney 
gene expression and morphology. qPCR analysis of kidney tissue at GD18.5 
identified a number of differentially expressed genes in zinc-deficient and zinc-
replete dams associated with blood pressure regulation (Supplementary Table 
S3.4). In particular, a 16% reduction in kidney expression of angiotensin converting 
enzyme (Ace) (P = 0.031) and a 44% reduction in inositol 1,4,5-triphosphate receptor 
type 2 (Itpr2) (P = 0.05) in the zinc-deficient dams occurred in association with 
reduced blood pressure observed at GD18.5 in mice implanted with blood 
pressure monitors. Ace protein expression in the kidneys was localised to the 
apical brush-borders of the proximal convoluted tubules and a 57% reduction in 
Ace protein expression in the kidneys of the zinc-deficient dams was 
demonstrated when compared to the zinc-replete dams (Fig. 3.7a-c; P <0.01). Zinc 
deficiency also caused changes to glomerular morphology which can have 
implications for blood pressure. An 11% reduction in glomeruli basement 
membrane (GBM) thickness was observed in the zinc-deficient dams, compared 
to the zinc-replete dams at GD18.5 (Fig. 3.7d-f; P <0.01), which would affect 
glomerular filtration capabilities and therefore maternal blood pressure. Overall, 
this data is consistent with blood pressure measurements in late gestation. Given 
that placental blood flow is dependent upon maternal hemodynamic alterations 
across gestation, the effects of zinc deficiency on maternal blood pressure are 
likely to contribute to placental dysfunction.














3.2.8 Maternal Zinc Deficiency Alters Immunological Parameters 
in Late Gestation 
In addition to renal function, maternal blood pressure in pregnancy is influenced 
by immune cells, particularly T cells and natural killer (NK) cells [35]. These cells 
impact maternal hemodynamics and placental development by suppressing 
FIGURE 3.7. Effects of marginal zinc deficiency on renal parameters at 
GD18.5. Decreased gene expression of angiotensin converting enzyme (Ace) was 
associated with a decrease in Ace protein expression within the kidneys of 
zinc-deficient dams (a). Representative image of Ace expression in a zinc-
replete (b) and zinc-deficient (c) kidney section. Ace protein was localised to 
the proximal convoluted tubules (PCT). Marginal maternal zinc deficiency 
also decreased glomeruli basement membrane thickness (d). Representative 
images of a glomerulus in a zinc-replete (e) and zinc-deficient (f) kidney 
section. Data are median and interquartile range (n = 10 zinc-replete and 9 
zinc-deficient dams). Statistical significance was determined using Mann-
Whitney Test. *P˂0.05, **P˂0.01. G: glomerulus. T: tubule. 














inflammatory mediators in the implantation site [36] and promoting appropriate 
uterine vascular adaptation [37]. Spleen hypotrophy, as indicated by a 50% 
decrease in maternal spleen weight as a percentage of carcass weight, was 
observed in the zinc-deficient dams compared to zinc-replete dams at GD18.5 
(Supplementary Fig. S3.3a; P = 0.01). There was also a significant reduction in 
liver, kidney and lung weights as a percentage of carcass weight in the zinc-
deficient dams suggesting aberrant maternal adaptation to pregnancy 
(Supplementary Fig. S3.3b-d; P<0.05 for all). The failure to exhibit the spleen 
hypertrophy typical of late gestation [38,39] is consistent with an impaired 
immune response to pregnancy. Histological analysis of the spleen at GD18.5 
showed no difference in the percentage area of white pulp, the splenic region 
populated by lymphocytes, between the two diet groups (Supplementary Fig. 
S3.4a). However, there was a decrease in the absolute number of cells, calculated 
based on splenic weight, within the white pulp in the spleens of the zinc-deficient 
animals compared to the zinc-replete indicative of a reduced lymphocyte pool 
(Supplementary Fig. S3.4b; P = 0.051). We investigated changes to immune cell 
populations within the spleen at GD18.5 using qPCR to analyse marker genes 
and found a 41% reduction in the expression of Fasl, a marker expressed by 
activated T cells and NK cells and a 1.26-fold increase in the expression of Il10, 
which is expressed by regulatory T cells and type 2 T helper cells, in the zinc-
deficient dams (Supplementary Fig. S3.5a,b; P = 0.043 for both, respectively). 
Furthermore, a trend toward elevated Ifna1 (Supplementary Fig. S3.5c; P = 0.07) 
expression was observed in the spleens of zinc-deficient dams compared to 
controls. This data indicates a possible imbalance in the residual lymphocyte 
subpopulations [40] which would be expected to contribute to the cardiovascular 
and placental anomalies seen in the zinc-deficient dams. Maternal immune 
adaptations to pregnancy are crucial to placental development during the 
implantation period and an altered immune balance may contribute to the 














mechanisms through which zinc deficiency disturbs placental morphogenesis 
and fetal growth. 
3.3 Discussion 
Correct placental morphogenesis underpins pregnancy success and 
offspring phenotype, through tight regulation of transport of nutrients, gases and 
waste between the mother and fetus. This study confirms that maternal zinc 
status is a key determinant of fetal growth and shows that the effects of limited 
zinc are likely to be mediated through adverse placental development and 
function. Additionally, we show that altered placental development is associated 
with and likely to be a consequence of combined effects of altered maternal 
cardiovascular adaptations to pregnancy and altered renal function and immune 
changes. An interaction between zinc and other micronutrients within the 
placenta has also been identified, demonstrating the existence of micronutrient 
bioavailability interactions within this complex physiological network. 
Reduced fetal growth has been described in a number of rodent models 
assessing the effect of marginal and severe dietary zinc restriction during 
pregnancy [19-23]. In our model, reduced fetal growth at GD18.5 was associated 
with an 8% reduction in placental weight, a common phenotype of growth 
restriction in humans and animals [26,41]. We sought to further investigate 
perturbations in placental development by defining impact on the placental 
architecture which regulates nutrient transport and fetal growth. A lower 
placental weight was reported at GD12.5 in a model of severe zinc restriction (˂1 
mg/kg) [21]. Unlike this earlier study, we did not observe a difference in labyrinth 
zone area at GD18.5 but IHC analysis of labyrinth zone composition 
demonstrated a change in placental structure indicative of a compensatory 
mechanism. Nutrients transfer from the maternal circulation to the fetus requires 
passage through a layer of trophoblast cells which surround the fetal capillaries 
[42]. Increases to the exchange surface area and the volume density of fetal 














capillaries, as well as decreases in the trophoblast barrier thickness of the zinc-
deficient placentas suggest an increase in the transfer efficiency of nutrients per 
gram of placenta. However, the reduction in total placental size and thus 
labyrinthine volume is likely to elicit a greater effect on the transport of nutrients 
to the fetus than the difference in the magnitude of nutrient transfer per gram of 
placenta. This is supported by the observed similar placental efficiency between 
dietary zinc groups, as measured by the fetal-placental weight ratio, indicating 
these compensatory changes to the labyrinth zone structure are insufficient to 
rescue fetal growth.  
The structure of the placenta at term is determined by events that occur 
much earlier in placental morphogenesis to drive differentiation of various 
trophoblast cell lineages and mesenchymal cells from stem cells in a defined 
stochastic relationship [26,43]. Alterations in gross placental structure as well as 
to the ultrastructure of the labyrinthine zone can confer either a functional 
advantage or disadvantage for nutrient transfer and fetal growth. Changes in 
developmental patterning that result in altered surface area, barrier thickness 
and fetal capillary volume can in part be influenced by the maternal immune 
adaptation to pregnancy, and the capacity of immune cells to support or limit 
early placental development44. Since the spleen is a key source of NK cells and T 
lymphocyte recruited into the uterine decidua and gestational tissues [35], the 
reduced reservoir of splenic lymphocytes and the altered gene expression in 
spleen cells found in zinc-deficient females suggests that the immune response is 
aberrant in zinc-deficient mice. This is consistent with observations of the impact 
of zinc on T cell responses in non-pregnant animals [45-47]. Given the critical 
impacts of lymphocytes on maternal vascular remodeling and systemic 
cardiovascular adaptations to accommodate pregnancy [35] the effects of zinc 
deficiency mediated via immune cells may contribute to placental 
dysmorphogenesis. 














In pregnancy, placental function and the maternal circulatory system are 
intricately dependent upon one another. Perturbations in placental function are 
likely to influence the maternal circulation and vice-versa [24]. Increases in blood 
pressure late in gestation are a characteristic of rodent pregnancies as indicated 
by the blood pressure profile in the zinc-replete dams of this experiment and by 
others [48]. This presumably facilitates maintenance of adequate perfusion of 
multiple placental beds as mice are litter-bearing species. Reduced uterine blood 
flow can also be used as a predictor of FGR in human pregnancies [49,50] as 
transport of oxygen and nutrients needs to keep pace with fetal growth and this 
can only occur with adequate blood flow to the placenta. The decrease in blood 
pressure during late pregnancy, as well as reduced pulse pressure which was 
observed in the zinc-deficient dams is likely to result in reduced blood flow to 
the placenta, impairing nutrient delivery. The renin-angiotensin system (RAS) is 
one of the major physiological regulators of blood pressure mediated by the 
kidneys. Zinc is important to the function of a number of the RAS enzymes which 
catalyse the production of vasoconstrictors thereby increasing blood pressure 
[51]. Ace is a zinc metalloenzyme and chelation of zinc inhibits Ace functionality 
[52]. We also identified a reduction in Itpr2 expression which is a protein that 
controls vascular tone and is thought to alter the responsiveness of cells to 
components of the renin-angiotensin system [53]. These data support the 
importance of zinc in correct functioning of the RAS, particularly in the kidneys, 
and therefore blood pressure control which is necessary to maintain adequate 
placental perfusion and transplacental nutrient exchange. 
Not only is blood flow a crucial determinant of placental function and fetal 
growth, but it also has implications for oxidative stress. Fluctuations in the 
perfusion of the placenta and therefore oxygenation is a major inducer of 
oxidative stress within the placenta which can severely affect placental transport 
capabilities [54] and increased oxidative stress has been characterised in the 
placenta of human pregnancies complicated by FGR [33,34]. Zinc itself is capable 














of acting as an antioxidant but is also required as a structural component of a 
number of first line defence antioxidant molecules [55,56]. Studies have shown 
that zinc deficiency leads to increased oxidative stress in vitro as well as in plasma 
of in vivo animal models [28-30]. Furthermore, zinc concentrations have also been 
shown to be positively correlated with superoxide dismutase concentrations in 
cord blood [57]. Zinc deficiency in this model did not increase the amount of lipid 
peroxidation within the placentas which is not entirely surprising as a similar 
result in human FGR placentas has been documented [34,58] and may reflect the 
placenta’s ability to rapidly metabolise 4HNE [59]. Furthermore, there did not 
appear to be a disruption to the expression of Cu/Zn-SOD in the near term 
placenta. However, conservation of zinc within the gestational tissues may have 
ameliorated any effect on Cu/Zn-SOD expression or function characterised in 
other studies [60,61]. There was however, a significant elevation in DNA damage, 
particularly within the giant trophoblast cells present within the labyrinth zone 
of the placentas suggesting possible disruption to DNA repair mechanisms 
within these cells similar to that previously seen in cell culture models of zinc 
deficiency [17,18]. The giant trophoblast cells within the labyrinth zone function 
to produce hormones such as placental lactogen II and are positioned in order to 
facilitate delivery of hormones and nutrients into the fetal circulation [62,63]. 
Consequently, increased DNA damage would likely reduce cellular integrity 
which could then effect aspects of giant trophoblast function and nutrient 
delivery, potentially amplifying already poor nutrient delivery from the 
maternal circulation resulting in fetal growth restriction. 
There may also be a strong relationship between increased DNA damage 
in the placentas and the reduction of both placental and fetal iron in the zinc-
deficient dams. Iron deficiency results in impaired mitochondrial function and 
increased oxidative stress in a number of different tissues [31,32] hence it is 
reasonable to assume a reduction in placental iron is influencing oxidative stress 
pathways in a similar manner. Perturbed iron transport in the placentas also 














suggested a shift in iron transport out of the placenta occurring as part of a 
response to conserve zinc. Similar to our study, placental Tfrc expression has 
been shown to be inversely related to fetal liver iron concentrations [64] 
suggesting a dialogue between the fetus and placenta which mediates iron 
transport. However, how this may be mediating zinc conservation within the 
gestational tissues - so why iron is reduced is unknown. Iron is known to be 
extremely important in supporting cell growth and metabolism [65,66] and 
therefore reduced transport to the fetus would contribute to growth reduction. 
Previous studies have shown an accumulation of iron in tissues including the 
placenta and fetus in zinc deficient animal models [67,68]. The disparity with the 
current results likely reflects that previous studies utilised models of severe zinc 
restriction (˂0.5 mg/kg). Nevertheless, this new data further highlights a strong 
association between zinc and iron transport in the placenta worthy of further 
investigation. 
In conclusion, this study describes the effects of moderate maternal zinc 
deficiency on placental development and function, as well as responses of the 
maternal cardiovascular system to reduced zinc. Furthermore, the work 
implicates mechanistic pathways involving altered kidney and immune function 
by which inadequate zinc intake and stores during pregnancy impact on 
offspring phenotype. Zinc deficiency contributes substantially to the predicted 
3.5 million deaths per year that are attributed to child and maternal 
undernutrition [69]. Reducing the prevalence of zinc deficiency in developing 
countries was a key aspect of the Millennium Development Goal 1 [70]. Our 
findings highlight the importance of adequate zinc status in pregnancy as 
deficiency impairs fetal growth. Since the trajectory of placental development is 
set in very early pregnancy, our data point to a need for further research to define 
the most critical window for zinc effects in pregnancy, and to develop strategies 
to reduce the impact of zinc deficiency in vulnerable women. 














3.4 Materials and Methods 
3.4.1 Animals and diets 
Seven-week-old C57Bl/6J female mice (Laboratory Animal Services, University 
of Adelaide) were fed either a zinc replete diet containing 40 mg/kg zinc 
(Modified AIN93G, SF09-093; Specialty Feeds) or a marginally zinc deficient diet 
containing 10 mg/kg zinc (Zinc modified AIN93G, SF14-087; Specialty Feeds) as 
determined by inductively coupled plasma atomic emission spectrometry (ICP-
MS). Animals were housed and maintained at Laboratory Animal Services, 
University of Adelaide on a 12 h: 12 h light-dark cycle with both water and food 
provided ad libitum. After six weeks on the respective diets, females were 
randomly allocated to either blood pressure monitoring by radio-telemetry 
(Cohort 1; n = 8) or analysis of placental and fetal growth (Cohort 2; n = 30). Mice 
in Cohort 2 were mated with a C57BL/6J male fed standard chow (Specialty 
Feeds). The presence of a vaginal copulatory plug was designated gestational day 
0.5 (GD0.5). Given the difficulty associated with implanting the radio-telemetry 
probe into very small mice, the mice in Cohort 1 were maintained on  respective 
diets until 21 g (17-18 weeks-old), when radio-telemetry surgery was performed. 
All animals were maintained on diets until conclusion of experiments. Animal 
use complied with the Australian Code of Practice for the Care and Use of 
Animals and ethics approval was obtained from the University of Adelaide 
Ethics Committee (Approval #M-2014-84). 
 
3.4.2 Elemental Analysis 
Elemental analysis on maternal plasma, placental and fetal tissues was 
undertaken to determine the effect of dietary zinc restriction on calcium, 
potassium, magnesium, sodium, sulphur and phosphorus, determined using 
inductively-coupled plasma optical emission spectrometry (ICP-OES) (Agilent 
5100 ICP-OES; CSIRO Analytical Services, South Australia) and zinc, iron, 














copper, and selenium determined by ICP-MS (Agilent 7700 ICP-MS). Details of 
the sample preparation procedure are provided in Supplementary Materials and 
Methods. Disruptions to long term zinc stores were analysed by measuring liver 
metallothionein at GD18.5 and 21 days post-birth using a 109Cd/heme affinity 
assay [71]. 
 
3.4.3 Placental and Fetal Characteristics 
Post-mortem was performed on the dams in cohort 2 between 1000-1200 h on 
GD18.5, described in full in Supplementary Materials and Methods.  Maternal, 
placental and fetal tissue was collected and the number of total, viable and 
resorbing implantation sites was counted. From each dam, 2 placentas were fixed 
and 5 µm thickness full-face sections were stained with Masson’s Trichrome 
following standard protocols in order to determine the mid sagittal total, 
labyrinth zone and junctional zone cross sectional areas. In depth analysis of 
labyrinth structure was performed using immunohistochemistry (IHC) as 
previously described [72,73] and details of antibodies and dilutions used are 
provided in Supplementary Table S5. Microarray, qPCR, IHC and Western blot 
analysis were employed to analyse gene and protein parameters and are detailed 
in Supplementary Materials and Methods. Microarray data have been deposited 
to NCBI GEO under the accession GSE97112. 
 
3.4.4 Radio-telemetry surgery, blood pressure monitoring and 
kidney function 
Dams in cohort 1 were anaesthetised (2.5% isofluorane and 1 L/minute O2, then 
maintained at 1.5% isofluorane and ½ L/minute O2; AttaneTM Isoflurane, 
Bomac) and a radio-telemetry probe (PAC10, Data Sciences International) was 
inserted into the left carotid artery. The probe body was placed subcutaneously 
on the right flank. Mice recovered for 10 days, then MAP and HR were monitored 














for 10 seconds every 10 minutes for 5 days prior to the dams being placed with 
males. The presence of a copulatory plug designated GD0.5 and MAP and HR 
continued to be measured through pregnancy, birth and lactation. Pups were 
counted on the day of birth and weighed at 3, 5 and 7 days post-birth and at 
weaning. 21 days post-birth, dams and pups were killed and post-mortems 
performed between 1000-1200 h to collect maternal and pup tissues as described 
in Supplementary Materials and Methods. 
 To further investigate the effects of zinc deficiency on maternal blood 
pressure, the left kidney was fixed as per the protocol outlined in Supplementary 
Materials and Methods. The right kidney was snap-frozen for molecular 
analyses. 5 µm full-faced, mid-sagittal sections were stained using Masson’s 
Trichrome in order to determine the cortex and medullary zone area. Picrosirius 
red staining was used to determine collagen deposition and Jones’ membrane 
staining was used to assess glomeruli morphology. These staining procedures as 
well as details of qPCR gene expression analysis, IHC and Western blot analysis 
of protein expression are detailed in Supplementary Materials and Methods. 
 
3.4.5 Statistics 
All statistical analysis was performed in R (v3.1.1) [74] using Mann-Whitney Test 
unless otherwise specified. Maternal organ weights, fetal and placental weight 
were corrected for viable litter size using the lme function in the nlme package to 
generate predicted values based on an average litter size of 7, then Mann-
Whitney test was used to calculate exact P-values based on the predicted results. 
Significant differences in 24 h MAP and HR between the two diet groups were 
determined using a generalized additive mixed-model, as detailed in 
Supplementary Materials and Methods. Results are reported as median and 
interquartile range unless otherwise stated. 
 
Data Availability 
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3.5 Supplementary Information 
S3.5.1 Materials and Methods 
Post-mortems and pregnancy parameters 
Dams were anaesthetised with an intraperitoneal injection of 0.75 µg/g Avertin 
(2,2,2-tribromomethanol, Sigma Aldrich) in 2-methyl-2-butanol. Blood was 
collected in a heparinised tube via retro-orbital bleed to which plasma was 
extracted after centrifugation at 10,000 x g and stored at -80°C. Dams were then 
killed via cervical dislocation. Placental and fetal tissue was dissected from the 
uterus, membranes removed and snaP frozen for molecular analysis. Two 
placentas from each dam were randomly selected to be fixed in 4% (wt/vol) 
paraformaldehyde/2.5% polyvidone-40 (wt/vol) in 70 mM phosphate buffer [pH 
7.0] overnight at 4°C, washed in 4 changes of PBS and paraffin-embedded. 
Maternal tissues including spleen, liver, kidneys, lungs, heart and parametrial fat 
were also excised with the left kidney and heart being fixed following the same 
procedure as the placentas. 
 
Elemental analysis of maternal plasma and placental and fetal tissues 
Briefly, 200 μL of plasma, approximately 25 mg of placental tissue and the torso 
of the GD18.5 fetus were digested in Teflon vessels at room temperature in 
concentrated nitric acid (~70% HNO3) for approximately 2 h before further 
digestion under pressure at approximately 90°C overnight. The following day, 
the heat was further increased to approximately 140°C and left a further 24 h. The 
samples were then diluted with milliQ water and made uP to 20 mL to be injected 
onto the relevant apparatuses for analysis. For ICP-MS, samples were run 
alongside two internal standards: iridium and rhodium (Choice Analytical) at a 
concentration of 200 ppb and an 8-point calibration, including blank, was carried 
out between 0.01 µg/L and 100 µg/L. An 8-point calibration (including blank) was 
also carried out between 500 mg/L and 1000 mg/L for the ICP-OES analysis.  














Kidney and spleen morphological analysis 
For kidneys, full-face mid-sagittal sections were stained using Masson’s 
Trichrome in order to determine the cortex and medullary zones following 
standard protocols. Collagen deposition was measured using picrosirius red 
staining. De-waxed sections were immersed in a solution of 0.1% Direct Red 
(Sigma-Aldrich) and 1.2% picric acid (Sigma-Aldrich) in water for 1 h, rinsed in 
running taP water, counter stained with Wiegert’s haematoxylin for 20 mins then 
dehydrated, cleared and mounted. Slides were scanned using the Nanozoomer 
2.0-HT C9600-13 and random systematic sampling of the cortex area was used to 
select 10 images of each section at 20x magnification using the NDP View2 
software (Hamamatsu). ImageJ Version 1.48 software (National Institutes of Health) 
colour deconvolution plugin was used to measure percentage of collagen. 
Glomeruli morphology was assessed using Jones Basement Membrane (PAS-M) 
staining kit (cat. # AR18011-2, Dako) following manufacturers protocol. 
Glomeruli basement membrane thickness, area, perimeter and roundness 
((perimeter^2)/(4*π*area)) were calculated using the NDP View2 software. 
 For spleens, frozen sections were fixed for 10 mins in cold methanol, 
washed in PBS and then stained using hematoxylin and eosin following standard 
protocols. Slides were scanned using the Nanozoomer 2.0-HT C9600-13. Using 
the NDP View2 software, total spleen area and the areas of red and white pulP 
were measured. Random systematic sampling was used to select 10 images of 
each section at 80x magnification. The total number of cells in each image was 
counted using the Particle Analysis tool in the Image J Version 1.48 software. 
 
Placental and Kidney protein expression analysis 
Immunohistochemistry and western blots were used to quantitate protein 
expression of angiotensin converting enzyme (Ace), transferrin receptor, 
hydroxynonenal (4-HNE), Cu/Zn-Superoxide Dismutase (SOD) and 8-hydroxy-














2’-deoxyguanosine (8-OHdG). Antibodies and dilutions are provided in 
supplementary table 1 (Table S3.5).  
As for placental and kidney morphometric analyses, cut sections were de-
waxed, rehydrated according to standard protocols. Where required, antigen 
retrieval was performed and endogenous peroxidase activity was suppressed by 
incubating the slides in 3% hydrogen peroxide. Primary antibodies were diluted 
in 5% serum in PBS and applied overnight at 4°C in a humidified chamber. 
Negative controls were also included by omitting the primary antibody from the 
diluent. Secondary antibodies were diluted in 5% serum and slides were 
incubated for 1 h at room temperature. Primary antibody binding was amplified 
using streptavadin horseradish peroxidase (strep-HRP) (Dako) and detected 
using DAB (Sigma-Aldrich). Video Image Analysis (VIA) software (Leading Edge 
Software) was used to calculated intensity and percent positivity of DAB staining.  
For western blotting, placental and kidney tissue were homogenised in 
ice-cold RIPA buffer. Protein concentrations were determined using a Bradford 
Assay (Bio-rad). 25 µg of protein was run on a 10% mini PROTEANTM TGXTM pre-
cast gel (Bio-Rad) following manufacturer’s protocols and then transferred onto 
nitrocellulose membranes using the CriterionTM Blotter (Bio-Rad). Membranes 
were incubated overnight a 4°C in a blocking solution containing 3% skim milk 
in TBS-T (Tris-Buffered Saline containing Tween 20) before being incubated in 
the relevant primary antibody for 1 h at room temperature. After thorough 
washing in TBS-T, membranes were further incubated with a secondary antibody 
conjugated with HRP for 1 h at room temperature. Protein bands were visualised 
by chemiluminescence with ECL (GE Healthcare) on the Chemidoc MP (Bio-Rad). 
Levels of protein expression were normalised to HSP-90 or β-actin. 














RNA extraction, placental microarray analysis and placenta, spleen and kidney 
qPCR 
Placental, spleen and kidney tissues were homogenised using a Powerlyzer with 
ceramic 1.4 mm beads (Mo Bio Laboratories, Inc). Total RNA was extracted using 
Trizol (Invitrogen) following the manufacturer’s instructions and RNA integrity 
was determined using the Experion (Bio-Rad) system. 
For placental microarray, 31 placentas from 10 zinc-repletezinc-replete 
and 7 zinc-deficient dams were analysed as described by [73]. Affymetrix Mouse 
Gene 2.1 ST array data were checked for quality, RMA background-corrected and 
quantile normalised in R [74], using the aroma.affymetrix package [75] and 
v19.0.0 of an Ensembl-derived CDF 
(http://brainarray.mbni.med.umich.edu/Brainarray/). Detection above 
background (DABG) was performed by estimating non-specific binding (NSB) 
properties of the antigenomic probes using a modified version of the MAT 
background model [76] and obtaining empirical distributions of residuals across 
10 bins of fitted values. After training the model on the set of antigenomic probes, 
fitted NSB estimates were obtained for the PM probes based on their sequence 
content. Fitted NSB estimates were subtracted from the observed PM intensities 
on the log2 scale and residuals were compared to the empirical distributions 
obtained from the antigenomic probes to provide p-values for detection of signal 
above the background. Probe-level P values were obtained using Fisher’s method 
across the set of arrays, and only PM probes with a p-value < 0.05 were 
considered as containing “true” signal, giving 51.4% of probes which were able 
to be used for estimation of expression levels. Differential expression between 
diet groups was assessed using the package limma [77], and all p-values were 
corrected for multiple testing using the Benjamini-Hochberg method [78] to 
provide estimates of the false discovery rate (FDR). 
The outcome of the microarray analysis was validated using qPCR on 
RNA samples from all placentas collected at post-mortems (n=72, 50 from zinc-














replete and 32 from zinc-deficient dams). PrimerPCRTM assays (Bio-Rad) specific 
for mouse Transferrin Receptor (Tfrc) (cat. # QMMUCID0039655) and Transferrin 
(Trf) (cat. # QMMUCID0061477) were purchased along with housekeeping assays 
for Tbp (cat. # QMMUCID0040542) and Hmbs (cat # QMMUCID0022816). Tfrc and 
Trf gene expression was also quantified in kidney samples from dams collected 
at GD18.5 (n=23, 12 zinc-replete and 11 zinc-deficient). Extracted RNA was 
DNase treated using TURBO DNA-freeTM (Ambion) as per manufacturer’s 
instructions and quality zinc-replete for DNase-treatment was double-checked 
using PCR for primers specific for mouse genomic DNA. 500 ng of DNase-treated 
RNA was reverse transcribed using iScriptTM Reverse Transcriptase Kit (Bio-Rad) 
following manufacturer’s instructions. Each cDNA sample was diluted 1:5 and 
added to a PCR reaction containing the relevant primer assay and Ssofast 
Evergreen Supermix (Bio-Rad). qPCR was performed in triplicate following 
cycling conditions recommended by the manufacturer. Data was analysed using 
the Bio-Rad CFX Manager Software v3.1 and all gene expression data was 
normalised to Tbp and Hbms. 
Expression of genes associated with blood pressure zinc-replete and 
immune function were assessed in the kidneys and spleens of dams collected at 
GD18.5, respectively (n=17, 10 replete and 7 deficient). RNA from each kidney or 
spleen was DNAse treated as previously mentioned and 4 µg of DNase-treated 
RNA was reverse transcribed using iScriptTM Advanced cDNA Synthesis Kit (Bio-
Rad). cDNA was diluted 1:15 and added to a reaction mix containing 
SsoAdvancedTM SYBR® Green Supermix (Bio-Rad) and then added to 
PrimePCRTM Pre-eclampsia Tier 1 M384 plates (cat. # 10039501, Bio-Rad) for 
kidney RNA or PrimePCRTM Immune Tier 1 M384 plates (cat. # 10029798, Bio-
Rad) for spleen RNA. Plates were run on the CFX384 PCR machine (Bio-Rad) with 
cycling conditions according to the manufacturer’s protocol. The Bio-Rad CFX 
Manager Software v3.1 was used to analyse the data. For kidney gene expression, 














data was normalised to Tbp and Gapdh while spleen gene expression was 
normalised to Hprt and Gapdh. 
 
Statistics for radio-telemetry data 
A generalized additive mixed model was fitted to the 24 h MAP and HR data in 
order to determine the effects of the diet on blood pressure using the gamlss R 
package in Revolution R Open (RRO) 3.2.0. For 24 h MAP, the model was 
adjusted for age, weight, log of activity and heart rate using a non-linear time 
trend using cubic spline. A random effect was also fitted for each dam. The 
estimated means of the two diet groups across days of gestation were then 
examined for each pregnancy state (pre-pregnancy, pregnancy; including mating 
and birth and lactation), as well as within pregnancy based on pivotal placental 
development events (day 0-5, 6-10 and 11-19).



















FIGURE S3.1. Maternal zinc deficiency reduced pup weight gain during 
lactation. Pup weight was significantly lighter in those from the zinc-deficient 
dams at 3 day post-natal (a), 1 week post-natal (b), 2 weeks post-natal (c) and at 
weaning, 3 weeks post-natal (d). Data are median and interquartile range (n = 17 
and 30 pups from 4 zinc-replete and 6 zinc-deficient dams, respectively). 
Statistical significance was determined using Mann-Whitney Test on data based 
on an average litter size of 7.00. **P˂0.01, ***P˂0.001.















FIGURE S3.2. The effect of zinc on maternal systolic blood pressure (SBP) 
and diastolic blood pressure (DBP) as well as the influence of the day-night 
cycle. The SBP and DBP profiles prior to pregnancy, during pregnancy and 
in lactation were abhorrent within the animals fed the zinc deficient diet 
compared to those on a zinc replete diet (a). A clear circadian rhythm was 
observed in both diet groups as evident by higher 24 h mean arterial 
pressure (MAP) between the hours of 7pm to 6.50am compared to 7am to 
6.50pm (b). During pregnancy differences in MAP between the two diet 
groups were driven by significant differences in MAP between the day light 
hours (7am-6.50pm). No significant differences between MAP in the night 
hours (7pm-6.50am) were observed between the two diet groups across 
pregnancy. 24 h heart rate (HR) was decreased in the zinc-deficient dams 
across all time periods assessed (c). Each data point represents the average 
24 h SBP/DBP (a), MAP (b) or average 24 h HR (c) for each diet group ± 
SEM. n = 4 zin-replete and 4 zinc-deficient dams. Statistical differences were 
determined using a general additive model.  















FIGURE S3.3. Liver (a), total kidney (b), spleen (c) and lungs (d) weight as 
a percentage of carcass weight were all reduced in the zinc-deficient dams 
at GD18.5. Heart (e) and parametrial fat (f) weight as a percentage of carcass 
weight did not change between the two diet groups. Data are median and 
interquartile range (n = 12 zinc-replete and 11 zinc-deficient dams). 
Statistical significance was determined using Mann-Whitney Test on data 
based on an average litter size of 7.00. *P˂0.05, **P˂0.01. 
  















FIGURE S3.4. Histological analysis was used to determine the effects of 
zinc deficiency on spleen morphology at GD18.5. There was no difference 
in the percentage area of white pulp within the spleens between the two 
diet groups (a) but there was a decrease in the number of cell present within 
the white pulp of the zinc-deficient animals when compared to the zinc-
replete animals (b). Analysis of the red pulp revealed no difference in the 
number of cells present within this area of the spleen (c) nor was there any 
difference in the red pulp to white pulp cell ratio (d). Data are median and 
interquartile range (n = 13 zinc-replete and 12 zinc-deficient dams). 
Statistical significance was determined using Mann-Whitney Test. *P=0.051. 
  















FIGURE S3.5. Maternal zinc deficiency resulted in differential gene 
expression of a number of cytokines specific for certain T cell populations 
in the spleens at GD18.5. A decrease in Fas ligand (Fasl) (A) and an increase 
in interleukin 10 (IL10) expression (B) was observed in the spleens of the 
zinc-deficient dams. There was also a trend for an increase in the expression 
of interferon alpha 1 (Ifna1). Date are median ± interquartile range (n = 10 
zinc-replete and 7 zinc-deficient dams). Statistical significance was 
determined using Mann-Whitney Test. *P˂0.05, #P = 0.07.  















FIGURE S3.6. Full length western blot image of placental Tfrc expression. Tfrc 
protein band was observed at ~100kD whilst the corresponding β-actin band was 
observed at ~48kD 














TABLE S3.1. Differences in elemental compositions of maternal plasma, 
placental tissue and fetal tissue 
Element Plasma 
Content 

















40.1] vs. 41.90 
[34.4-51.6]* 
2287.46 [1683.7-
























18] vs. 19.61 
[18.6-22.4]** 
2148.78 [1655.7-














3023.9] vs. 3024.66 
[1874.7-3734.8]NS 
2233.05 [2022.5-
















Data are presented as median [interquartile range]. n = 10 zinc-replete and 7 zinc-
deficient dams and n= 19 and 13 placentas and fetuses from zinc-replete and zinc-
deficient dams, respectively. Statistical significance was determined using a Mann-
Whitney test. *P˂0.05, **P˂0.01 NS, not significant. 
 
  














TABLE S3.2. Elemental composition of the zinc-replete and zinc-deficient 
diets as determined by mass spectrometry 





Iron (mg/kg) 41 ± 7.3 35 ± 3.3 NS 
Manganese (mg/kg) 10 ± 1.7 17 ± 13.7 NS 
Copper (mg/kg) 8 ± 0.2 5 ± 1.2 P˂0.05 
Zinc (mg/kg) 39 ± 0.3 11 ± 1.3 P˂0.001 
Calcium (mg/kg) 6500 ± 141.4 6133 ± 115.5 NS 
Magnesium (mg/kg) 715 ± 7.1 660 ± 26.5 NS 
Sodium (mg/kg) 1850 ± 14.1 1963 ± 63.5 NS 
Potassium (mg/kg) 4700 ±141.4 7267 ± 321.5 P˂0.01 
Phosphorus (mg/kg) 2300 ± 141.4 3600 ± 200.0 P˂0.01 
Sulphur (mg/kg) 3400 ± 0 3733 ± 152.8 NS 
Aluminium (mg/kg) 4 ± 0.9 7 ± 0.2 NS 
Elemental analysis of the diet composition was performed on two independent samples 
of zinc-replete chow and three independent samples of zinc-deficient chow and 
analysed by inductively-coupled plasma atomic emission spectrometry. Data are mean 
± standard deviation. Statistical significance was determined using a two-tailed T-test, 
assuming unequal variances. NS, not significant 
 














TABLE S3.3. Genes differentially expressed between zinc-replete and zinc 
deficient placentas 





P value FDR 
Transferrin Receptor (Tfrc) 8.59 ↑ 8.77E-06 0.112 
Sclerostin domain containing 1 (Sostdc1) 2.70 ↑ 4.10E-05 0.182 
Elongation of very long chain fatty acids-like 4 
(Elovl4) 
2.57 ↑ 4.70E-05 0.182 
Interferon-related developmental regulator 1 
(Ifrd1) 
1.69 ↓ 6.95E-05 0.182 
RIKEN cDNA 1700023L04 (1700023L04Rik) 2.40 ↓ 7.13E-05 0.182 
WD repeat domain 60 (Wdr60) 1.67 ↓ 1.09E-04 0.231 
TSC22 domain family, member 3 (Tsc22d3) 1.74 ↓ 1.27E-04 0.232 
Glutamate receptor interacting protein 1 
(Grip1) 
2.21 ↓ 1.67E-04 0.266 
Catsper channel auxiliary subunit delta 
(Catsperd) 
2.80 ↓ 2.29E-04 0.324 
 
  














TABLE S3.4. Effect of zinc deficiency on renal expression of seven genes at 
GD18.5 as quantified by qPCR 
Gene Normalised Expression (zinc-




Ace 1.15 [1.04-1.75] vs. 0.97 [0.65-1.30] ↓16% 0.031 
Actg2 0.26 [0.14-0.52] vs. 0.68 [0.43-1.08] ↑162% 0.011 
Aldh3a2 1.36 [1.18-1.50] vs. 1.11 [1.01-1.32] ↓18% 0.031 
Braf 1.46 [1.28-1.74] vs. 1.07 [1.03-1.31] ↓27% 0.005 
Calcoco1 1.57 [1.26-1.71] vs. 1.01 [0.85-1.09] ↓36% 0.002 
Cbx7 1.45 [1.28-1.74] vs. 1.03 [0.76-1.17] ↓29% 0.003 
Itpr2 1.03 [0.77-1.37] vs. 0.58 [0.55-1.03] ↓44% 0.05 
Data represented as median [IQR]. Gene expression was normalised to TbP and Gapdh.  n = 9 
and 7 kidneys from zinc-replete and zinc-deficient dams, respectively. Statistical significance 
was determined using a Mann-Whitney test. 
  














TABLE S3.5. Antibodies and dilutions used for immunohistochemistry and 
western blots 







Vimentin Dako Monoclonal 
Mouse 







AE1/AE3 1/100 Yes, 
Pronase 
 
ACE Santa Cruz Polyclonal 
Rabbit 




















8-OHdG JaICa Monoclonal 
Mouse 







SOD1 1/2000 Yes, 
Citrate 
 
HSP-90 Santa Cruz Polyclonal 
Rabbit 
H-114   1/2000 
β-actin Santa Cruz Polyclonal 
Rabbit 
   1/1000 
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ABSTRACT 
Maternal micronutrient deficiencies in pregnancy can have profound 
effects on fetal development and pregnancy outcome. Plasma trace 
minerals including copper, zinc, selenium and iron have been shown 
to be extremely important in supporting reproduction. We sought to 
determine whether there is an association between maternal trace 
mineral status in early pregnancy and pregnancy complications using 
a prospective cohort study of 1065 pregnant Australian women who 
were recruited as part of the Screening for Pregnancy Endpoints 
(SCOPE) study in Adelaide. Copper, zinc, selenium and iron present 
in the plasma were measured using mass spectrometry in samples 
collected at 15±1 weeks’ gestation. After adjusting for covariates, 
women with lower plasma copper (<27.9 µmol/L and 27.9-32.5 
µmol/L) had decreased risk for any pregnancy complication when 
compared with women with high plasma copper (>32.5 µmol/L) (aRR 
= 0.87; 95% CI = 0.76, 0.99 and aRR = 0.88; 95% CI = 0.78, 1.00, 














respectively). This was also observed when adjusting for plasma zinc 
and selenium status (aRR = 0.86; 95% CI = 0.74, 1.00). Combined low 
copper and zinc status was also associated with a reduced risk of any 
pregnancy complication as compared with high copper and zinc 
status (aRR = 0.80; 95% CI = 0.70, 0.93). These results provide 
justification for further work into elucidating the mechanistic role of 
trace elements in early pregnancy, as well as their interactions in 
supporting successful pregnancy outcomes. 
 
4.1 Introduction 
Maternal nutrient stores and diet supply all the macro- and micro-nutrients to 
support optimal fetal growth essential for successful pregnancy [1]. Hence, it is 
not surprising that maternal deficiencies in key micronutrients can have 
profound effects on fetal development and pregnancy outcome [2]. Pregnancy 
complications including preeclampsia (PE), gestational diabetes mellitus (GDM), 
spontaneous preterm birth (sPTB) and fetal growth restriction (FGR) together 
affect 25% of first pregnancies and predict lifelong morbidity and mortality for 
both the mother and infant [3]. Furthermore, micronutrient deficiencies which 
tend to be associated with decreased consumption of foods rich in 
micronutrients, have also been associated with the development of PE, GDM, 
sPTB, FGR, as well as gestational hypertension (GH) [2]. 
Extensive investigations into micronutrient deficiencies have focused on 
those common within pregnant populations including folate and vitamin D [4]. 
However, evidence is emerging about the importance of trace minerals like iron, 
zinc and copper in supporting successful pregnancy [5]. It is known that trace 
minerals are crucial for the maintenance of cell proliferation and function with 
severe deficiencies in copper and zinc during pregnancy having been shown to 
have a teratogenic effect on the fetus [6]. This is likely driven by a reduction in 
the activity of key enzymes which require these metals structurally in order to 
function, as well as compromised oxidant defence systems [6]. It is also important 














to acknowledge the importance of micronutrients in mediating inflammation and 
the immune response. Animal models of iron, copper and zinc deficiencies have 
been shown to be associated with compromised immunity and increased 
susceptibility to infection [7]. Pregnancy complications including PE and FGR 
have been associated with increased oxidative stress and circulating markers of 
inflammation [8, 9] and therefore there may be a causal connection between 
micronutrient deficiencies in pregnancy and the development of pregnancy 
complications mediated by oxidative stress and inflammation. 
The association between trace minerals and pregnancy have been 
described previously [10-17], however many of these studies have been 
conducted in late pregnancy or at term. Given that many of these pregnancy 
complications originate in early gestation, it is important to also understand how 
micronutrient status in the first trimester is associated with adverse pregnancy 
outcomes. Marginal micronutrient deficiencies early in pregnancy may lead to 
more severe deficiencies later in pregnancy due to increased metabolic demands 
from the rapidly growing placenta and fetus. Thus we aimed to determine 
whether deficiencies in the trace minerals copper, zinc, selenium and iron at 15±1 
weeks’ gestation may be associated with a number of pregnancy complications. 
As copper and zinc share similar electro-chemical properties and biological 
pathways [18], we also explored interactions between zinc and copper status in 
early pregnancy and their relationship with adverse pregnancy outcomes with 
the goal of better understanding how these minerals may be important to 
successful pregnancy. 
4.2 Methods 
4.2.1 Study Participants 
Plasma samples were obtained from Adelaide participants recruited as part of 
the international prospective Screening for Pregnancy Endpoints (SCOPE) study. 
Nulliparous women carrying a singleton pregnancy were recruited at 15±1 














weeks’ gestation from the Lyell McEwin Hospital, Adelaide, Australia between 
November 2004 and September 2008. Ethics approval was gained from the 
University of Adelaide ethics committee and all women provided written 
consent (approval no: REC 1712/5/2008). At recruitment, women were 
interviewed by a research midwife and asked questions on maternal 
demographics and had physical measurements recorded. These included age, 
body mass index (BMI) and smoking status [19]. Biochemical markers were also 
measured at 15±1 weeks’ gestation and included plasma C-reactive protein (CRP) 
[20]. Women were not eligible to participate in the study if they suffered from a 
pre-existing medical condition or had obstetric history which placed them at high 
risk of developing PE, sPTB or delivering a small-for-gestational age (SGA) 
infant. Those who had suffered three or more miscarriages or had undergone 
three or more pregnancy terminations were also excluded. 
Uncomplicated pregnancies were defined as those without any pregnancy 
disorder and included normotensive women who delivered an appropriate 
weight for gestational age infant at term (≥37 weeks’ gestation) [21]. GH was 
diagnosed as the development of high blood pressure (systolic blood press ≥140 
mmHg and/or diastolic blood pressure ≥90 mmHg) on at least two occasions after 
20 weeks’ gestation. PE was defined as GH in conjunction with proteinuria (24 h 
urinary protein ≥300 mg or a spot urine protein:creatinine ratio ≥30 mg/mmol 
creatinine or urine dipstick protein ≥2) or any multisystem complication of PE or 
uteroplacental dysfunction [22]. GDM was diagnosed according to the 
International Associations of Diabetes and Pregnancy Study Groups criteria [23]. 
sPTB was defined as the spontaneous onset of labour at <37 weeks’ gestation. 
SGA was defined as birth weight below the 10th customised centile adjusted for 


















4.2.2 Elemental Analysis 
Venous blood samples were provided at 15±1 weeks’ gestation and collected into 
heparinised tubes in order to obtain plasma samples. Plasma samples were then 
analysed using inductively-coupled plasma mass spectrometry (ICP-MS) 
(Agilent 7700 ICP-MS) (Agilent 5100 ICP-OES; CSIRO Analytical Services, South 
Australia) to measure the concentrations of copper, selenium, iron and zinc. Prior 
to analysis, 250 µL of plasma was digested in concentrated nitric acid (~70% 
HNO3) in sealed Teflon containers for approximately 48 hours and then diluted. 
Samples were run alongside two internal standards: iridium and rhodium (Choice 
Analytical) at a concentration of 200 ppb and an 8-point calibration, including 
blank, was carried out between 0.01 µg/L and 100 µg/L. There were 47 (4.4%) 
women with plasma iron levels below the detection limit of 7.16 µmol/L and were 
therefore assigned 7.15 µmol/L. 
 
4.2.3 Statistical Analysis 
All statistical analysis was performed in R (v3.1.1) [24]. Baseline characteristics 
were tested for normality using the Shapiro-Wilk test and summarised according 
to pregnancy outcome. Fisher’s exact tests were performed for categorical 
variables and Welch’s t test for continuous variables comparing women with 
each pregnancy complication to all other women. Plasma copper, zinc, selenium 
and iron were expressed as mean (± standard deviation: SD) and compared 
between each pregnancy complication and all women using a non-parametric 
Mann-Whitney U. Spearman’s correlations were used to examine the 
relationship between each of the trace minerals with each other, as well as with 
circulating CRP; a marker of inflammation. 
In order to assess the effects of each trace mineral on pregnancy outcome, 
plasma copper, zinc, selenium and iron were divided into tertiles based on their 
distribution amongst all women in this study. Relative risks (RR) and 95% 
confidence intervals (CIs) of pregnancy complications from any complication, 














PE, GH, GDM, sPTB and SGA for copper, zinc, selenium and iron were examined 
using multivariable Poisson regression with robust variance estimation. 
Multivariable adjustment was made for maternal age, maternal BMI and 
smoking status at 15±1 weeks’ gestation (yes compared to no) as covariates. 
Maternal socioeconomic status, determined by assigning the New Zealand 
socioeconomic index score (SEI) [25], was initially included in the adjusted model 
but did not change any effects observed and was subsequently removed in the 
final analyses. The final analyses were also repeated for copper, zinc and 
selenium adjusting for each other as well as covariates previously mentioned. 
4.3 Results 
Of the 1164 SCOPE women recruited in Adelaide, 1065 (91%) plasma samples 
from 15±1 weeks’ gestation were available for analysis of trace minerals. These 
included 558 (52%) women whose pregnancies were uncomplicated, 85 (8%) who 
later developed PE, 108 (10%) who were diagnosed with GH, 51 (5%) who were 
diagnosed with GDM, 65 (6%) who delivered spontaneously preterm and 134 
(13%) who delivered an SGA infant. Mean maternal age and BMI for all women 
whose plasma was analysed was 24±5 years and 27.01±6.52 kg/m2 (Table 4.1). 
Compared to those whose pregnancies were uncomplicated, women who went 
on to have a pregnancy complication had a higher BMI in early pregnancy but 
there was no difference in maternal age, smoking status or use of supplements at 
15±1 weeks’ gestation. 
Plasma trace minerals in all women ranged from 10.3 to 52.99 µmol/L for 
copper, 3.24 to 34.70 µmol/L for zinc, 0.253 to 1.785 µmol/L for selenium and 7.14 
to 72.60 μg/L for iron. Mean plasma copper at 15±1 weeks’ gestation was higher 
in women who went onto have a pregnancy complication when compared to 
those whose pregnancies remained uncomplicated (Table 4.1; P<0.001). Moderate 
differences in circulating levels of zinc, selenium and iron were also observed in 














the women who later developed a pregnancy complication compared to those 
who did not (Table 4.1). 
TABLE 4.1 Participant characteristics of the Adelaide SCOPE cohort in which plasma 
trace minerals were measured at 15±1 weeks’ gestation. 
 
All 
(n = 1065) 
Uncomplicated 
(n = 558) 
Complicated 
(n = 507) 
P 
value 
Age yrs, mean (SD) 23.71 (5) 23.59 (5) 23.85 (5) 0.399 
[range] [14-43] [14-40] [15-43]  
BMI kg/m2, mean (SD) 27.01 (6.52) 26.30 (5.86) 27.77 (7.12) 0.000 
[range] [16.2-58.5] [16.2-49.7] [16.4-58.5]  
Smoking status, n (%)    0.063 
No 651 (61) 352 (54) 299 (46)  
Quit 152 (14) 85 (56) 67 (47)  
Smoking 262 (25) 121 (46) 141 (54)  
Education, n (%)    0.410 
No Secondary 422 (40) 211 (50) 211 (50)  
Secondary 608 (57) 327 (54) 381 (46)  
Tertiary 35 (3) 20 (57) 15 (43)  
Supplement Use, n (%)    0.535 
No 105 (10) 51 (49) 53 (51)  
Yes 960 (90) 506 (53) 454 (47)  
Plasma Cu µmol/L, mean (SD) 30.30 (5.49) 29.61 (5.18) 31.07 (5.72) 0.000 
[range] [10.30-52.99] [14.76-47.73] [10.30-52.99]  
Plasma Zn µmol/L, mean (SD) 9.39 (2.32) 9.28 (2.11) 9.51 (2.52) 0.077 
[range] [3.24-34.70] [4.83-21.36] [3.24-34.70]  
Plasma Se µmol/L, mean (SD) 0.919 (0.151) 71.96 (11.06) 73.36 (12.74) 0.055 
[range] [0.253-1.785] [0.544-1.380] [0.253-1.785]  
Plasma Fe µmol/L, mean (SD) 19.06 (7.77) 19.49 (7.90) 18.61 (7.61) 0.053 
[range] [7.14-72.60] [7.14-71.06] [7.14-72.60]  
Supplement use was defined as using any form of mineral or vitamin supplement at 15±1 
weeks’ gestation. 
P values for continuous variables were determined using Welch t-test, categorical variables 
a Fisher’s exact test and plasma trace elements a Mann-Witney U test comparing women 
with a pregnancy complication to those whose pregnancies remained uncomplicated. BMI: 
body mass index; Cu: Copper; Zn: Zinc; Se: Selenium; Fe: Iron 
 
 
Circulating copper was positively correlated with both zinc (Supplementary Fig. 
S4.1A; R2=0.263) and selenium (Supplementary Fig. S4.1B; R2=0.303) but 
negatively correlated with iron (Supplementary Fig. S4.1C; R2=-0.156). Iron on the 
other hand, was positively correlated with zinc (Supplementary Fig. S4.1E; 
R2=0.107) and selenium (Supplementary Fig. S4.1F; R2=0.204). 
 















FIGURE 4.4. Spearman’s correlations between plasma trace minerals at 15±1 weeks’ 
gestation and serum CRP at 15±1 weeks’ gestation. A significant positive correlation was 
seen between plasma copper and CRP (A), whilst significant negative correlations were 
observed between plasma zinc (B) and plasma iron (D) with CRP. No correlation was 
found between plasma selenium and CRP (C). 
A significant positive correlation between plasma copper and plasma CRP 
was observed at 15±1 weeks’ gestation (Fig. 4.1A: R2= 0.423, P<0.001) while there 
was an inverse, albeit not as strong, correlation between plasma zinc and plasma 
iron and CRP (Fig. 4.1B: R2=-0.066, P=0.048 and Fig. 4.1D R2= -0.274, P<0.001, 
respectively). When BMI was categorised as underweight (≤20 kg/m2), normal 
weight (20.1-24.9 kg/m2), overweight (25-29.9 kg/m2) and obese (≥30 kg/m2), 
compared with normal weight women, plasma zinc, selenium and iron was 
lower in the obese women (Fig. 4.2). Plasma copper on the other hand was 
significantly higher in the obese women when compared to underweight, normal 
weight and overweight women (Fig. 4.2). 















FIGURE 4.5. Relationship between plasma trace minerals at 15±1 weeks’ gestation and 
maternal body mass index (BMI). Compared with normal weight (BMI 20.1-24.9) 
women, plasma copper was lower in lean (BMI≤20) women, higher in obese (BMI≥30) 
and no different in overweight (BMI 25-29.9) (A). Plasma zinc (B), plasma selenium (C) 
and plasma iron also did not change between normal weight and overweight women, 
however, were significantly lower in the obese women when compared to normal 
weight women. Box plots represent median: 10th-90th centile. Groups compared using a 
Dunn’s test with a Bonferroni post-hoc test. 
The adjusted relative risks (aRR) for each pregnancy complication with 
plasma copper, zinc, selenium and iron categories based on population tertiles 
are shown in Table 4.2. Women with lower plasma copper (1st and 2nd tertile) 
had decreased risk for any pregnancy complication combined compared with 
women with high plasma copper (3rd tertile) (aRR = 0.77; 95% CI = 0.66, 0.91 and 
aRR = 0.81; 95% CI = 0.70, 0.95, respectively). When the pregnancy complications 
were separated, this protective effect of low plasma copper was seen in all but 
GH however, these were not statistically significant. Women with lower plasma 
zinc and selenium (1st tertile) also had decreased risk of any pregnancy 














complication when compared to high plasma zinc and plasma selenium (aRR = 
0.86; 95% CI = 0.74, 1.00 and aRR: 0.84; 95% CI = 0.73, 0.96, respectively). Given 
that the strongest effect was observed with plasma copper, we sought to assess 
whether an association between plasma copper status at 15±1 weeks’ gestation 
was still observed after adjust for plasma zinc and plasma selenium 
(Supplementary Table S4.1). A significant decreased risk for any complication 
was observed in women within the first and second tertile of plasma copper 
when compared to women in the third tertile indicating a relationship 
independent of plasma zinc or selenium status (aRR = 0.81; 95% CI = 0.69, 0.61 
and aRR = 0.84; 95% CI = 0.72, 0.98, respectively). There was no significant effect 
of maternal iron status in early pregnancy on developing any pregnancy 
complication. However, women with plasma iron in the 1st and 2nd tertile were 
at increased risk of GH when compared to women in the 3rd tertile (aRR = 1.78; 
95% CI = 1.05, 3.02 and aRR = 1.87; 95% CI = 1.12, 3.11, respectively). 
A sensitivity analysis was performed on the relationship between plasma 
copper and CRP in order to determine the relationship between copper, 
inflammation and pregnancy outcome. Serum CRP measured at 15±1 weeks’ 
gestation was used as an indirect marker of inflammation. Women with CRP 
≥20.3 ng/mL were excluded as normal circulating CRP ranges between 0.4 to 20.3 
ng/mL [26] and levels higher than 20 ng/mL are often associated with infection. 
Supplementary Table 2 shows the effects of plasma copper status in all (n = 1065) 
women as well as those with CRP <20.3 ng/mL (n = 717). The point estimates for 
the effects for lower plasma copper in the women whose CRP was <20.3 ng/mL 
was similar to those for all women (1st tertile: all women = 0.77 vs. women with 
CRP <20.3 ng/mL = 0.74 & 2nd tertile: all women = 0.81 vs. women with CRP <20.3 
ng/mL = 0.78) indicating the possibility that the effects of plasma copper status in 
this study were likely to be independent of inflammation. 
 Given that copper and zinc share similar electro-chemical properties and 
biological pathways [18], the interactions between these two trace minerals was 














analysed in relation to pregnancy complications (Table 4.3). Combined low zinc 
status (1st tertile) and low copper status (1st tertile) was associated with a 
reduced risk of any pregnancy complications  compared with high zinc status 
and high copper status (2nd and 3rd tertile combined for both trace 
minerals)(aRR = 0.72; 95% CI = 0.62, 0.85). Similarly, combined low copper and 
high zinc was also associated with reduced risk of any pregnancy complication 
when compared to combined high zinc and high copper (aRR = 0.76; 95% CI = 
0.62, 0.94) suggesting copper status is a more important determinant of 
pregnancy outcome. When each pregnancy complication was analysed 
separately, a similar protective effect of combined low copper and low zinc was 
seen in PE, GDM, sPTB and SGA. For SGA, this was statistically significant (aRR 
= 0.62; 95% CI = 0.41, 0.94). For GDM, combined low copper and high zinc, as well 
as high copper and low zinc, also appeared to increase the risk when compared 
to combined high copper and high zinc although, these were not statistically 
significant (aRR = 1.46; 95% CI = 0.57, 3.69 and RR = 1.78; 95% CI = 0.77, 4.10, 
respectively). 
4.4 Discussion 
In this study, we have comprehensively assessed plasma trace minerals in early 
pregnancy and their association with multiple pregnancy complications. 
Contrary to previous observations of the negative impacts of poor trace element 
status on pregnancy outcome, we observed a protective effect of lower levels of 
plasma copper, zinc and selenium at the beginning of pregnancy on the risk of 
any pregnancy complication. However, this relationship is highly likely to be 
driven by copper status rather than zinc or selenium as plasma copper was found 
to be associated with adverse pregnancy outcome after adjusting for plasma zinc 
and selenium. This provides justification for further work into elucidating the 
role of copper in pregnancy, and the interaction with other trace elements, 





























TABLE 4.2. Adjusted relative risks of pregnancy complications from all complications, preeclampsia (PE), gestational hypertension (GH), 
gestational diabetes mellitus (GDM), spontaneous preterm birth (sPTB) and small-for-gestational age (SGA) according to plasma levels of trace 
minerals categorised based on population tertiles 
  Pregnancy Complication 
 All 
women Any Complication PE GH GDM sPTB SGA 



















<27.9 µmol/L 360 150 (42) 
0.77 
(0.66, 0.91) 21 (6) 
0.71 
(0.42, 1.18) 33 (9) 
1.11 
(0.71, 1.75) 13 (4) 
0.69 
(0.35, 1.37) 20 (6) 
0.62 























>32.5 µmol/L 356 201 (56) 1.0† 37 (10) 1.0† 39 (11) 1.0† 25 (7) 1.0† 29 (8) 1.0† 51 (14) 1.0† 
Zinc 
<8.3 µmol/L 
357 160 (45) 
0.86 
(0.74, 1.00) 26 (7) 
0.80 
(0.48, 1.32) 42 (12) 
1.01 
(0.66, 1.56) 15 (4) 
0.82 
(0.43, 1.55) 15 (4) 
0.85 
(0.47, 1.52) 42 (12) 
0.75 
(0.52, 1.08) 


















>9.9 µmol/L 356 182 (51) 1.0† 30 (8) 1.0† 34 (10) 1.0† 22 (6) 1.0† 23 (6) 1.0† 56 (16) 1.0† 
Selenium 
<0.9 µmol/L 449 203 (45) 
0.84 
(0.73, 0.96) 33 (7) 
0.72 
(0.45, 1.18) 49 (11) 
0.94 
(0.62, 1.42) 19 (4) 
1.08 
(0.55, 2.15) 25 (6) 
0.76 























>1.0 µmol/L 417 221 (53) 1.0† 37 (9) 1.0† 43 (10) 1.0† 21 (5) 1.0† 31 (7) 1.0† 60 (14) 1.0† 
Iron 
<15.6 µmol/L 356 180 (51) 
1.08 
(0.92, 1.27) 31 (9) 
0.81 
(0.49, 1.35) 47 (13) 
1.78 
(1.05, 3.02) 19 (5) 
1.16 
(0.53, 2.56) 24 (7) 
1.11 























>21.2 µmol/L 355 155 (44) 1.0† 28 (8) 1.0† 20 (6) 1.0† 12 (3) 1.0† 23 (6) 1.0† 37 (10) 1.0† 






























TABLE 2.3. Adjusted relative risks (aRR) of pregnancy complications from all complications, preeclampsia (PE), gestational hypertension (GH), 
gestational diabetes mellitus (GDM), spontaneous preterm birth (sPTB) and small-for-gestational age (SGA) based on stratification by combined 
plasma copper and plasma zinc concentrations 
  Pregnancy complication 
 
All 
women Any Complications PE GH GDM sPTB SGA 






















































































































Low Copper (Cu) ≤32.5 µmol/L (1st and 2nd tertile combined), High Copper >32.5 µmol/L (3rd tertile) , Low Zinc (Zn) ≤9.91 µmol/L (1st and 2nd tertile combined), High Zinc 
>9.91 µmol/L (3rd tertile) 
*Adjusted relative risks were adjusted for age, maternal body mass index and smoking status at 15±1 weeks' gestation (no versus yes). 
†Reference category 
 













Trace elements like copper, zinc and selenium are integral to supporting 
cellular and tissue physiology [27]. Indeed, animal models of copper, zinc and 
selenium deficiency in pregnancy consistently show negative effects on fertility, 
fetal growth and offspring health and wellbeing [28-32]. Copper status in 
pregnancy has been infrequently reported in the literature and has focused 
predominantly on copper deficiency as adequate supply of copper during 
pregnancy is necessary for early embryonic development [33]. Circulating levels 
of copper increase during pregnancy due to the increase in copper-carrying 
proteins in the blood mediated by estrogen [34, 35]. Furthermore, in this 
population, circulating plasma copper was similar to pregnancy reference ranges 
(10-90th centile: 26.4 to 33.8 µmol/L) and to those reported in other populations 
of pregnant women [26, 34, 36-38]. Thus, our findings of higher copper in early 
pregnancy in women who subsequently develop a pregnancy complication, 
which are similar to other studies that have measured copper concentrations in 
late pregnancy [15-17], suggest higher levels of circulating copper may contribute 
to adverse pregnancy outcomes. 
Of the three trace minerals, zinc in pregnancy has been most widely 
studied. In human populations, zinc deficiency in pregnancy may be associated 
with delivery of a low birthweight infant as well as with hypertensive disorders 
of pregnancy, particularly in populations of women vulnerable to inadequate 
zinc intakes in pregnancy [39]. However, inconsistencies between the studies on 
the effect of zinc deficiency in pregnancy reflects real uncertainty within the 
literature. Furthermore, the evidence with respect to the relationship between 
selenium status and adverse pregnancy outcomes has not clearly been 
established [40]. Never-the-less, our findings that lower levels of zinc and 
selenium at 15±1 weeks’ gestation is associated with a protective effect on 
pregnancy outcome is in conflict with current dogma that deficiencies in these 
nutrients are detrimental to pregnancy health. However, given that both plasma 
zinc and selenium positively correlated with plasma copper, and the protective 













effect of lower plasma copper persisted once plasma zinc and selenium were 
adjusted for, implicates plasma copper status as the main contributor to adverse 
pregnancy outcomes in this study. This is further supported by the finding on 
combined copper and zinc status as whilst combined low copper and low zinc 
was associated with reducing the risk of all pregnancy complications, 
equivalently, low copper and high zinc also appeared to reduce the risk. 
The greatest effect observed in this study was in the association between 
lower plasma copper in early pregnancy and the development of any pregnancy 
complication. This suggests a role for this trace mineral either within the causal 
pathway of, or as an early pregnancy biomarker for, adverse pregnancy 
outcomes. PE, GDM, sPTB and SGA are all often associated with placental 
dysfunction [41]. Pregnancies complicated by placental dysfunction can be 
characterised by impaired trophoblast invasion and transformation of the uterine 
spiral arteries resulting in inadequate uteroplacental blood flow or compromised 
fetal placental vasculature development [42]. It is still unclear as to what causes 
the initial failure of the placenta to form correctly. However, it is likely to be a 
combination of both genetic and environmental factors with increased oxidative 
and cellular stress, as well as inflammatory mediators, thought to be key [43]. 
Elevated free copper can be a source of oxidative stress [44] and thus, it is possible 
that elevated copper may be a potential contributor to increased oxidative stress 
in the placenta, particularly in early pregnancy. 
 Another potential hypothesis is that early pregnancy copper status may 
be a biomarker for an increased inflammatory response which itself predisposes 
women to developing a pregnancy complication. Pregnancy itself is considered 
a pro-inflammatory state, particularly during the peri-implantation period [45]. 
However, even in pregnancy, the inflammation response is tightly regulated and 
slight deviations can result in compromised tissue function. Indeed, 
inflammation, as well as obesity which induces persistent low-grade 
inflammation, are associated with increasing the risk of a number of pregnancy 













complications like PE and GDM [46-49]. However, we observed a protective 
effect of lower copper concentrations on the risk of pregnancy complications after 
adjusting for BMI. Furthermore, in the sensitivity analysis, in which all women 
with a possible infection or exacerbated inflammatory response were excluded, 
very little change to the point estimates for risk of a pregnancy complication with 
copper levels in the first and second tertiles compared to the third tertile was 
found suggesting plasma copper is not necessarily just a biomarker for 
inflammation. 
 The overall aim of this study was to determine whether early pregnancy 
plasma trace mineral status was associated with pregnancy complications. 
Despite the tight biological regulation of these minerals in the circulation [50], 
lower levels of plasma copper, zinc and selenium may be protective against a 
number of the major pregnancy complications assessed. However, there are a 
number of limitations, most notably lack of high quality dietary intake data, 
which may have implications for the results of this study. Plasma and serum 
measures are not generally considered accurate determinants of nutrient status 
[51] and non-fasting blood samples were collected which is also likely to have an 
effect on short-term mineral status. Although, it is possible that higher circulating 
levels of these trace elements represent reduced bioavailability within cells, 
where the minerals are required. Hence, it is conceivable that lower circulating 
levels of copper, zinc and selenium may be associated with a reduced risk of 
pregnancy complications as more of the trace elements are being utilised with 
tissues where required. Furthermore, given the lack of suitable alternatives in 
which to determine women’s nutritional status in this pregnancy cohort, 
measuring plasma minerals may still be informative in understanding the 
physiology of pregnancy and pregnancy complications. 
 In conclusion, we observed a very clear association between plasma 
copper concentrations in early pregnancy and the risk of pregnancy 
complications that warrants further investigation particularly within the context 













of other trace element status. It is conceivable that elevated plasma copper status 
at the beginning of pregnancy may simply be a biomarker of inflammation which 
may underlie the development of a particular pregnancy complication. However, 
our data suggest it is more likely to have a mechanistic role, potentially in the 
placenta through oxidative stress or inflammatory pathways that warrants 
further investigation. Much could be gained if we expand our understanding of 
maternal nutrition in pregnancy to incorporate simultaneous mechanistic and 
epidemiological studies, particularly on multiple micronutrients and their 
interactions in order to fully elucidate the importance of these factors in 
pregnancy success. 
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SUPPLEMENTARY FIGURE S4.1. Correlations between each of the plasma trace 
minerals at 15±1 weeks’ gestation. Positive correlations were found between copper, zinc 
and selenium (A,B and D). Iron on the other hand was negatively correlated with copper 





























SUPPLEMENTARY TABLE S4.1. Adjusted relative risks of pregnancy complications from all complications, preeclampsia (PE), gestational 
hypertension (GH), gestational diabetes mellitus (GDM), spontaeous preterm birth (sPTB) and small-for-gestational age (SGA) according to 
plasma levels of copper, zinc and selenium categorised based on population tertiles. 
  Pregnancy Complications 
 All 
women Any Complication PE GH GDM sPTB SGA 



















<27.9 µmol/L 360 150 (42) 
0.81 
(0.69, 0.96) 21 (6) 
0.72 
(0.43, 1.23) 33 (9) 
1.10 
(0.69, 1.77) 13 (4) 
0.69 
(0.32, 1.48) 20 (6) 
0.72 























>32.5 µmol/L 356 201 (56) 1.0† 37 (10) 1.0† 39 (11) 1.0† 25 (7) 1.0† 29 (8) 1.0† 51 (14) 1.0† 
Zinc** 
<8.3 µmol/L 357 160 (45) 
0.95 
(0.80, 1.11) 26 (7) 
0.85 
(0.48, 1.50) 42 (12) 
1.02 
(0.66, 1.60) 15 (4) 
0.98 
(0.48, 2.00) 15 (4) 
1.00 























>9.9 µmol/L 356 182 (51) 1.0† 30 (8) 1.0† 34 (10) 1.0† 22 (6) 1.0† 23 (6) 1.0† 56 (16) 1.0† 
Selenium*** 
<0.9 µmol/L 449 203 (45) 
0.94 
(0.80, 1.10) 33 (7) 
0.74 
(0.44, 1.24) 49 (11) 
0.91 
(0.59, 1.39) 19 (4) 
 
1.45 
(0.68, 3.10) 25 (6) 
0.90 























>1.0 µmol/L 417 221 (53) 1.0† 37 (9) 1.0† 43 (10) 1.0† 21 (5) 1.0† 31 (7) 1.0† 60 (14) 1.0† 
*Adjusted relative risks compared to all women were adjusted for age, maternal body mass index, smoking status at 15±1 weeks' gestation (no versus yes) and plasma zinc 
and selenium at 15±1 weeks’ gestation. 
** Adjusted relative risks compared to all women were adjusted for age, maternal body mass index, smoking status at 15±1 weeks' gestation (no versus yes) and plasma copper 
and selenium at 15±1 weeks’ gestation. 
***Adjusted relative risks compared to all women were adjusted for age, maternal body mass index, smoking status at 15±1 weeks' gestation (no versus yes) and plasma copper 































SUPPLEMENTARY TABLE S4.2. Sensitivity analysis to determine the relationship between plasma copper and inflammation where by 
women with serum C-reactive protein (CRP) levels ≥20 mg/L were excluded and then relative risks of pregnancy complications from all 
complications, preeclampsia (PE), gestational hypertension (GH), gestational diabetes mellitus (GDM), spontaeous preterm birth (sPTB) and 
small-for-gestational age (SGA). 
   Pregnancy Complications 
  All women All Complications PE GH GDM sPTB SGA 
 


















All Women              
Copper              
<27.9 µmol/L 























27.9 -32.5 µmol/L 























>32.5 µmol/L 356 
















CRP <20.3 ng/mL              
Copper              
<27.9 µmol/L 





















27.9 -32.5 µmol/L 





















>32.5 µmol/L 174 
















*Adjusted relative risks compared to all women were adjusted for age, maternal body mass index and smoking status at 15±1 weeks' gestation (no versus yes). 
†Reference category 
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ABSTRACT 
Background: Pregnant women are at increased susceptibility to 
vitamin D deficiency. Hence, there is continuing interest in 
determining how vitamin D influences pregnancy health. We aimed 
to compare vitamin D status in two distinct populations of pregnant 
women in Australia and New Zealand and to investigate the 
relationship between vitamin D status and pregnancy outcome. This 
included evaluating possible effect measure modifications according 
to fetal sex. 
Methods: Serum 25-hydroxy vitamin D (25(OH)D) was measured at 
15±1 weeks’ gestation in 2800 women from Adelaide and Auckland 
who participated in the multi-centre, prospective cohort SCreening 
fOr Pregnancy Endpoints (SCOPE) study.  














Results: Mean serum 25(OH)D in all women was 68.1 ± 27.1 nmol/L 
and 28% (n = 772) were considered vitamin D deficient (<50 nmol/L). 
Serum 25(OH)D was lower in the women recruited in Adelaide when 
compared to the women recruited in Auckland and remained lower 
after adjusting for covariates including maternal body mass index and 
socioeconomic index (Adelaide: 58.4 ± 50.3 vs. Auckland: 70.2 ± 54.5 
nmol/L, P<0.001). A 53% decreased risk for gestational diabetes 
mellitus (GDM) was observed with high (>81 nmol/L) “standardised” 
vitamin D status when compared to moderate-high (63-81 nmol/L, 
aRR: 0.47; 95% CI: 0.23, 0.96). Marginal sex-specific differences 
occurred between vitamin D status and GD: women carrying a female 
fetus had a 56% decreased risk for GDM in those with low-moderate 
levels of standardised vitamin D (44-63 nmol/L) compared to 
moderate-high levels (aRR: 0.44; 95% CI: 0.20, 0.97), whilst in women 
carrying a male fetus, a 55% decreased risk of GDM with found with 
high standardised vitamin D when compared to moderately-high 
vitamin D, but this was not statistically significant (aRR: 0.45; 95% CI: 
0.15, 1.38). 
Conclusions: High serum 25(OH)D at 15±1 weeks’ gestation was 
shown to be protective against the development of GDM. A possible 
association between fetal sex, vitamin D status and GDM provides 
further questions and encourages continual research and discussion 
into the role of vitamin D in pregnancy, particularly in vitamin D 
replete populations. 
5.1 Introduction 
With an increasing prevalence of vitamin D deficiency and insufficiency reported 
both in Australia and New Zealand, as well as worldwide [1], there is continuing 
interest in determining how vitamin D deficiency may influence health in 














pregnancy. Evidence suggests that vitamin D deficiency is associated with a 
number of pregnancy complications including preeclampsia (PE), gestational 
diabetes mellitus (GDM) and spontaneous preterm birth (sPTB) [2, 3]. However, 
inconsistencies between studies reflect uncertainty about the true effect of 
vitamin D deficiency on pregnancy outcome [4, 5]. This may be explained, in part, 
by inadequate control of related risk factors and confounders in statistical 
analyses, variations between assays that measure vitamin D and significant 
heterogeneity between studied populations [5]. 
Vitamin D status is determined by measuring circulating serum levels of 
25-hydroxy vitamin D2+3 (25(OH)D). In Australia and New Zealand, the 
deficiency cut-offs are based on the role of vitamin D in bone health where serum 
25(OH)D ≥50 nmol/L at the end of winter is required for optimal musculoskeletal 
health [1]. Furthermore, it has been established that serum 25(OH)D ≥50 nmol/L 
is recommended during pregnancy and lactation [6]. The incidence of vitamin D 
deficiency (˂50 nmol/L) is frequent among pregnant women even in areas such 
as Australia and the North Island of New Zealand where sunlight exposure is 
high. Studies focused on high-risk populations, for example, veiled, dark-
skinned or obese women in Australia and New Zealand, report between 50-94% 
of women to be vitamin D deficient [7-9]. Reports from lower-risk groups have 
indicated that vitamin D deficiency occurs in 25-55% of pregnant women [10-12]. 
There are numerous studies which have shown that vitamin D deficiency 
is associated with adverse pregnancy outcomes, particularly in populations that 
reside at higher latitudes [4]. However, studies in women from Australia and 
New Zealand are less consistent. Previous studies on pregnant Australian and 
New Zealand women have reported that while circulating 25(OH)D was 
significantly lower in women with PE, sPTB, GDM and those who delivered a 
small-for gestational age (SGA) infant, no association between vitamin D 
deficiency and these pregnancy complications was found after adjusting for 
covariates [13-15]. Differences in ethnicity [16], solar exposure and geographical 














location, as well as genetics [17], are known to affect 25(OH)D status and 
therefore influence study outcomes. Furthermore, the gestation at which vitamin 
D was measured is also important. Measuring circulating 25(OH)D in early 
pregnancy is common and potentially clinically useful as this is prior to when 
many of the pregnancy complications that affect late gestation manifest. 
Using a robust, validated chemiluminescent-based assay to measure 
serum 25(OH)D [18], we aimed to investigate the differences between vitamin D 
status in early pregnancy in two distinct populations of nulliparous women from 
Australia and New Zealand. We also aimed to examine the relationship between 
serum 25(OH)D at 15±1 weeks’ gestation and the risk of an adverse pregnancy 
outcome and included determining the effect modification of fetal sex on the 
association between maternal vitamin D status and pregnancy outcome. 
5.2 Methods  
5.2.1 Study Participants 
This study utilised data collected from the multi-centre, prospective cohort 
Screening for Pregnancy Endpoints (SCOPE) study [19]. Nulliparous women 
carrying a singleton pregnancy were recruited between November 2004 and 
September 2008 in Adelaide (Australia) and Auckland (New Zealand). At 15±1 
weeks’ gestation, women were interviewed by a research midwife and asked 
questions on maternal demographics and lifestyle and had physical 
measurements taken, including height and weight. Records included ethnicity, 
age, body mass index (BMI), socioeconomic index (SEI) and multivitamin use 
[20]. BMI was calculated as weight (kg)/height2 (m2). Obesity was defined as BMI 
≥30 kg/m2, overweight as BMI ≥25 and <30 kg/m2, normal weight as BMI >20 and 
<25 kg/m2 and underweight as BMI ≤20 kg/m2. SEI was calculated using the New 
Zealand SEI of occupational status, deriving a number between 10 and 90 based 
on the woman’s occupation; a higher number indicates higher socioeconomic 
status [21]. This population of women was predominantly Caucasian and thus 














maternal ethnicity was categorised into 2 main groups; Caucasian and non-
Caucasian. Uncomplicated pregnancies were defined as those without any 
pregnancy disorder who delivered an appropriate weight for gestational age 
infant at term (≥37 weeks gestation) [22]. Pregnancy complications studied 
included PE, gestational hypertension (GH), GDM, sPTB and SGA and have been 
previously defined [19, 20, 22, 23]. 
 
5.2.2 Measurement of serum 25(OH)D 
Non-fasting whole peripheral blood samples were collected into non-heparinised 
tubes at 151 weeks’ gestation. Serum was processed within 4 hours of collection 
and stored at -80°C until required. Unlike the previously published data on 
vitamin D in the Auckland cohort [15], serum 25(OH)D was measured using the 
IDS-iSYS chemiluminescent-based assay (Abacus, ALS) as per the 
manufacturer’s instructions. Both serum 25(OH)D3 and 25(OH)D2 were 
measured independently and combined to provide a total 25(OH)D in nmol/L 
[18]. 
 
5.2.3 Statistical Analysis 
Statistical analyses were performed in R (v3.1.1) [24]. Data were checked for 
normality using a Shapiro-Wilks test and differences between women recruited 
in Adelaide compared to Auckland were tabulated and compared using a 
Welch’s t-test (continuous variables) or Fisher’s exact test (categorical variables). 
Given that the month in which the serum was sampled heavily influences 
vitamin D status, “standardised” serum 25(OH)D concentrations were calculated 
as previously described [25] in order to normalise against seasonal variation. 
Quartiles within the standardised concentrations were then used to create cut-
points and designated ‘low’ (<44 nmol/L), ‘low-moderate’ (44-63 nmol/L), 
‘moderate-high’ (63-81 nmol/L) and ‘high’ (>81 nmol/L) categories of serum 
25(OH)D.  














Generalised linear models (Poisson with log link and robust variance 
estimates) were used to calculate the risk ratios for pregnancy complications by 
standardised serum 25(OH)D concentrations calculated among the women who 
had an uncomplicated pregnancy. Potential confounders on vitamin D status was 
assessed using linear modelling. Maternal age, BMI, SEI, alcohol consumption at 
15±1 weeks’ gestation (never/former vs. current), recreational walking (1-3 
times/week and ≥4 times/week vs. never), ethnicity (Caucasian vs. non-
Caucasian) and recruitment site (Adelaide vs. Auckland) were significantly 
associated with serum 25(OH)D and along with smoking status at 15±1 weeks’ 
gestation (never/former vs. current) included as main effects within the 
generalised linear models. These analyses were also repeated but using the 
current definitions of vitamin D deficiency: <25, 25-50, 50-75 and >75 nmol/L in 
the non-standardised data [6]. We also stratified based on fetal sex to evaluate 
possible effect measure modifications according to whether the mother was carry 
a male or female fetus. 
5.3 Results 
5.3.1 Population Characteristics 
Of 3229 women recruited as part of SCOPE at the Adelaide and Auckland 
centres, serum samples at 15±1 weeks’ gestation to measure 25(OH)D were 
available for 2800 (87%) women of whom, 1156 (41%) were recruited in Adelaide 
and 1644 (59%) were recruited in Auckland. Maternal characteristics are shown 
in Table 5.1. Compared to women who were recruited at the Adelaide site, 
women recruited in Auckland were older, had a lower BMI, less likely to smoke 
or drink alcohol during pregnancy and more likely to eat fruit and undertake 
recreational walks. Mean ± SD SEI of the Auckland women was also higher 
compared to that in women recruited in Adelaide (Auckland: 48.0 ± 14.8 vs. 
Adelaide: 27.7 ± 10.5, P<0.001). Given that all these factors significantly 
influenced serum 25(OH)D in the linear regression model, it was unsurprising 














that vitamin D status of the women was significantly different between the two 
recruitment sites. However, after adjusting for maternal age, BMI, SEI, smoking 
status and alcohol consumption at 15±1 weeks’ gestation, ethnicity, recreational 
walking and season, the women recruited in Adelaide still had significantly 
lower serum 25(OH)D when compared with those in Auckland (Adelaide: 58.4 ± 
50.3 vs. Auckland: 70.2 ± 54.5 nmol/L, P<0.001) indicating the influence of other 
confounders not measured as part of the study on vitamin D status. 
 
TABLE 5.1. Participant characteristics and comparison of characteristics between 
women recruited at the Adelaide SCOPE site versus Auckland 
 All women (n = 2800) 
Adelaide 
(n = 1156) Auckland (n = 1644) P value* 
Age yrs, mean (SD) 28 (6) 23.73 (5.11) 30.44 (4.82) <0.0001 
BMI kg/m2, mean (SD) 25.8 (5.44) 27.04 (6.56) 24.88 (4.26) <0.0001 
Ethnicity  
  <0.0001 
Caucasian 2449 (87) 1060 (92) 1389 (84)  
Non Caucasian 351 (13) 96 (8) 255 (16)  
Smoking status, n (%)  
  <0.0001 
No 2152 (77) 704 (61) 1448 (88) 
 
Quit during pregnancy 306 (11) 175 (15) 131 (8)  
Smoking 342 (12) 277 (24) 65 (4)  
Alcohol Consumption, n 
(%) 
   <0.0001 
No 1480 (53) 708 (61) 772 (47) 
 
Stopped during pregnancy 1185 (42) 397 (34) 788 (48)  
Consuming alcohol 135 (5) 51 (4) 84 (5)  
Fruit Intake, n (%)  
  <0.0001 
≥1x per day 2032 (73) 586 (51) 1446 (88) 
 
3-6x per week 405 (14) 272 (24) 133 (8)  
1-2x per week  223 (8) 181 (16) 42 (3)  
1-3x per month or less 140 (5) 117 (10) 23 (1)  
Recreational Walking  
  <0.0001 
Never 428 (15) 265 (23) 163 (10) 
 
1-3 times/week 1773 (63) 668 (58) 1105 (68)  
≥4 times/week 590 (22) 221 (19) 369 (23)  
Time watching TV  
  <0.0001 
<5 hours per day 2404 (86) 901 (78) 1503 (92) 
 
≥5 hours per day 387 (14) 253 (22) 134 (8)  
Season serum was sampled  
  0.3213 
Summer 636 (23) 278 (24) 358 (22) 
 
Autumn 705 (25) 273 (24) 432 (26)  














Winter 727 (26) 300 (26) 427 (26)  
Spring 732 (26) 305 (26) 427 (26)  
Serum 25(OH)D nmol/L, 
mean (SD) 
68.09 (27.14) 60.06 (23.68) 73.74 (27.99) <0.0001 
Vitamin D Status  
  <0.0001 
<25 nmol/L 99 (4) 48 (4) 51 (3) 
 
25-50 nmol/L 673 (24) 375 (32) 298 (18)  
50-75 nmol/L 928 (33) 422 (37) 506 (31)  
>75 nmol/L 1098 (39) 311 (27) 787 (48)  
*P values for continuous variables were determined using a Welch’s t-test and categorical variables a 
Fisher’s exact test comparing Adelaide and Auckland women. 
 
 
FIGURE 5.6. Seasonal variation in serum 25(OH)D. a. Comparison of serum 25(OH)D 
levels based on month of sampling in the women recruited in Adelaide (black line & left 
axis) and average hours of sunlight per day in Adelaide (grey line & right axis). Seasonal 
variation in vitamin D followed a similar pattern to hours of sunlight although was 
slightly shifted. b. Seasonal variation of serum 25(OH)D based on month of sampling 
between women recruited in Adelaide compared to Auckland. Data are mean ± SD 














5.3.2 Standardising serum 25(OH)D based on seasonal variation 
As expected, there was a seasonal influence on serum 25(OH)D and thus, 
“standardised” vitamin D concentrations were calculated to account for the 
month of serum collection. Average hours of sunlight per day in Adelaide from 
September 2005 to September 2008 were obtained and compared against serum 
vitamin D measured in the women recruited in Adelaide (Figure 1a; black 
line/left axis serum 25(OH)D and grey line/right axis average hours of sunlight). 
The means for serum 25(OH)D by month of sampling were also separated for 
women recruited in Adelaide and women recruited in Auckland (Fig. 5.1b). 
 
5.3.3 Serum 25(OH)D and pregnancy outcome 
Of the 2800 women present in this study, 1217 (43%) women went on to develop 
a pregnancy complication and included 13% (n = 161) who developed PE, 18% (n 
= 213) who developed GH, 8% (n = 92) who developed GDM, 11% (n = 139) who 
delivered preterm and 24% (n = 298) who delivered an SGA infant. 
 The association between “standardised” 25(OH)D with pregnancy 
complications is presented in Table 5.2. Using moderate-high as a reference 
(standardised vitamin D 63-81 nmol/L), there was no appreciable effect of having 
a low, low-moderate or high vitamin D with the risk of developing any 
pregnancy complication after adjusting for confounders. However, when each 
pregnancy complication was analysed separately, a 53% decreased risk for GDM 
was observed with high vitamin D status when compared to moderate-high 
status (aRR: 0.47; 95% CI: 0.23, 0.96). When women were categorised based on 
clinical definitions of vitamin D deficiency and serum 25(OH)D between 50-75 
nmol/L used as the reference, no significant relationship between vitamin D 
status and adverse pregnancy outcome was found (Table 5.3). Although, the 
point estimates indicated a marginal increased risk for developing any preg-
nancy complication with severe (<25 nmol/L) vitamin D deficiency compared to 





























TABLE 5.2. Adjusted relative risks (aRR) of pregnancy complications from any complication, preeclampsia (PE), gestational hypertension (GH), 
gestational diabetes mellitus (GDM), spontaneous preterm birth (sPTB) and small-for-gestational age (SGA) according to vitamin D status 
categorised based on standardised quartiles and clinical definitions of vitamin D status 
  Pregnancy Complications 
 All women 
 
Any Complication PE GH GDM sPTB SGA 
 n (%) n (%) 
aRR* 
(95% CI) n (%) 
aRR* 
(95% CI) n (%) 
aRR* 
(95% CI) n (%) 
aRR* 
(95% CI) n (%) 
aRR* 
(95% CI) n (%) 
aRR* 
(95% CI) 
Standardised Quartiles**           
Low 711 (25) 328 (46) 
0.95 
(0.85, 1.07) 46 (6) 
1.02 










(0.54, 1.29) 84 (12) 
1.02 
(0.75, 1.39) 


























1.0† 81 (12) 1.0† 
High 630 (23) 258 (41) 0.93 
(0.82, 1.06)† 
35 (6) 1.24 
(0.78, 1.96) 










60 (10) 0.80 
(0.57, 1.11) 
Vitamin D Status            
<25 nmol/L 99 (4) 51 (52) 
1.10 
(0.89, 1.36) 8 (8) 
1.44 
(0.68, 3.03)) 6 (6) 
0.70 
(0.32, 1.52) 5 (5) 
0.98 
(0.38, 2.52) 7 (7) 
1.44 







































435 (40) 0.95 
(0.86, 1.04) 
60 (5) 1.28 
(0.87, 1.87) 










104 (9) 0.86 
(0.67, 1.12) 
*Relative risks compared to all women  were adjusted for age, maternal body mass index, ethnicity (non Caucasian vs. Caucasian), smoking status at 15±1 weeks' gestation (no 
vs. yes), alcohol consumption at 15±1 weeks' (no vs yes), recreational walking (1-3x/week and ≥4x/week vs. never) and recruitment site (Auckland vs. Adelaide). 































TABLE 5.3. Adjusted relative risks (aRR) of pregnancy complications from any complication, preeclampsia (PE), gestational hypertension (GH), 
gestational diabetes mellitus (GDM), spontaeous preterm birth (sPTB) and small-for-gestational age (SGA) according to vitamin D status and 
stratified by fetal sex 
  Pregnancy Complications 
 All women Any Complication PE   GH   GDM   sPTB   SGA 
 n (%) n (%) 
aRR* 
(95% CI) n (%) 
aRR* 
(95% CI) n (%) 
aRR* 
(95% CI) n (%) 
aRR* 
(95% CI) n (%) 
aRR* 
(95% CI) n (%) 
aRR* 
(95% CI) 
Standardised Quartiles**           
Males              
Low 
























































1.0† 35 (10) 1.0† 
High 






















             
Low 























































1.0† 31 (9) 1.0† 
High 





















*Relative risks compared to all women were adjusted for age, maternal body mass index, ethnicity (non Caucasian vs. Caucasian), smoking status at 15±1 weeks' gestation 
(no vs. yes), alcohol consumption at 15±1 weeks' (no vs yes), recreational walking (1-3x/week and ≥4x/week vs. never) and recruitment site (Auckland vs. Adelaide). 
** Serum 25(OH)D was standardised for month that serum was sampled based as previously described [25]. 
†Reference category 
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5.3.4 Serum 25(OH)D, pregnancy outcome and fetal sex 
As there is evidence to suggest that vitamin D metabolism within the 
placenta may differ with respect to fetal sex [26], we assessed the effect of 
“standardised” vitamin D status on pregnancy outcome stratified by fetal sex 
(Table 5.3). Although not statistically significant, point estimates for women 
carrying a male fetus indicated decreased risk of having any pregnancy 
complication with high serum 25(OH)D compared to moderately-high (aRR: 
0.86; 9%% CI: 0.71, 1.04) . This was largely driven by a 55% decreased risk of GDM 
in women with a male fetus with high standardised serum 25(OH)D when 
compared to those carrying a male fetus with moderate-high serum 25(OH)D 
(aRR: 0.45; 95% CI: 0.15, 1.38). Conversely, if a woman was carrying a female 
fetus, there was generally no effect of having low, low-moderate or high 
standardised serum 25(OH)D on developing any pregnancy complication 
compared to moderate-high levels (Table 5.3). Although, a 56% decreased risk 
for GDM was observed in those with low-moderate levels of standardised 
vitamin D when compared to moderate-high levels for women carrying a female 
fetus (aRR: 0.44; 95% CI: 0.20, 0.97). 
5.4 Discussion 
This study adds to the current body of literature on vitamin D status in a 
population of pregnant Australian and New Zealand women and provides 
insight into normal circulating levels of 25(OH)D in early pregnancy. It is the 
largest prospective cohort study to assess vitamin D status within the 
international SCOPE cohort, comparing and combining two distinct populations 
of pregnant women living at similar latitude and provides a greater 
understanding of vitamin D deficiency and the risk of adverse pregnancy 
outcomes. We found, despite being at similar latitudes, circulating 25(OH)D was 
different between women recruited in Adelaide compared to women recruited 
in Auckland. This was independent of diet and lifestyles factors including BMI 
C h a p t e r  5   P a g e  |  1 5 9  
 
 
and SEI and highlights the difficulty in understanding the role of vitamin D in 
pregnancy in human cohort studies. However, there was a protective association 
of having high vitamin D at 15±1 weeks’ gestation and GDM once standardised 
based on month serum was sampled. Furthermore, there may be possible fetal 
sex specific differences in vitamin D status worth considering in future studies. 
Despite the similar latitudes of Adelaide and Auckland (Adelaide: 34.93°S 
and Auckland 36.85°S), serum 25(OH)D was lower in the women recruited in 
Adelaide. Given the significant number of characteristic and lifestyle differences 
between the two populations, this is not overly surprising. Previous studies have 
shown a positive association between socioeconomic status and vitamin D in 
both pregnant and non-pregnant women [27, 28]. The lower SEI of the Adelaide 
women could therefore make them more susceptible to lower circulating 
25(OH)D because of factors relating to disadvantage. Furthermore, increased 
BMI is known to be associated with reduced serum 25(OH)D [29-31] as adipose 
tissue is thought to sequester 25(OH)D [32]. However, after adjusting for factors 
shown to be associated with vitamin D status including BMI and recreational 
walking, serum 25(OH)D remained significantly lower in the women recruited 
in Adelaide suggesting the influence of other factors not measured as part of 
SCOPE for example, hours spent outside in the sun. As indicated by the seasonal 
variation in serum 25(OH)D, amongst women recruited in Adelaide, vitamin D 
status declined significantly from February to April whilst in the women 
recruited in Auckland, serum 25(OH)D in March and April remained elevated 
before declining. 
Vitamin D deficiency has previously been associated with insulin 
resistance and type 2 diabetes given its role in supporting insulin secretion and 
pancreatic β-cell function [33]. Furthermore, inverse relationships between 
serum 25(OH)D and both fasting glucose and fasting insulin have been shown 
during pregnancy indicating poorer glycaemic control [14, 34]. Therefore, the 
protective role of high 25(OH)D 15±1 weeks’ gestation against GDM, as seen with 
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an decreased risk of GDM in women within the ‘high’ quartile of standardised 
vitamin D compared to moderate-high, is consistent with knowledge about 
vitamin D and diabetes. This offers a potential physiological connection between 
vitamin D status and the progression of insulin resistance in pregnant women. 
Furthermore, studies have shown that vitamin D supports early placental 
development [35, 36] in which, abnormal placentation can be a characteristic of a 
number of pregnancy complications including GDM, PE, sPTB and SGA [37]. 
The placenta expresses all the necessary components to convert 25(OH)D 
to the active form and thus utilise active vitamin D either locally or in a paracrine 
manner [36, 38]. Vitamin D metabolism in the placenta has been shown to be 
influenced by testosterone production and thus varies by fetal sex [26]. 
Furthermore, sex specific differences in pregnancy outcome have also been 
reported whereby the risk of sPTB, PE and GDM are all higher in pregnancies 
with a male fetus [39-41]. In this study, we observed marginal sex-specific 
differences between early pregnancy vitamin D status and pregnancy outcome 
where-by high vitamin D status and carrying a male fetus was moderately 
associated with decreasing the risk of having any pregnancy complication. 
Conversely, high vitamin D status and carrying a female fetus was not associated 
with changing the risk of having any pregnancy complication. Indeed, for the 
risk of GDM an opposite effect of vitamin D status in early pregnancy was 
observed depending on fetal sex. This is similar to what has previously been 
shown in the relationship between vitamin D status at ≤26 weeks’ gestation and 
placental pathology in pregnancy [42] suggesting that male and female fetuses 
respond differently to maternal vitamin D status. 
Lack of statistically significant associations with other pregnancy 
complications may reflect the fact that this was a largely vitamin D-replete 
population (>72% with serum 25(OH)D >50 nmol/L) likely due to their residence 
latitude as low serum 25(OH)D was found in the SCOPE Ireland cohort [43]. 
Indeed many of the studies that have assessed the association between vitamin 
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D status and adverse pregnancy outcome that have reported statistically 
significant differences have been in populations with higher rates of vitamin D 
deficiency [2]. Inconsistencies in the literature may also reflect other causative 
factors in which vitamin D is a mediator. For example, active vitamin D (1,25-
dihydroxyvitamin D3) is the principal hormone that regulates calcium absorption 
within the intestine [44] and is integral to maintaining calcium homeostasis. 
During gestation, fetal demand for calcium increases and it is imperative that 
maternal vitamin D status remain adequate to support increased calcium 
absorption from the gut [45]. Therefore, vitamin D status may be important in 
populations where dietary calcium intake is low which is unlikely in the 
population of women studied here.  
In conclusion, once standardised against month of sampling, we 
demonstrate a protective effect of high vitamin D with GDM. However, 
differences in vitamin D status between the women recruited in Adelaide and 
those recruit in Auckland reflect obvious difficulties in studying how vitamin D 
may support healthy pregnancies. A possible connection between fetal sex, 
vitamin D status and pregnancy complications provides further questions and 
encourages continual research and discussion into the role of vitamin D in 
pregnancy, particularly in vitamin D replete populations. 
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Background: Adequate calcium intake and vitamin D status during 
pregnancy are integral to maintaining appropriate calcium supply to 
the fetus for fetal growth and development. Fetal growth restriction is 
associated with pregnancies complicated by preeclampsia (PE) and 
delivery of a small-for-gestational age (SGA) infant as well as with 
placental dysfunction. Vitamin D deficiency in pregnancy has been 
associated with PE and SGA but reports are inconsistent, possibly due 
to maternal calcium status. 
Objectives: This study investigated the relationship between maternal 
vitamin D and calcium status at 15±1 weeks’ gestation with the 












development of PE and SGA, as well as mid-gestation measures of 
uteroplacental circulation. 
Design: We used the SCOPE (Screening for Pregnancy Endpoints) 
Adelaide prospective pregnancy cohort that included 1065 pregnant 
nulliparous women. Total plasma calcium, serum 25-hydroxyvitamin 
D (25(OH)D), urinary calcium and urinary deoxypyridinoline (DPD) 
were measured at 15±1 weeks’ gestation, uterine and umbilical artery 
resistance index (RI) was measured at 19-21 weeks’ gestation. 
Results: Total maternal plasma calcium (mean ± SD) was 2.06 ± 0.141 
mmol/L and serum 25(OH)D was 59.41 ± 23.13 nmol/L in the whole 
cohort. Lower urinary calcium excretion was associated with greater 
risk of having an abnormal umbilical artery RI (aRR: 1.57; 95% CI: 1.11, 
2.22) and delivering an SGA infant (aRR: 2.13; 95% CI: 1.29, 3.51) 
compared to excretion of higher levels of calcium. When combined, 
having both higher serum 25(OH)D and lower urinary calcium was 
associated with increased risk of SGA and an abnormal uterine artery 
RI (aRR: 1.55; 95% CI: 1.07, 2.24 and aRR: 1.79; 95% CI: 1.19, 2.68, 
respectively) compared to having higher levels of both suggesting 
maternal calcium status to be a more important determinant of 
placental development and fetal growth. 
Conclusions: This is one of the first studies to assess both early 
pregnancy calcium and vitamin D status and their association with PE, 
SGA and measures of placental function in a large pregnancy cohort. 
Altered calcium homeostasis at 15±1 week’s gestation was associated 
with an increased risk of uteroplacental dysfunction which can have 
subsequent consequences on fetal growth and development. 













Maternal calcium homeostasis during pregnancy is integral to supporting fetal 
bone growth and development. It is estimated that the average calcium demand 
of a human fetus is 30 g until birth, with the majority required in the third 
trimester when most bone mineralisation occurs [1]. Vitamin D and its 
metabolites, parathyroid hormone (PTH) and dietary calcium intake function 
together to regulate calcium metabolism [2]. Low circulating calcium stimulates 
the release of PTH which then acts to increase resorption of bone, reabsorption 
of calcium in the kidneys and the production of 1,25(OH)D3, the active vitamin 
D metabolite, which functions to increase intestinal calcium absorption [3]. Once 
circulating calcium levels are restored, a negative feedback system signals to 
cease production of PTH. During pregnancy, calcium absorption approximately 
doubles, largely due to the significantly increased expression of 1,25(OH)D3 as 
well as other factors like increased prolactin and placental lactogen production 
[4]. Placental expression of vitamin D metabolites and pathway enzymes also 
increases [5-7]. Hence, the system is designed to maintain the transfer of calcium 
from mother to fetus without any detriment to maternal bone health. However, 
in women with very low calcium intakes (<500 mg/day) or those who are vitamin 
D deficient/insufficient, this can result in a net calcium loss [8, 9] and have 
downstream consequences for fetal growth and maternal health. 
Fetal growth restriction can be an outcome of pregnancies complicated by 
preeclampsia (PE) or accompany the delivery of a small-for-gestational age 
(SGA) infant [10] with the pathogenesis of these complications including 
placental dysfunction and insufficiency. Placental dysfunction can result from 
improper transformation of the maternal spiral arteries by invading placental 
trophoblast cells, as well as defective fetal villus formation and function 
(reviewed in [11]). The consequences are poor blood flow and nutrient exchange 
resulting in restricted fetal growth. Doppler ultrasound in mid-pregnancy 












enables the assessment of the uteroplacental circulation in vivo and determine 
whether there is inadequate perfusion that may result in problems for the mother 
and/or fetus later in gestation [12]. Improper trophoblast invasion of the spiral 
arteries can be detected through the assessment of uterine artery blood flow [13] 
whilst Doppler assessment of the umbilical artery blood flow reflects the 
arborisation of the fetal chorionic villous tree [14]. Studies have shown that high 
resistance flow demonstrated by the waveforms from both uterine and umbilical 
arteries are associated with subsequent stillbirth, fetal growth restriction and PE 
[15-19] and thus provide a method by which to monitor placental function. 
The link between vitamin D deficiency in pregnancy and adverse 
pregnancy outcomes has been studied extensively [20, 21]. In particular, there 
have been numerous reports on the association between vitamin D deficiency 
and PE, as well as with delivery of an SGA infant [22, 23]. However, these reports 
are inconsistent with other studies finding no association between vitamin D 
deficiency and the risk of pregnancy complications [20, 21]. Furthermore, less is 
known about the association between maternal calcium status and PE or SGA. 
Indeed, calcium supplementation is recommended as a preventative measure for 
PE based on studies which have shown an association between higher calcium 
intake and a lower risk of PE [24-28]. This is supported by a decreased urinary 
calcium-creatinine ratio both in early and late pregnancy in women who develop 
PE [29, 30] suggesting disrupted calcium homeostasis as a possible mechanism 
in the pathogenesis of PE. However, whether this is a consequence of low vitamin 
D, low maternal calcium intake or both has not clearly been defined. 
The association between vitamin D status and adverse pregnancy 
outcomes in women from Australia and New Zealand remains uncertain and 
highly sample population dependant [31-33]. This is because vitamin D status is 
highly dependent upon variables such as ethnicity and body mass index (BMI) 
[34], geographic location and solar exposure, as well as genetics [35]. 
Furthermore, very few studies have assessed the association between vitamin D 












status and calcium status with the risk of pregnancy complications. Recently, we 
reported that higher vitamin D levels in early pregnancy may be protective 
against the risk of developing gestational diabetes mellitus in a cohort of 
pregnant women recruited in Adelaide (Australia) and Auckland (New Zealand) 
[Chapter 5, Wilson et al., Revisions pending BMC Pregnancy and Childbirth]. 
However, no association was found between vitamin D status and the risk of PE 
or SGA. The purpose of the present study was to further investigate maternal 
calcium status in addition to circulating 25(OH)D in early pregnancy with the 
development of PE and SGA, as well as placental function as both PE and SGA 
are associated with placental pathology. We hypothesised that, within this 
largely vitamin D replete population, maternal calcium status may be an 
important determinant of pregnancy outcome, placental development and fetal 
growth. 
6.2 Methods  
6.2.1 Design and Study Population 
This study used data collected as part of the Screening for Pregnancy 
Endpoints (SCOPE) Study, a multi-centre, prospective cohort study of 
nulliparous pregnant women and was confined to those women attending the 
Lyell McEwin Hospital in Adelaide, Australia. Women were recruited at 15±1 
weeks’ gestation between November 2004 and September 2008. The study was 
approved by the Queen Elizabeth Hospital and Lyell McEwin Hospital Human 
Research Ethics committee (approval no: REC 1712/5/2008) and all women 
provided written consent. 
 
6.2.2 Birth Outcomes 
Uncomplicated pregnancies were defined as those without any pregnancy 
disorder and included women who delivered an appropriate weight for 
gestational age infant at term (≥37 weeks gestation) [36]. PE was diagnosed as 












having high blood pressure (systolic blood press ≥140 mmHg and/or diastolic 
blood pressure ≥90 mmHg) on at least two occasions after 20 weeks gestation in 
conjunction with proteinuria (24 h urinary protein ≥300 mg, a spot urine 
protein:creatinine ratio ≥30 mg/mmol, or urine dipstick protein ≥2) or any 
multisystem complication of PE or uteroplacental dysfunction [37]. SGA was 
defined as delivering an infant whose birthweight was <10th customised centile 
[38]. Ultrasound examination was performed at 19-21 weeks’ gestation on both 
the umbilical and uterine arteries [39, 40]. Both the left and right uterine artery 
resistance index (RI) was measured and used to calculate mean uterine artery RI. 
Women who had a uterine or umbilical RI >90th centile were considered 
abnormal. 
 
6.2.3 Maternal blood and urinary measures of calcium, 25(OH)D 
and deoxypridinoline 
Maternal venous blood was collected at 15±1 weeks’ gestation for both heparin 
plasma and serum samples, as well as a urine sample. Measurements of total 
plasma calcium and serum 25(OH)D have been described previously [Chapter 5, 
Wilson et al., Revisions pending BMC Pregnancy and Childbirth, 41]. Urinary 
deoxy-pyridinoline (DPD), a marker of bone turnover, was measured using the 
Microvue Total DPD EIA Kit (Quidel Corporation) following manufacturer’s 
protocol while the Cobas Integra 400+ Analyser (Roche Diagnostics) was used to 
measure urinary calcium and creatinine. Each assay was run on the Triad Multi 
Mode Microplate Reader (Dynex Technologies) and concentrations determined 
from standard curves. Values for urinary calcium and DPD were expressed as 
ratios to creatinine in order to correct for variations in urine volume and dilution. 
 
6.2.4 Statistics 
All statistical analyses were performed in R (v3.1.1) [42]. Spearman’s 
correlational analyses were used to assess the relationships between 












“standardised” serum 25(OH)D, plasma calcium, urinary calcium-creatinine 
(Ca:Cr) and urinary DPD-creatinine (DPD:Cr) as well as with uterine and 
umbilical artery RI as measures of placental function. Generalised linear models 
(Poisson with log link and robust variance estimates) were used to calculate the 
adjusted risk ratios (aRR) for PE, SGA and uteroplacental dysfunction. 
Population tertiles were used to create cut-points for each biochemical measure. 
For “standardised” serum 25(OH)D: lower <41 nmol/L, medium 41-61 nmol/L, 
higher >61 nmol/L. For plasma calcium: lower <2.0 mmol/L, medium 2-2.1 
mmol/L, higher >2.1 mmol/L. For urinary Ca:Cr: lower <0.46, medium 0.46-0.83, 
higher >0.83. For urinary DPD:Cr: lower <7.2, medium 7.2-10.8, higher >10.8. 
Maternal age, body mass index (BMI), smoking status at 15±1 weeks’ gestation 
(no vs. yes), alcohol consumption at 15±1 weeks’ gestation (no vs. yes) and fruit 
intake at 15±1 weeks’ gestation (≥3x per month vs. <3x per month) were included 
as main effects within the generalised linear models. These analyses were 
repeated for combinations of vitamin D and calcium status: serum 25(OH)D and 
plasma calcium, serum 25(OH)D and urinary calcium, plasma and urinary 
calcium and urinary calcium and DPD. Each participant was assigned to one of 
four categories based on whether they had “lower” levels of both (1st tertile), 
“higher” levels of both (2nd and 3rd tertile combined) or a combination of “lower 
and higher”. Finally, multinomial logistic regression analysis was performed 
using the nnet package in R to assess the effect of vitamin D and calcium status 
on PE and/or SGA with or without an abnormal uterine or umbilical artery RI. 
Women who did not have PE and/or SGA nor an abnormal uterine or umbilical 
artery RI were selected as the reference category. Significance was determined 
with a P<0.05. 
 
 













6.3.1 Study Participants 
Of the 1164 women recruited in Adelaide, plasma samples were available for 
1065 (92%). Maternal characteristics of the study participants are summarised in 
Table 6.1. The mean ± SD maternal age and BMI was 24 ± 5.1 y, and 27 ± 6.52 
kg/m2, respectively. One quarter of the women were smoking cigarettes at 15±1 
week’s gestation but very few (4%) were regularly drinking alcohol. Low fruit 
consumption (<3 times/month) was recorded for 112 women (11%) indicating a 
proportion of the population were likely to have poorer dietary habits. Data from 
Doppler ultrasound assessment at 19-21 weeks’ gestation of uterine and 
umbilical artery RI were available for 1043 (98%) women, for whom, 12% 
recorded an abnormal uterine artery RI and 18% recorded an abnormal umbilical 
RI (Table 6.1). 
 
6.3.2 Calcium and Vitamin D Status 
Total maternal plasma calcium and 25(OH)D in serum (mean ± SD) for all women 
studied were 2.06 ± 0.141 mmol/L and 59.41 ± 23.13 nmol/L, respectively (Table 
6.1). The interquartile range for plasma calcium was from 2.00 to 2.15 mmol/L 
and similar to normal reference ranges for women in the second trimester of 
pregnancy [43]. Mean ± SD urinary Ca:Cr and DPD:Cr ratios were 0.69 ± 0.42 and 
10.28 ± 18.01, respectively (Table 6.1). 
Spearman’s correlational analyses showed a positive correlation between 
plasma calcium and serum 25(OH)D and between urinary Ca:Cr and urinary 
DPD:Cr (Fig. 6.1). Serum 25(OH)D was negatively correlated with urinary 
DPD:Cr. Neither serum 25(OH)D nor urinary DPD:Cr were correlated with 
urinary Ca:Cr.  












TABLE 6.3. Baseline characteristics of the women recruited to the SCOPE1 Adelaide 
pregnancy cohort at 15±1 week’s gestation 
  Participants (n = 1065) 
Age y, mean (SD) 24 (5.1) 
BMI kg/m2, mean (SD) 27.0 (6.52) 
Smoking status, n (%)  
No 651 (61) 
Quit during pregnancy 152 (14) 
Smoking 262 (25) 
Alcohol Consumption, n (%)  
No 658 (62) 
Stopped during pregnancy 362 (34) 
Consuming alcohol 45 (4) 
Fruit Intake, n (%)  
≥3x per month 953 (89) 
<3x per month 112 (11) 
Abnormal uterine artery resistance index, n (%)  
No 923 (88) 
Yes 122 (12) 
Abnormal umbilical artery resistance index, n (%)  
No 854 (82) 
Yes 189 (18) 
Plasma Ca mmol/L, mean (SD) 2.06 (0.14) 
Serum 25(OH)D nmol/L, mean (SD) 59.41 (23.13) 
Urinary Ca:Cr, mean (SD) 0.69 (0.42) 
Urinary DPD:Cr, mean (SD) 10.28 (18.01) 
1SCOPE: Screening for Pregnancy Endpoints 
 
6.3.3 Pregnancy Outcome 
There were 85 women who developed PE (8%) and the incidence of SGA was 
13% (134 pregnancies). Table 6.2 shows the association between calcium and 
vitamin D status with PE and SGA. Using higher levels (>0.83) as the reference 
category, we found that women categorised as having lower urinary Ca:Cr ratio 
(<0.46) were 2.13 times more likely to deliver an SGA infant (aRR: 2.13; 95% CI: 
1.29, 3.51). Moderate protective effects of lower plasma calcium (<2.0 mmol/L) 
with PE and SGA were also found, although these were not statistically 
significant. Maternal vitamin D status and urinary DPD excretion were not 
associated with PE or SGA. However, an increasing trend in the risk for PE with 
decreasing DPD:Cr was observed (P = 0.045). 













FIGURE 6.7. Spearmans’s correlations between plasma calcium, serum 25(OH)D, 
urinary calcium-creatinine ratio (Ca:Cr) and urinary deoxypyridinoline-creatinine ratio 
(DPD:Cr) at 15±1 week’s gestation. Significant positive correlations were found between 
plasma calcium and serum 25(OH)D (A), urinary Ca:Cr (B) and urinary DPD:Cr (C). No 
significant correlations were found between serum 25(OH)D and urinary Ca:Cr (D) but 
there was a negative correlation with urinary DPD:Cr (E). No significant correlation was 
found between urinary Ca:Cr and urinary DPD:Cr (F). 
 
We further sought to determine if there was any relationship between 
combinations of vitamin D, plasma calcium and urinary calcium or DPD status 
and PE or SGA (Table 6.3). The medium and higher categories were combined 
for serum 25(OH)D, plasma calcium and urinary calcium or DPD. There was a 
55% increased risk for SGA in women with higher standardised 25(OH)D and 
lower urinary calcium excretion when compared to women who had higher 
standardised 25(OH)D and higher urinary calcium excretion (aRR: 1.55; 95% CI: 
1.07, 2.24). Similarly, women who had both lower urinary calcium and urinary 
DPD excretion had a more than 2-fold increased risk for SGA compared to those 
who had higher urinary calcium and DPD excretion (aRR: 2.05; 95% CI: 1.31, 
3.20). There was no association between any of the combinations of vitamin D or 




























TABLE 6.4. Adjusted relative risks (aRR) of preeclampsia (PE), small-for-gestational age (SGA) infant and indictors of uteroplacental 
dysfunction with maternal vitamin D and calcium status categorised based on population tertiles at 15±1 weeks’ gestation 
 
All women 
(n = 1065) PE (n = 85) SGA (n = 134) 
Abnormal Uterine Artery RI  
(n = 122) 
Abnormal Umbilical Artery RI 
(n = 189) 
  n n (%) aRR* (95% CI) n (%) aRR* (95% CI) n (%) aRR* (95% CI) n (%) aRR* (95% CI) 
Standardised serum 25(OH)D** (nnmol/L)       
<41 336 29 (9) 0.96 (0.60, 1.54) 40 (12) 0.78 (0.53, 1.14) 53 (16) 0.90 (0.60, 1.35) 96 (29) 1.17 (0.86, 1.59) 
41-61 343 24 (7) 0.80 (0.48, 1.33) 38 (11) 0.78 (0.53, 1.14) 47 (14) 0.92 (0.61, 1.37) 57 (17) 1.01 (0.73, 1.39) 
>61 385 32 (8) 1.00† 56 (15) 1.00† 22 (6) 1.00† 36 (9) 1.00† 
  P for trend 0.852  0.191  0.744  0.419 
Plasma Calcium (mmol/L)         
<2.0 307 20 (7) 0.64 (0.35, 1.15) 30 (10) 0.78 (0.47, 1.30) 32 (10) 0.78 (0.51, 1.18) 50 (16) 0.84 (0.61, 1.16) 
2.0-2.1 378 25 (7) 0.79 (0.46, 1.36) 50 (13) 1.13 (0.74, 1.73) 38 (10) 0.74 (0.50, 1.10) 65 (17) 0.88 (0.65, 1.18) 
>2.1 380 40 (11) 1.00† 54 (14) 1.00† 52 (14) 1.00† 74 (19) 1.00† 
  P for trend 0.069  0.094  0.210  0.281 
Urinary Ca:Cr         
<0.46 359 32 (9) 1.18 (0.65, 2.16) 59 (16) 2.13 (1.29, 3.51) 53 (15) 1.51 (0.98, 2.32) 82 (23) 1.57 (1.11, 2.22) 
0.46-0.83 366 31 (8) 1.33 (0.74, 2.39) 38 (10) 1.38 (0.81, 2.37) 38 (10) 1.23 (0.77, 1.98) 65 (18) 1.42 (1.00, 2.04) 
>0.83 328 22 (7) 1.00† 36 (11) 1.00† 28 (8) 1.00† 42 (13) 1.00† 
  P for trend 0.387  0.033  0.055  0.010 
Urinary DPD:Cr         
<7.2 341 32 (9) 1.71 (1.00, 2.91) 54 (16) 1.39 (0.94, 2.06) 34 (10) 1.55 (1.02, 2.37) 40 (12) 0.78 (0.54, 1.11) 
7.2-10.8 358 31 (9) 1.50 (0.88, 2.55) 40 (11) 1.05 (0.69, 1.60) 40 (11) 1.32 (0.86, 2.05) 63 (18) 1.24 (0.92, 1.66) 
>10.8 354 22 (6) 1.00† 39 (11) 1.00† 45 (13) 1.00† 86 (24) 1.00† 
  P for trend 0.045  0.096  0.102  0.346 
*aRR are compared to all women who were not diagnosed with the outcome of interest and were adjusted for maternal age, maternal body mass index and smoking status at 
15±1 weeks' gestation (no versus yes), alcohol consumption at 15±1 weeks’ gestation (no vs. yes) and fruit intake at 15±1 weeks’ gestation (≥3x per month vs. <3x per month) 
**Serum 25(OH)D was standardised against month serum sample was taken 
†Reference category 





























TABLE 6.5. Adjusted relative risks (aRR) of preeclampsia (PE), small-for-gestational age (SGA) infant and PE and/or SGA as an indictor of 
uteroplacental dysfunction with combinations of maternal vitamin D and calcium status at 15±1 weeks’ gestation 
 
All women 
(n = 1065) PE (n = 85) SGA (n = 134) 
Abnormal Uterine Artery RI (n 
= 122) 
Abnormal Umbilical Artery 
RI (n = 189) 
  n n (%) aRR* (95% CI) n (%) aRR* (95% CI) n (%) aRR* (95% CI) n (%) aRR* (95% CI) 
Standardised Serum 25(OH)D** (nmol/L) and Plasma Calcium (mmol/L)     
<41 & <2.0 112 11 (10) 1.06 (0.57, 1.97) 13 (12) 0.75 (0.43, 1.30) 14 (13) 0.82 (0.45, 1.50) 27 (24) 1.21 (0.82, 1.79) 
<41 & >2.0 224 18 (8) 0.86 (0.52, 1.43) 27 (12) 0.80 (0.53, 1.20) 39 (17) 0.97 (0.63, 1.49) 69 (31) 1.00 (0.72, 1.39) 
>41 & <2.0 196 9 (5) 0.52 (0.26, 1.05) 17 (9) 0.61 (0.37, 1.01) 18 (9) 0.92 (0.58, 1.46) 23 (23) 0.71 (0.47, 1.06) 
>41 & >2.0 533 47 (9) 1.00† 77 (14) 1.00† 51 (10) 1.00† 70 (13) 1.00† 
Standardised Serum 25(OH)D** (nmol/L) and Urinary Ca:Cr      
<41 & <0.46 121 12 (10) 1.21 (0.66, 2.20) 17 (14) 1.19 (0.71, 2.01) 17 (14) 0.97 (0.51, 1.83) 44 (36) 1.43 (0.96, 2.13) 
<41 & >0.46 214 17 (8) 0.90 (0.52, 1.56) 23 (11) 0.96 (0.60, 1.54) 36 (17) 1.41 (0.89, 2.25) 52 (24) 1.21 (0.84, 1.73) 
>41 & <0.46 238 20 (8) 0.93 (0.54, 1.58) 42 (18) 1.55 (1.07, 2.24) 36 (15) 1.79 (1.19, 2.68) 38 (16) 1.34 (0.97, 1.85) 
>41 & >0.46 479 36 (8) 1.00† 51 (11) 1.00† 30 (6) 1.00† 55 (11) 1.00† 
Plasma Calcium (mmol/L) and Urinary Ca:Cr       
<2.0 & <0.46 109 7 (6) 0.65 (0.26, 1.63) 12 (11) 1.46 (0.84, 2.54) 16 (15) 1.28 (0.76, 2.17) 25 (23) 1.24 (0.83, 1.84) 
<2.0 & >0.46 194 13 (7) 0.78 (0.40, 1.50) 41 (21) 0.53 (0.27, 1.07) 15 (8) 0.78 (0.45, 1.35) 25 (13) 0.80 (0.53, 1.20) 
>2.0 & <0.46 250 25 (10) 1.07 (0.62, 1.86) 45 (18) 1.58 (1.04, 2.38) 37 (15) 1.26 (0.85, 1.86) 57 (23) 1.21 (0.89, 1.64) 
>2.0 & >0.46 500 40 (8) 1.00† 18 (4) 1.00† 51 (10) 1.00† 82 (16) 1.00† 
Urinary DPD:Cr and Urinary Ca:Cr        
<0.46 & <7.2 95 11 (12) 1.36 (0.70, 2.63) 23 (24) 2.05 (1.31, 3.20) 16 (17) 1.90 (1.20, 3.02) 15 (16) 0.80 (0.49, 1.29) 
<0.46 & >7.2 181 18 (10) 1.49 (0.88, 2.53) 21 (12) 1.25 (0.80, 1.94) 18 (10) 1.16 (0.73, 1.86) 25 (14) 0.80 (0.53, 1.18) 
>0.46 & <7.2 292 22 (8) 1.15 (0.68, 1.96) 39 (13) 1.35 (0.90, 2.03) 37 (13) 1.20 (0.77, 1.85) 67 (23) 1.39 (1.04, 1.87) 
>0.46 & >7.2 485 34 (7) 1.00† 50 (10) 1.00† 48 (10) 1.00† 82 (17) 1.00† 
*aRR are compared to all women who were not diagnosed with the outcome of interest and were adjusted for maternal age, maternal body mass index and smoking status at 
15±1 weeks' gestation (no versus yes), alcohol consumption at 15±1 weeks’ gestation (no vs. yes) and fruit intake at 15±1 weeks’ gestation (≥3x per month vs. <3x per month) 
**Serum 25(OH)D was standardised against month serum sample was taken 
†Reference category 
 












6.3.4 Uteroplacental Dysfunction 
The strongest association was observed between maternal calcium status and 
SGA and indicated the greatest effect on fetal growth. Thus, we tested the 
association between maternal vitamin D and calcium status on mid-gestation 
abnormal uterine and umbilical artery RI as indicators of potential uteroplacental 
dysfunction. Whilst there was no association between serum 25(OH)D, plasma 
calcium, urinary Ca:Cr with abnormal uterine artery RI at 19-21 weeks’ gestation, 
women in the 1st tertile (<7.2) urinary DPD:Cr, were at an increased risk of having 
an abnormal RI when compared to those in the 3rd tertile (>10.8)(Table 6.2: aRR: 
1.55; 95% CI: 1.02, 2.37). Furthermore, decreasing urinary calcium excretion at 
15±1 weeks’ gestation was associated with increased risk of an abnormal 
umbilical artery RI (Table 6.2, Lower: aRR: 1.57; 95% CI: 1.11, 2.22 and Medium: 
1.42; 95% CI: 1.00, 2.04). 
For combinations of vitamin D and calcium levels, similar to the results 
found with SGA, there was a 1.79-fold increased risk of having an abnormal 
uterine artery RI in women with both higher serum 25(OH)D and lower calcium 
excretion when compared to those with higher levels of both  (Table 6.3, aRR: 
1.79; 95% CI: 1.19, ). Furthermore, women with lower urinary DPD and calcium 
were also at an increased risk of having an abnormal uterine artery RI at 19-21 
weeks’ gestation (Table 6.3, aRR: 1.90; 95% CI: 1.20, 3.02). On the other hand, 
women with higher urinary DPD excretion, indicating more bone reabsorption, 
and lower calcium excretion were at an increased risk of having an abnormal 
umbilical artery RI when compared to women with higher urinary excretion of 
both (Table 6.3, aRR 1.39; 95% CI: 1.04, 1.87). 
Finally, we further classified women based on whether there was evidence 
of placental dysfunction based on Doppler ultrasound who also went on to 
develop a pregnancy complication given that not all women who had an 
abnormal uterine or umbilical artery RI in mid-pregnancy developed PE or SGA 
(Table 6.4 and Table 6.5). A 3- to 4-fold increased risk of having an abnormal 












uterine artery RI and having PE and/or SGA in women was found with 
decreasing urinary DPD (Lower: aRR: 4.30; 95% CI: 1.55, 11.92 and Medium: aRR: 
3.20; 95% CI: 1.13, 9.02). There was also an increased risk of having both an 
abnormal uterine artery RI and having PE and/or SGA with lower and medium 
urinary calcium excretion (Lower: aRR: 1.57; 95% CI: 1.11, 2.22 and Medium: aRR: 
1.42; 95% CI: 1.00, 2.04). Women with plasma calcium levels in the 2nd tertile (2-
2.1 mmol/L) were protected against having both an abnormal uterine artery RI 
and developing PE and/or SGA (aRR: 0.32; 95% CI: 0.13-0.76). 
6.4 Discussion 
To our knowledge, this is one of the first studies to assess the relationship 
between maternal calcium and vitamin D status and PE, SGA, and measures of 
placental function in mid-gestation that provide an indication of impaired 
uteroplacental blood flow. We have demonstrated, in this large prospective 
study, a protective association between higher urinary calcium excretion and 
outcomes associated with abnormal fetal growth and placental dysfunction. 
Urinary calcium excretion can be used as a representation of maternal calcium 
intake [44, 45] and provides further evidence for the importance of calcium and 
vitamin D in pregnancy that may have implications for placental development 
and function. 
Incomplete trophoblast invasion into the maternal uterine spiral arteries 
has been described in pregnancies complicated by fetal growth restriction, as well 
as PE [11]. However, not all women who develop PE or deliver a SGA infant 
demonstrate this defect. Doppler ultrasound of the uterine arteries provides a 
surrogate of trophoblast invasion whereby a high RI indicates reduced perfusion 




























TABLE 6.4. Adjusted relative risks (aRR) of preeclampsia (PE) and/or small-for-gestational age (SGA) infant with and without an abnormal 
UTERINE artery RI with maternal vitamin D and calcium status categorised based on population tertiles at 15±1 weeks’ gestation 
 
No PE, SGA or abnormal 
uterine artery RI (n = 768) 
No PE, SGA but an abnormal 
uterine artery RI (n = 83) 
PE and/or SGA, no abnormal 
uterine artery RI (n = 155) 
PE and/or SGA and abnormal 
uterine artery RI (n = 39) 
 n (%) n (%) aRR* (95% CI) n (%) aRR* (95% CI) n (%) aRR* (95% CI) 
Standardised serum 25(OH)D** (nmol/L)    
<41 244 (73) 24 (7) 0.80 (0.46-1.40) 49 (15) 0.81 (0.54-1.24) 13 (4) 0.96 (0.43-2.10) 
41-61 253 (74) 26 (8) 0.83 (0.48-1.43) 44 (13) 0.75 (0.49-1.15) 12 (3) 0.93 (0.42-2.06) 
>61 270 (70) 33 (9) 1.00† 62 (16) 1.00† 14 (4) 1.00† 
Plasma Calcium (mmol/L)   
<2.0 238 (78) 22 (7) 0.85 (0.47-1.52) 34 (11) 0.63 (0.40-1.00) 10 (3) 0.49 (0.23-1.08) 
2.0-2.1 273 (72) 31 (8) 0.99 (0.58-1.70) 61 (16) 1.01 (0.68-1.52) 7 (2) 0.32 (0.13-0.76) 
>2.1 257 (68) 30 (8) 1.00† 60 (16) 1.00† 22 (6) 1.00† 
Urinary Ca:Cr   
<0.46 252 (70) 41 (11) 1.82 (1.04-3.19) 75 (21) 1.60 (1.05-2.42) 12 (3) 1.57 (1.11, 2.22) 
0.46-0.83 266 (73) 18 (5) 0.74 (0.38-1.43) 35 (10) 0.75 (0.46-1.21) 20 (5) 1.42 (1.00, 2.04) 
>0.83 242 (74) 21 (6) 1.00† 44 (13) 1.00† 7 (2) 1.00† 
Urinary DPD:Cr   
<7.2 233 (68) 26 (8) 1.27 (0.71-2.26) 54 (16) 1.28 (0.83-1.97) 19 (6) 4.30 (1.55-11.92) 
7.2-10.8 265 (74) 26 (7) 1.07 (0.60-1.89) 49 (14) 1.02 (0.66-1.58) 15 (4) 3.20 (1.13-9.02) 
>10.8 262 (74) 28 (8) 1.00† 51 (14) 1.00† 5 (1) 1.00† 
*aRR are compared to women who were not diagnosed with PE or SGA and did not have an abnormal uterine artery resistance index (RI) and were 
adjusted for maternal age, maternal body mass index and smoking status at 15±1 weeks' gestation (no versus yes), alcohol consumption at 15±1 weeks’ 
gestation (no vs. yes) and fruit intake at 15±1 weeks’ gestation (≥3x per month vs. <3x per month) 
**Serum 25(OH)D was standardised against month serum sample was taken 
†Reference category 





























TABLE 5. Adjusted relative risks (aRR) of preeclampsia (PE) and/or small-for-gestational age (SGA) infant with and without an abnormal 
UMBILICAL artery RI with maternal vitamin D and calcium status categorised based on population tertiles at 15±1 weeks’ gestation 
 
No PE, SGA or abnormal 
umbilical artery RI (n = 713) 
No PE, SGA but an abnormal 
umbilical artery RI (n = 136) 
PE and/or SGA, no abnormal 
umbilical artery RI (n = 141) 
PE and/or SGA and abnormal 
umbilical artery RI (n = 53) 
 n (%) n (%) aRR* (95% CI) n (%) aRR* (95% CI) n (%) aRR* (95% CI) 
Standardised serum 25(OH)D** (nmol/L)    
<41 222 (66) 46 (14) 1.14 (0.73-1.79) 42 (13) 0.78 (0.50-1.21) 20 (6) 1.17 (0.60-2.28) 
41-61 235 (69) 44 (13) 1.03 (0.65-1.62) 42 (12) 0.78 (0.50-1.22) 14 (4) 0.82 (0.40-1.69) 
>61 255 (66) 46 (12) 1.00† 57 (15) 1.00† 14 (4) 1.00† 
Plasma Calcium (mmol/L)   
<2.0 228 (74) 32 (10) 0.67 (0.41-1.08) 26 (8) 0.47 (0.29-0.78) 18 (6) 0.83 (0.43-1.59) 
2.0-2.1 250 (66) 53 (14) 0.99 (0.64-1.52) 56 (15) 0.95 (0.63-1.44) 12 (3) 0.51 (0.25-1.06) 
>2.1 235 (62) 51 (13) 1.00† 59 (16) 1.00† 23 (6) 1.00† 
Urinary Ca:Cr   
<0.46 241 (67) 52 (14) 1.46 (0.91-2.35) 57 (16) 1.26 (0.81-1.96) 30 (8) 3.12 (1.44-6.77) 
0.46-0.83 231 (63) 51 (14) 1.49 (0.92-2.41) 41 (11) 1.01 (0.63-1.62) 14 (4) 1.63 (0.69-3.89) 
>0.83 230 (70) 33 (10) 1.00† 42 (13) 1.00† 9 (3) 1.00† 
Urinary DPD:Cr   
<7.2 232 (68) 27 (8) 0.62 (0.37-1.04) 54 (16) 1.44 (0.91-2.27) 19 (6) 1.36 (0.65-2.84) 
7.2-10.8 232 (65) 58 (16) 1.29 (0.84-1.97) 44 (12) 1.16 (0.72-1.85) 20 (6) 1.58 (0.77-3.25) 
>10.8 238 (67) 51 (14) 1.00† 44 (12) 1.00† 20 (6) 1.00† 
*aRR are compared to women who were not diagnosed with PE or SGA and did not have an abnormal umbilical artery resistance index (RI) and were 
adjusted for maternal age, maternal body mass index and smoking status at 15±1 weeks' gestation (no versus yes), alcohol consumption at 15±1 weeks’ 
gestation (no vs. yes) and fruit intake at 15±1 weeks’ gestation (≥3x per month vs. <3x per month) 
**Serum 25(OH)D was standardised against month serum sample was taken 
†Reference category 
Ca:Cr = calcium-creatinine ratio; DPD:Cr = deoxypyridinoline-creatinine ratio 
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Our finding that reduced urinary calcium excretion is associated with increased 
risk of having an abnormal uterine artery RI and pregnancy complicated by PE 
and/or SGA indicates a strong association between maternal calcium status, early 
placental development and fetal growth. The relationship between urinary 
calcium excretion, calcium intake and intestinal calcium absorption is complex 
and not fully understood but higher calcium intakes do result in higher calcium 
excretion [44, 45]. Adequate calcium intake during pregnancy is essential to 
support fetal growth, particularly bone growth and development. In cases where 
maternal calcium intakes are low or insufficient, this may result in increased 
maternal bone resorption in order to mobilise calcium for the fetus [7]. Indeed, 
the risk for having an abnormal uterine artery RI and pregnancy complicated by 
PE and/or SGA was highest in the women with lower urinary DPD. This may 
indicate problems whereby the mother does not supply an adequate amount of 
calcium to support fetal growth and placental development and is worthy of 
further investigation. 
In pregnancies in which fetal growth restriction has occurred, the 
placentas may lack the functional or structural capabilities to support optimal 
fetal growth [46]. The fetal chorionic villi are composed of several different cell 
types of which, the syncytiotrophoblasts, the cells which line the intervillous 
space and cover the fetal villi, are extremely important in coordinating the 
exchange of oxygen, nutrients and wastes between maternal and fetal 
circulations [47]. Indeed, particular dysfunction of syncytiotrophoblast cells is 
thought to underlie the pathophysiology of PE and contribute to fetal growth 
restriction [48]. Once again, lower urinary calcium excretion was associated with 
increasing the risk of having an abnormal umbilical artery RI and pregnancy 
complicated by PE and/or SGA and highlights the importance of calcium to the 
development of the feto-placental circulation. Calcium is a universal intracellular 
second messenger involved in many cellular processes [49] and likely to be 
extremely important in maintaining syncytiotrophoblast function. Furthermore, 
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a protective effect of having lower plasma calcium was observed in women who 
developed PE and/or SGA but no abnormal uterine or umbilical RI at 19-21 
weeks’ gestation. One explanation for this may be that more calcium is being 
utilised where required in cells and tissues such as the placenta, lowering levels 
in the circulation to allow proper establishment of the uteroplacental circulation. 
Hypocalciuria has been previously associated with PE and was thought to 
result from decreased dietary calcium intakes, decreased absorption of calcium 
in the digestive system, increased fetal and/or placental calcium demands or 
renal dysfunction [50-52]. Indeed, it has been proposed that the early pregnancy 
urinary Ca:Cr ratio may be a predictor of the development of PE [30] as reduced 
calcium excretion has been shown to be a characteristic of the disease. In the 
current study however, we did not find any association between the urinary 
Ca:Cr ratio nor vitamin D status at 15±1 weeks’ gestation and PE. This may reflect 
the fact that surveys of pregnant Australian women indicate that the majority 
meet the recommended daily intakes of calcium [53, 54]. Although dietary intake 
of calcium was not measured directly in this population, circulating plasma 
levels of total calcium fell between the reference range of 2.05-2.25 mmol/L for 
women in the second trimester of pregnancy [43] indicating that the women 
included in the present study were not calcium deficient. Furthermore, calcium 
supplementation has been shown to reduce the risk of PE and is more effective 
in women with low dietary calcium intakes [28, 55, 56]. 
 As previously mentioned, the literature suggesting associations between 
maternal vitamin D deficiency and pregnancy complications is equivocal [20, 21]. 
In this study, maternal vitamin D status was not associated with PE, SGA or 
uteroplacental dysfunction. However, significant relationships were found when 
combined with maternal calcium status. Women with both lower vitamin D and 
lower urinary calcium excretion at 15±1 weeks’ gestation were at increased risk 
of having an abnormal umbilical artery RI at 19-21 weeks’ gestation compared to 
those who had higher levels of both. This is consistent with mechanistic 
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understanding of vitamin D metabolism in pregnancy as higher levels of vitamin 
D are required to increase intestinal calcium absorption and renal reabsorption 
to meet fetal and placental calcium demands [3]. However, having both higher 
serum 25(OH)D and lower urinary calcium was associated with increasing the 
risk of delivering an SGA infant or having an abnormal uterine artery RI at 19-21 
weeks’ gestation. This suggests that, at least within this population, calcium 
status is likely a more important determinant of appropriate placental 
development and fetal growth. 
The current study is strengthened by the use of a well-characterised cohort 
of pregnant women. However, there are a number of limitations which need to 
be considered when interpreting the data. Plasma calcium for example, is subject 
to a number of inter- and intra-patient variability [57] that cannot be controlled 
for in a real-world study design. This study assumes calcium intake was 
adequate in this population of women as this information is not available. 
However, evidence from other surveys in pregnant Australian women show 
adequate calcium consumption [53, 54]. Therefore, it is highly likely that the 
majority of the studied population were meeting their recommended daily 
intakes of calcium.  Furthermore, urinary calcium excretion was measured. This 
best reflects chronic calcium status and thus incorporates dietary calcium intake 
over time, offering a surrogate from limited dietary data and supports the 
findings between plasma calcium and pregnancy outcome.  Finally, given how 
tightly regulated plasma calcium is, and the difference of just 0.1 mmol/L calcium 
between the lower, medium and higher calcium groups, renders the biological 
importance of the findings on plasma calcium in the present study uncertain. As 
this is an observational study, the mechanisms by which disrupted calcium 
homeostasis may contribute to uteroplacental dysfunction cannot be determined. 
However, the associations in this study would suggest a strong effect of calcium 
in mediating appropriate placental development worth further research. 
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 In conclusion, the current study shows altered calcium homeostasis in 
early pregnancy is associated with increased risk of uteroplacental dysfunction 
with consequences for fetal growth. Continued research is required to determine 
whether these associations are causal but highlights the importance of adequate 
calcium intakes in pregnancy and the potential use of urinary and plasma 
calcium measurements in early pregnancy to assist stratifying women at risk for 
a placental dysfunction. Furthermore, calcium status may explain the disparate 
published findings on the association of vitamin D deficiency and pregnancy 
complications and this should be assessed in future studies. 
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human placenta cell types across 
gestation 
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ABSTRACT 
The placenta is one of the most important organs to human 
reproduction. However, very little is understood about placental 
development at a molecular level. Placental dysfunction is often 
associated with pregnancy complications including preeclampsia (PE) 
as well as with maternal micronutrient deficiencies. Whilst the exactly 
how micronutrient deficiencies cause placental dysfunction remain 
unclear, disruption of epigenetic mechanisms, such as DNA 
methylation have been implicated in the mechanistic link. However, 
studying placental DNA methylation is complicated by the presence 
of multiple different cell types each of which is likely to have its own 
unique methylome. We used immunohistochemistry (IHC) and 












immunofluorescence (IF) to localise 5-methylcytosine (5-mC) and 5-
hydroxy-methylcytosine (5-hmC) in placenta tissue from first/second 
trimester and term. IHC analysis of tissue sections showed levels of 5-
mC increased across gestation. When specific trophoblast cell 
subtypes: cytotrophoblasts (CTB) and syncytiotrophoblasts (STB), 
were isolated and labelled using IF, levels of both 5-mC and 5-hmC 
were increased in term CTBs compared to first/second trimester. 
Staining intensity of 5-hmC was also increased in first trimester STBs 
compared to CTBs. Finally, comparison of IHC staining in term tissue 
from PE and uncomplicated pregnancies revealed levels of 5-mC to be 
higher in placentas from PE pregnancies. Our analysis confirmed that 
5-mC and 5-hmC staining intensity increased across gestation and was 
different between CTB and STB and provides a solid foundation for 
future research focused on single cell populations. Very little is known 
about the role of 5-hmC in placental development but our data suggest 
it is not merely an intermediate step during demethylation but also a 
marker of cellular identity likely to influence gene expression and 
placental function. Finally, differences in DNA methylation profiles 
between different cell types of the placenta may be indicative of 
different functions and requires further study in order to elucidate 
what changes accompany placental pathologies as well as how 
perturbed micronutrient status affects DNA methylation profiles. 
7.1 Introduction 
The placenta is arguably the most important organ for human reproduction. It is 
shared by both mother and fetus, conducts oxygen, nutrient and waste transfer 
to the growing fetus and is responsible for the secretion of a variety of hormones 
and steroids imperative to correct maternal adaptation to pregnancy [1]. Thus, it 
is unsurprising that defective placentation and consequently placental 












dysfunction underlies many of the major obstetric diseases including 
preeclampsia (PE) and fetal growth restriction (FGR) [2]. However, whilst a 
significant amount is understood about the down-stream effects of placental 
dysfunction, the cause of inadequate placental development and function are 
poorly understood. 
Placental development is highly organised and results in numerous cell 
types with specialised functions. The most important cell types of the placenta 
are the trophoblasts which derive from the trophectoderm [3]. Trophoblast 
differentiation can follow one of two pathways: the villous pathway to form 
cytotrophoblasts (CTBs) and syncytiotrophoblasts (STBs) or CTB cell column 
pathway to form extravillous CTBs [4]. In terms of mediating oxygen, nutrient 
and waste exchange between maternal and fetal circulation, the CTBs and STBs 
are imperative to this process. STBs form a continuous epithelial layer on the 
surface of the villous tree and is maintained throughout pregnancy by constant 
fusion of the underlying CTBs [5]. Furthermore, STB stress is hypothesised to be 
a major factor associated with placental dysfunction in pregnancies complicated 
by PE [6]. Yet despite an intense amount of research in recent years, 
comprehensive analysis of key molecular processes which govern human 
trophoblast differentiation as well as how disruption to these processes may 
contribute to STB stress are poorly understood.  
Epigenetic regulation of the placental transcriptome is emerging as an 
important mediator of placental cell differentiation. Environmental factors such 
as smoking, obesity, poor nutrition and micronutrient deficiencies, which are 
associated with placental dysfunction, are also known to impact the epigenome 
[7, 8]. The most widely studied epigenetic modification in the placenta is DNA 
methylation: the addition of a methyl group to primarily the cytosine DNA base 
forming 5-methylcytosine (5mC) [9]. DNA methylation is crucial to many cellular 
processes including the regulation of gene expression and genomic imprinting. 
The genome of the placenta is hypomethylated compared to other organs [10, 11]. 












However, how or why this is the case is unclear. To add complexity, data is 
emerging on the oxidised derivative of 5-mC, 5-hydroxymethylcytosine (5-hmC) 
[12], and the roles this modification plays in the regulation of cellular processes. 
Indeed, there is increasing evidence to suggest 5-hmC is not merely a passive 
intermediate in the DNA demethylation process but contributes its own 
epigenetic functions [13]. 
Recently, we reported that DNA methylation in the placenta could 
accurately predict gestational age and was accelerated in placentas from 
pregnancies complicated by early onset PE [14]. However, studying DNA 
methylation in the placenta is complicated by the presence of numerous different 
cell types which carry their own unique methylomes [9]. Furthermore, before a 
detailed understanding of what changes occur to the epigenome of the placenta 
in pregnancy complications, we first need to develop a greater understanding of 
how the placental transcriptome is epigenetically regulated in normal placental 
development. In this study, we sought to use visualisation techniques, 
immunohistochemistry (IHC) and immunofluorescence (IF), to characterise the 
localisation of 5-mC and 5-hmC in placenta tissue across gestation, as well as in 
tissues from pregnancies complicated by PE. Furthermore, we aimed to 
determine whether localisation of both markers differed between isolated CTB 
and STB cells with the hypothesis that the different trophoblast populations 
would display different staining intensities based on previous published 
literature [15]. Our analysis confirmed that 5-mC and 5-hmC staining intensity 
increased across gestation and is different between CTB and STB cells. Moreover, 
the staining intensity of 5-mC appeared to be greater in placenta tissue from 
pregnancies complicated by PE and reinforces the need to use more sensitive 
methodologies on extracts from individual cell populations rather than whole 
tissue.












7.2 Materials and Methods 
7.2.1 Tissue samples 
First and second trimester placenta tissue was obtained with written informed consent 
from the Adelaide Pregnancy Advisory Centre (PAC) with ethics approved by the 
University of Adelaide Human Ethics committee (ethics number: 
HREC/16/TQEH/33). Term placental tissue was collected from women recruited as 
part of the Screening Tests to Predict Poor Outcomes of Pregnancy (STOP) study. The 
study was also approved by the University of Adelaide Human Ethics committee 
(ethics number: HREC/14/WCHN/90) and all women provided written informed 
consent. 
 
7.2.2 Immunofluorescent labelling of 5-mC, 5-hmC, PEG-10 and 
PSG-1 in placenta tissue 
Paraffin-embedded paraformaldehyde (first and second trimester) or formalin (term) 
fixed sections, cut at 3 µm thickness, were used for double-label IF or IHC. Tissue 
sections were dewaxed and rehydrated according to standard protocols. Antigen 
retrieval was performed using boiling citrate buffer (10 mM, pH 6.0) for 15 minutes, 
followed by a hydrochloric acid digestion (1.5 M) step for 30 minutes at room 
temperature. Sections were then blocked in 10% goat serum with 0.3% Triton-X in PBS 
for 30 minutes to reduce non-specific binding. Antibodies were diluted in 10% bovine 
serum albumin (BSA) in PBS with 0.3% Triton-X as outlined in Table 7.1 and applied 
to the sections in a humidified environment overnight at 4°C. For IF, antigens were 
visualised by applying fluorophore-conjugated anti-mouse (5-mC and PSG-1) or anti-
rabbit (5-hmC and PEG-10) secondary antibodies (Table 1) for 3 hours at room 
temperature. Nuclei were counterstained using 4',6-diamidino-2-phenylindole 
(DAPI). For IHC, biotin conjugated anti-mouse or anti-rabbit secondaries (Table 1) 
were applied for 1 hour at room temperature followed by another hour incubation 
with streptavidin horseradish peroxidase (strep-HRP; Dako). Sections were washed 












and staining visualised using 3,3′-diaminobenzidine (DAB; Sigma). Nuclei were 
counter-stained with haematoxylin. 
 
TABLE 7.1. Antibodies and dilutions used for immunohistochemistry and 
immunofluorescence 
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7.2.3 Isolation of first and second trimester cytotrophoblast and 
syncytiotrophoblast cells 
First trimester cytotrophoblast and syncytiotrophoblast cells were isolated from tissue 
following a modified protocol outlined in [30]. Initially, villous tissue was washed in 
PBS in order to remove maternal blood before being incubated for 10 minutes at 37°C 
with 10 mL 0.25% trypsin (Life Technologies) with 200 µg/mL DNAse (Roche) in PBS per 
gram of tissue. The supernatant, containing largely syncytiotrophoblasts and 
extravillous cytotrophoblasts, was collected and the villous tissue washed eight times 
with 20 mL PBS. Each wash, together with the initial digest supernatant, was passed 
through a 100 µM filter into a 50 mL tube containing 5 mL fetal calf serum (FCS; Sigma) 
to remove debris before being passed through a 70 µM filter to remove smaller 












contaminating cells. The filtrate was discarded and the syncytiotrophoblast cells 
remaining on the filter collected for immunofluorescent labelling.  
Continuing with the cytotrophoblast isolations, the villous tissue was digested 
for a second time in 10 mL 0.25% trypsin with 200 µg/mL DNAse in PBS per gram of 
tissue on gentle agitation for 7 minutes at 4°C before being left stationary at 4°C 
overnight. The following morning, villi were washed ten times in PBS with the 
supernatant collected into 50 mL tubes containing 5 mL FCS and centrifuged at 450 g-
1 for 8 minutes. Supernatant was aspirated, cell pellets combined into 15 mL per gram 
of tissue DMEM media (Life Technologies) containing 10% FCS and 1% Antibiotic-
Antimycotic (Life Technologies) and then incubated for 10 minutes at 37°C in 5% CO2 
on a 10 cm petri dish to allow contaminating fibroblasts to adhere to the plastic 
surface. The cell suspension was then collected and the petri dishes washed twice with 
5 mL DMEM media in order to maximise recovery of cytotrophoblasts which were 
then used for immunofluorescent staining.  
 For isolation of cytotrophoblasts and syncytiotrophoblasts from second 
trimester tissues, the protocol follows that for isolation of first trimester with slight 
modifications on day two of the procedure. Following the second, overnight digest, 
villous tissue was washed ten times in PBS and the supernatant collected into 50 mL 
tubes containing 5 mL FCS. Tubes were centrifuged at 450 g-1 for 8 minutes and the 
cells resuspended in 6 mL of 1x Ca/Mg-free Hank’s buffered saline solution (HBSS) to 
yield approximately 8 mL of cell suspension. The cell suspension was gently layered 
onto two 50 mL falcon tubes containing a 70-5% Percoll® gradient (Sigma) and 
centrifuged for 20 minutes at 1200 g-1 without brake. Following centrifugation, the 
cytotrophoblasts, situated within the layer ranging from 27-12 mL was collected into 
a clean falcon tube, diluted with DMEM media and centrifuged at 1000 g-1 for 10 
minutes. The supernatant was aspirated, cells resuspended in 1x HBSS for cell counts 
and then centrifuged for another 5 minutes at 1000 g-1. Following this, the cells were 
resuspended in DMEM media to a concentration of 107 cells/mL and transferred to 1.5 
mL microcentrifuge tubes for negative selection and the removal of contaminating 












lymphocytes and fibroblasts. As per Dynabead® protocol (Life Technologies), mouse 
anti-human CD9 antibody (RnD Systems) was added to each microcentrifuge tube at 
a concentration of 1 µg/106 cells and incubated on a rotator for 10 minutes at 4°C. 
Following incubation, anti-mouse Dynabeads® were washed as suspended as per 
manufacturer’s protocol, added to the cells and incubated for a further 30 minutes on 
a rotator at 4°C to allow binding. After the incubation, microcentrifuge tubes were 
placed onto a magnetic separator and the supernatant containing the isolated 
cytotrophoblast cells collected to be used for immunofluorescent staining. 
 
7.2.4 Isolations of term cytotrophoblast cells 
Cytotrophoblasts and syncytiotrophoblasts were isolated from term placenta tissue 
following the protocol outlined in [31]. Placenta tissue was collected from elective 
caesarean sections, washed in PBS and heavily dissected to dissociate placenta villi 
fragments from vessels and connective tissue. Approximately 50 g of tissue was then 
digested three times for 20 mins in 150 mL of enzyme digestion buffer containing 
0.25% trypsin and 1% DNAse at 37°C in a shaking water bath. Between each digest, 
supernatant was collected into 50 mL tubes containing 5 mL FCS and cell pellets 
centrifuged at 1000 g-1 for 15 minutes. Cell pellets from all three digests were then 
combined in 1x HBSS solution and the remaining isolation protocol followed that 
outlined for second trimester placenta cytotrophoblast isolations. 
 
7.2.5 Immunofluorescent labelling of 5-mC, 5-hmC, PEG-10 and 
PSG-1 in isolated placenta cells 
Isolated cytotrophoblast and syncytiotrophoblast cells were spun onto slides using 
cytocentrifugation (6-8x105 cells/dot, 1000 g-1, 5 minutes; CytospinTM, Thermo Fisher 
Scientific). Cells were then fixed with 1:1 acetone-methanol for 10 minutes on ice and 
immunostaining proceeded as previously described. 
 
7.2.6 Microscopic analysis and image quantification 












IHC staining of 5-mC and 5-hmC in tissue sections were visualised using the 
Nanozoomer 2.0-HT C9600-13 (Hamamatsu). Random systematic sampling of the 
tissue was used to select 10 representative fields of each section at 40x magnification 
using the NDP View2 software (Hamamatsu). DAB staining intensity was then 
quantified using the VIA software (Leading Edge Software). Double-label IF was 
visualised using the Nikon A1+ Confocal microscope system and images created using 
the NIS-Element Advanced Research microscope imaging software (Nikon). Analysis 
of 5-mC and 5-hmC in isolated cells was visualised using the Nikon Eclipse Ni-U 
microscope and fluorescent intensity measured using ImageJ Version 1.48 software 
(National Institutes of Health) [32]. 
 
7.2.7 Statistics 
All statistical analysis was performed in R (v3.1.1) [33]. Analysis of Variance 
(ANOVA) with a Tukey post-hoc comparison or Mann-Whitney test was used to 
calculate exact P-values and results are reported as median and interquartile range. 
Statistical significance was deemed at P <0.05. 
7.3 Results 
7.3.1 Identification and isolation of CTB and STB cells 
Double-labelled IF was used to identify CTB and STB cells in tissue sections using 
antibodies against two proteins: Paternally-expressed gene 10 (PEG-10) and 
Pregnancy specific beta-1-glycoprotein 1 (PSG-1). These proteins are expressed by 
CTBs (PEG-10) [16] and STBs (PSG-1) [17], and allowed the two cell types to be clearly 
distinguished (Fig. 7.1A) and confirmed the purity of >95% CTBs with the occasional 
clump of contaminating STB in trophoblast isolations (Fig. 7.1B). Furthermore, 
double-labelled IF revealed punctate staining of both 5-mC and 5-hmC, confirmed co-
localisation of both marker (Fig. 7.2A) and allowed assessment of 5-mC and 5-hmC 
between different cell types in tissue sections staining with PEG-10 and PSG-1, 
respectively (Fig. 7.2B & 7.2C). 













FIGURE 7.1. Immunofluorescent double-labelling of Paternally-expressed gene 10 (PEG-10; 
cytotrophoblasts RED) and Pregnancy specific beta-1-glycoprotein 1 (PSG-1; 
syncytiotrophoblasts GREEN). Representative images are from an 8 weeks’ gestation tissue 
section (A) and trophoblast cell isolated from 15 weeks’ gestation tissue (B). 












7.3.2 Comparison of 5-mC and 5-hmC expression in placenta tissue 
across gestation 
DNA methylation in the placenta increases across gestation until term [10, 11]. IHC 
staining of 5-mC and 5-hmC revealed localisation within the nuclei the CTBs, STBs 
and stromal cells (Fig. 7.3). Staining intensity, quantified using Video Image Analysis 
(VIA), of 5-mC increased in placenta tissue across gestation (Fig. 7.3E, P = 0.031). 
Conversely, 5-hmC intensity did not differ between tissues from first trimester 
compared to term (Fig. 7.3F). 
 
FIGURE 7.2. Immunofluorescent double-labelling in first trimester (7 weeks’ gestation)  tissue 
sections. Panel A: Placental villous  tissue stained with 4',6-Diamidine-2'-phenylindole (DAPI; 
Blue, Nuclei), 5-methylcytosine (5-mC; Green), 5-hydroxymethylcytosine (5-hmC; Red) and 
all three images merged. Panel B: Placenta tissue section stained with Dapi (Blue, Nuclei), 
Pregnancy specific beta-1-glycoprotein 1 (PSG-1; Green, syncytiotrophoblasts), 5-hmC (Red) 
and PSG-1 and 5-hmC images merged. Panel C: First trimester placenta tissue section stained 
with DAPI (Blue, Nuclei), 5-mC (Green), Paternally-expressed gene 10 (PEG-10; Red, 
cytotrophoblasts) and 5-mC and PEG-10 images merged. 













FIGURE 7.3. Immunohistochemical labelling of 5-methylcytosine (5-mC) and 5-
hydroxymethylcytosine (5-hmC) in first trimester and term tissue sections. 
Representative images of 5-mC labelling in a first trimester section (A) and term tissue 
section (B). Representative images of 5-hmC labelling in a first trimester section (C) and 
term tissue section (D). Video image analysis (VIA) quantification of staining intensity 
revealed an increase in levels of 5-mC in tissue sections from term placenta compared to 
first/second trimester (E). There was no difference in the staining intensity of 5-hmC 
between first/second trimester and term tissue sections (F). Data are median and 
interquartile range. Significance was determined using a Mann-Whitney test. CTB: 
cytotrophoblast, FC: fetal capillary, IVS: intervillous space, SC: stromal cell, STB: 
syncytiotrophoblast.  












7.3.3 5-mC and 5-hmC expression in isolated CTB and STB cells 
CTB and STB cells were isolated from first and second trimester tissue, as well as 
term tissue, and stained for 5-mC and 5-hmC to determine whether staining 
intensity was similar in the different trophoblast subpopulations (Fig. 7.4). In the 
CTBs, mean fluorescence intensity (MFI) of 5-mC was significantly higher in cells 
isolated from term tissue when compared to first and second trimester CTBs (Fig. 
7.4E, P = 0.0021 and P = 0.0006, respectively). This was similar for 5-hmC staining 
intensity (Fig. 7.4F, P = 0.0005 and P = 0.0027, respectively). STBs were not readily 
obtained from term isolations and therefore could not be compared with STB 
cells collected in early gestation. However, in first and second trimester isolated 
cells, MFI of 5-hmC was significantly higher in STBs compared to CTBs (Fig. 
7.4H, P = 0.0011). 
 
7.3.4 Assessment of 5-mC and 5-hmC in placenta tissue from 
pregnancies complicated by PE 
DNA methylation profiles are different in placenta tissue from pregnancies 
complicated by PE compared to uncomplicated pregnancies [18-21]. Thus, we 
sought to determine whether there was a difference in 5-mC and 5-hmC staining 
between term placenta tissue collected from uncomplicated and PE pregnancies 
(Fig. 7.5). Staining intensity of 5-mC was significantly higher (Fig. 7.5A, P = 0.028) 
in placenta tissue from PE pregnancies compared to uncomplicated but 5-hmC 
staining intensity did not differ (Fig. 7.5B).  













FIGURE 7.4. Immunofluorescent labelling of 5-methylcytosine (5-mC) and 5-
hydroxymethylcytosine (5-hmC) in cytotrophoblast (CTB) and syncytiotrophoblast 
(STB) cells isolated from first (6-12 weeks’ gestation) and second trimester (13-22 weeks’ 
gestation) and term placenta tissue. Representative images of 4',6-Diamidine-2'-
phenylindole (DAPI; Blue, Nuclei) and 5-mC (Green) staining in cells from second 
trimester (15 weeks’ gestation) (A) and term (B). Representative images of DAPI (Blue) 
and 5-hmC (Red) staining in cells from first trimester (7 weeks’ gestation) (C) and term 
(D). Quantification of staining intensity using ImageJ image analysis software revealed 
an increase in levels of both 5-mC (E) and 5-hmC (F) in CTB cells isolated from term 
tissue compared to both first and second trimester. There was no difference in staining 
intensity of neither 5-mC nor 5-hmC between first and second trimester CTBs. A 
moderate increase in staining intensity of 5-mC in isolated STB cells compared to CTB 
cells collected from first/second trimester placenta (G) and a significant increase in levels 
of 5-hmC in STBs compared to CTBs (H) was found. Red dots indicate cells collected 
from first trimester placenta tissue (<13 weeks’ gestation). Data are median and 
interquartile range. Significance was determined using an ANOVA with Tukey post-hoc 
comparison (E & F) or Mann-Whitney test (G & H).




FIGURE 7.85. Video image analysis (VIA) of immunohistochemical staining of 5-
methylcytosine (5-mC) and 5-hydroxymethylcytosine (5-hmC) in term placenta sections 
from pregnancies complicated by preeclampsia (PE) and uncomplicated. Representative 
images of 5-mC staining in placenta samples from uncomplicated (A) and PE (B) 
pregnancies and 5-hmC staining in placenta in an uncomplicated (C) and PE (D) 
pregnancy. Intensity of 5-mC staining was greater in tissue sections from PE pregnancies 
compared to uncomplicated (E). However, staining intensity of 5-hmC did not differ (F). 
Data are median and interquartile range. Significance was determined using a Mann-
Whitney test. 
7.4 Discussion 
Studying DNA methylation in the placenta is complicated by the presence of 
numerous different cell types, each with their own unique and specific function 
and hence molecular and epigenetic profile. We sought to overcome this by using 
visualisation techniques to localise and quantify DNA methylation markers 5-
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mC and 5-hmC in placenta tissue and trophoblast cells across gestation. Our 
assessment revealed dynamic changes in levels of both markers across gestation, 
as well as between different trophoblast cell types at the same gestation. This 
preliminary data provides a platform for further work to elucidate how changes 
to epigenetic modifications, including how 5-mC and 5-hmC contribute to 
placental pathology and pregnancy complications.  
To our knowledge, there has only been one other study that has used IHC 
to assess 5-mC and 5-hmC localisation in human placenta tissue [15]. Fogarty et 
al. observed differences in the levels of 5-mC and 5-hmC in CTBs compared to 
STBs in tissue sections across gestation. 5-mC was more abundant in CTBs whilst 
STBs showed greater staining for 5-hmC. Indeed, in the current study, STBs 
isolated from first and second trimester tissue had a higher staining intensity of 
5-hmC compared to CTBs isolated from the same samples. However, 5-mC was 
also abundantly expressed within STB cells with a moderate increase in levels 
compared to CTBs. Differences between the two studies may be explained by 
different 5-mC antibodies, staining protocols and in this study, levels were 
measured in isolated cells not tissue sections. Furthermore, we used a more 
sensitive method of detection and quantification in IF. What both studies do 
highlight, however, is that the methylomes of the different trophoblast cell types 
are likely to vary substantially. Thus, further research into the biological 
importance of these differences is warranted. 
Of relevance to placental dysfunction is the observation that staining 
intensity of 5-mC was higher in placenta tissue sections collected from PE 
pregnancies compared to uncomplicated pregnancies. DNA methylation 
patterns, determined using sequencing arrays, have been shown to be different 
in placentas from PE pregnancies [18-20], as well as in placentas from other 
pregnancy complications [26-28] compared to uncomplicated pregnancies. 
However, evidence on whether or not these changes in DNA methylation result 
in differences in gene expression is conflicting [20, 21]. This may be explained, in 
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part, by the fact that DNA was extracted from whole tissue homogenates. The 
etiology of PE that is characterised by placental dysfunction suggests STB stress 
to be a major factor [6]. Our laboratory is currently optimising protocols to isolate 
STB cells from tissue in order to study this particular cell type more specifically.  
Future experiments including analysis of both DNA methylation profiles and 
gene expression patterns within the STB cell type and to assess changes to these 
molecular profiles under adverse conditions, for example, increased oxidative 
stress. Such research is integral to understand what governs molecular and 
cellular changes in placenta cells providing a solid foundation to elucidate what 
occurs in pathological pregnancies.  
One of the most interesting findings in this study is the increased staining 
intensity of 5-hmC in CTB cells across gestation. Oxidation of 5-mC to form 5-
hmC is mediated by the Ten-eleven translocation (Tet) enzymes and knockdown 
models of these enzymes have shown 5-hmC to be central to maintain 
developmental pathways  and early embryogenesis  [22, 23]. Furthermore, there 
is a strong association between active transcription and genomic regions with 
elevated 5-hmC levels [13], 5-hmC is known to localise to areas of DNA damage 
and promote genome stability [24] and progressive loss of 5-hmC is a hallmark 
of tumorigenesis [25]. Thus, there is accumulating evidence suggesting that 
perturbations to this DNA methylation modification may contribute significantly 
to disease phenotypes and genomic instability. From this study, the relevance of 
changes in 5-hmC levels across gestation in CTB and STB cells to trophoblast 
differentiation or function cannot be determined. Furthermore, there was no 
difference in staining intensity of 5-hmC in tissue sections from placentas from 
PE pregnancies compared to uncomplicated pregnancies. One disadvantage to 
using VIA to quantify staining intensity, is the inability to easily differentiate 
staining in different cell types. Indeed, visually, staining intensity of 5-hmC 
appeared greater in the syncytial knots of the placental tissue sections from PE 
compared to uncomplicated pregnancies. Further analysis is required to 
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determine whether there is a difference in 5-hmC staining intensity in STB cells 
of PE placentas but the results presented here provide the first steps to better 
understanding how 5-hmC contributes to placental development and placental 
dysfunction.   
One of the major advantages in using IHC and IF was the ability to 
visually assess which cell types expressed 5-mC and 5-hmC in placenta across 
gestation. In this study, we observed clear changes to the levels of both markers 
which were confirmed using quantification analyses. However, quantifying IHC 
and IF staining is inherently difficult due to a number of assumptions [29]. For 
example, quantification assumes a linear relationship between antigen-antibody 
binding; more antigen leads to more antibody binding and results in a greater 
visual signal either in the presence of darker staining or greater fluorescent 
intensity. Such assumptions cannot easily be validated and thus experiments 
using more sensitive techniques such as methylation sequencing should be 
undertaken to confirm our results here.  Never-the-less, the current study 
provides solid evidence that epigenetic profiles can differ significantly between 
different cell types within a complex tissue and reinforces the need to focus 
sequencing experiments on individual cell populations rather than whole tissue 
extracts. 
This study presents visual evidence of the dynamic localisation patterns 
of 5-mC and 5-hmC in placenta trophoblast cells across gestation. Importantly, it 
shows stark differences in the levels of these DNA methylation markers in 
different trophoblast subtypes, reinforcing the need to focus future sequencing 
experiments on individual cell populations. Furthermore, this is one of only a 
few studies to analyse 5-hmC in placenta, providing a solid rationale for further 
study on how this modification is important to placental development and 
function. Finally, key to fully understanding the importance of epigenetics in 
placental pathologies is to first determine how modifications such as DNA 
methylation influence normal placental development. Studies like the one 
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presented here pave the way to increasing knowledge of human placental 
development at a molecular level and will ultimately lead to novel therapeutic 
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The primary aims of this project were to further the understanding of how 
maternal micronutrient status during pregnancy influences placental 
development and function, as well as pregnancy outcome. Focusing on a number 
of key micronutrients: zinc, copper, vitamin D and calcium, the work presented 
in this thesis has provided novel insight into both the mechanisms behind how 
these micronutrient deficiencies influence pregnancy physiology, as well as how 
they are clinically relevant to human pregnancy. It is the first to report on how 
zinc deficiency in pregnancy affects maternal hemodynamic adaptations to 
pregnancy; one of the first to comprehensively assess both vitamin D and calcium 
status in pregnancy; and the first to use immunofluorescence to characterise and 
quantify changes in DNA methylation in placenta trophoblast cells across 
gestation. 
 
8.1 Overall Significance 
8.1.1 Zinc deficiency in pregnancy effects fetal growth and 
pregnancy physiology 
Chapter 1 and 2 present my research on the effects of zinc deficiency during 
pregnancy on pregnancy outcome and highlights the importance of adequate 
maternal zinc status on fetal growth and placental morphogenesis [1, 2]. In 
pregnant women, the systematic review of the literature indicated that being zinc 
deficient during pregnancy may be associated with increasing the risk for 
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reduced fetal birthweight and hypertensive disorders of pregnancy. Indeed, this 
was confirmed in my mouse model in which, moderate dietary zinc deficiency 
resulted in fetal growth restriction, disrupted placental morphogenesis and 
substantial alterations to the maternal blood pressure profile over pregnancy. 
Thus, this study provided a mechanistic interpretation of what is observed in 
human cohort studies. Furthermore, this study was one of the first to utilise the 
highly sensitive radio-telemetry technique in un-restrained mice during 
pregnancy to continuously measure blood pressure. Both studies illustrate the 
importance for continual education of women on appropriate nutrition and 
lifestyle choices when contemplating pregnancy. They also reinforce the need to 
develop strategies that alleviate the burden of zinc deficiency in pregnant women 
and women of reproductive age that is particularly prevalent in the developing 
world. 
 
8.1.2 Early pregnancy copper status is associated with increasing 
the risk of any pregnancy complication 
Our analysis of plasma trace elements in early pregnancy in the Adelaide SCOPE 
cohort [3] revealed a clear association between plasma copper status and adverse 
pregnancy outcome. A protective effect of lower plasma copper at the 15±1 
weeks’ gestation was observed and is in contrast with the current dogma that 
lower levels of trace elements are detrimental to human health [4]. This is an 
important finding as many pregnancy supplements contain these minerals on the 
basis of very minimal evidence to suggest the efficacy of their inclusion [5]. 
Furthermore, whilst this study cannot determine cause-effect scenarios, the data 
presented highlights possible mechanistic pathways by which higher circulating 
copper concentrations may impact placental development that has been 
previously unappreciated. These hypotheses need to be confirmed using animal 
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and in vitro models but provide focus for moving the pregnancy nutrition field 
forward. 
 
8.1.3 Evidence that both maternal vitamin D and calcium status are 
important for fetal growth and placental function 
I used the comprehensive, well-characterised SCOPE database to assess the 
effects of vitamin D status on pregnancy outcome in 2800 women across two 
distinct pregnancy populations; Adelaide and Auckland. This was the largest 
study to assess vitamin D status in pregnancy from the international SCOPE 
consortium to date. Furthermore, it offered a unique perspective on the effects of 
social demographics on vitamin D status by comparing the two different 
populations independent of different sampling and analysis techniques. A recent 
meta-analysis of 20 observational studies which included 16,515 individuals [6] 
supported the findings that the risk of GDM was lower with higher vitamin D 
levels. However, disparate published findings, of which my study contributes to, 
on the association between vitamin D deficiency and other pregnancy 
complications still remain [7,8]. This may be explained by differences in maternal 
calcium status within different populations that are studied. Indeed, my follow-
up study focused on calcium and vitamin D status in the Adelaide SCOPE 
women confirmed a clear relationship between markers of calcium status, 
placental function and fetal growth. To the best of our knowledge, this is one of 
the first detailed investigations to comprehensively assess both vitamin D and 
calcium status in pregnant women and their associations with adverse pregnancy 
outcomes. It also highlights the requirement for future endeavours to focus on 
multiple micronutrients and their interactions. This, despite increasing the 
complexity of the studies, will ultimately allow us to provide stronger nutritional 
recommendations to pregnant women. 
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8.1.4 Dynamic DNA methylation profiles are exhibited in the 
human placenta across gestation 
The final research in this thesis presents the first steps in understanding 
epigenetic regulation of placental cell development at the level of the individual 
cell type. This was in order to focus future studies on elucidating how 
perturbations in micronutrient homeostasis impacts placental function at an 
epigenetic level. Focusing DNA methylation, this study presented visual 
evidence on the dynamic localisation patterns of 5-methylcytosine (5-mC) and 5-
hydroxymethylcytosine (5-hmC) across gestation. Most importantly, it 
characterised potential difference in patterns of DNA methylation in the specific 
cytotrophoblast and syncytiotrophoblast subpopulations which is supported by 
recent single cell RNA-sequencing experiments [9, 10]. Thus, reinforces the 
requirement for future sequencing experiments to focus on single cell 
populations rather than whole tissue extracts. Finally, the study provides 
evidence to further explore potential epigenetic functions of 5-hmC in 
trophoblast differentiation. Whilst such a hypothesis would need to be confirmed 
using more sensitive methodologies, these results provide a new foundation for 
investigations into the functional significance of 5-hmC in regulating placental 
development. 
8.2 Problems Encountered and Limitations 
8.2.1 Animal models in studying the placenta 
Comprehensive analysis of the effects of zinc deficiency in pregnancy showed 
the influence of zinc on pregnancy physiology with a number of limitations. The 
radio-telemetry data suggested reduced placental perfusion may be a 
contributing factor to fetal growth restriction in this model. However, neither 
placental perfusion nor direct measures of placental function such as glucose 
uptake were measured. Whilst double-labelled immunohistochemical analysis 
C h a p t e r  8   P a g e  |  2 2 7  
 
 
was used to assess structural correlates of placental function, we can only assume 
that blood flow into the placental bed was perturbed. Although, this is highly 
likely given that fetal growth was restricted and does provide an avenue for 
future research.  
A second limitation of this study was with the use of radio-telemetry to 
continuously measure blood pressure. Whilst providing a huge amount of 
accurate, highly specific data on maternal blood pressure in an un-restrained 
animal, there were problems that occurred which reduced the number of animals 
in which useable data was obtained. Most notably, the length of time in which 
sampling occurred (45 days) meant a number of probes malfunctioned towards 
the end of the experiment. Furthermore, given the surgery occurred before the 
animals were mated, those that did not become pregnant despite multiple mating 
attempts could not be used in the study. However, a testament to the potential of 
this technology is that we were able to observe clear differences in the blood 
pressure profiles between the diet groups with a sample size of 8 highlighting 
the sensitivity and specificity of this technique. 
 
8.2.2 Circulating nutrients in human cohort studies 
Unfortunately, detailed information on dietary intakes of nutrients such as food 
frequency questionnaires were not included as part of the original SCOPE study. 
Whilst information such as frequency of fruit, green leafy vegetables and oily fish 
consumption was collected, and provided some basic understanding of dietary 
patterns within the women studied, lack of high quality dietary information 
presented a real limitation for my human cohort studies. Diet is the main source 
of zinc, copper, selenium and calcium; vitamin D can also be obtained from the 
diet, as well as through UV exposure. A more comprehensive analysis on the 
associations between maternal micronutrient status and adverse pregnancy 
outcome may have been undertaken if more detailed dietary information was 
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available. Consideration needs to be given when interpreting micronutrient 
status is circulation as trace elements, calcium and vitamin D levels are heavily 
influenced by inter- and intra-patient factors. However, given the lack of more 
suitable alternatives that assess maternal micronutrient status, and food 
frequency questionnaires have their own limitations [11], measuring 
micronutrients in circulation can still be informative in advancing our 
understanding of how different micronutrients contribute to pregnancy success. 
 
8.2.3 Immunofluorescence of DNA methylation markers 
One of the greatest benefits of using immunofluorescence and immuno-
histochemistry is the ability to visualise the location of specific proteins and other 
biomarkers within a complex tissue structure. However, to create visually 
stunning images whilst maintaining accuracy and specificity relies heavily on a 
number of factors including the primary antibody and staining protocol; both of 
which proved to be major limitations in studying 5-mC using immuno-
fluorescence. DNA denaturation using hydrochloric acid was required in order 
to allow antigen-antibody binding of the 5-mC antibody. Specific antigen 
retrieval was also necessary and results varied depending on whether heat-
mediated retrieval with citrate buffer or pronase digestion was used. Such steps 
within the protocol were particularly challenging for double-labelling with cell 
specific markers as these antigens were easily destroyed by such aggressive 
treatments. Never-the-less a functioning protocol was achieved in which 
studying DNA methylation using immunofluorescence in different cell types of 
the placenta was achieved and will be continually used in future experiments. 
8.3 Future Directions 
The importance of adequate nutrition in pregnancy has long been understood 
and unquestionable progress has been made in educating women on the 
importance of different micronutrients, such as folate and iodine, are for fetal 
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development and pregnancy success. However, despite decades of research, we 
have barely scratched the surface of all that we could possibly know. The 
research presented here continues to offer more detailed insights into how certain 
micronutrients support placental development and provides new avenues for 
future exploration. 
 The importance of considering micronutrient interactions was 
consistently explored through this thesis, however, a deeper understanding is 
still required. For example, my mouse model provided conclusive evidence that 
maternal zinc deficiency results in fetal growth restriction as a consequence of 
inappropriate placental morphogenesis. Yet zinc was conserved in the placenta 
and fetus at what appeared to be the expense of iron. This observation offers 
numerous questions about the importance of zinc-iron interactions. For example: 
what placental transport systems are affected by maternal zinc deficiency that 
causes a reduction in iron transport? And, is this transport system disrupted in 
the placentas from different species including humans? In our human cohort 
study, we did not observe an association between zinc deficiency at 15±1 weeks’ 
gestation and an increased risk of hypertensive disorders of pregnancy or SGA. 
However, we could not study in detail the influence of iron in this cohort due to 
the unavailability of more precise determinants of iron status. Future work 
focused on the interaction between zinc and iron, particularly within the 
placenta, will continue to untangle the mechanisms by which trace elements 
support fetal growth in utero. Moreover, this information may be useful in the 
development of strategies to combat micronutrient deficiencies in the developing 
world. 
Paradoxically, the placenta is one of the most important organs to human 
health yet one of the least understood at the cellular and molecular level. As 
indicated in the limitations section of this chapter, a significant proportion of time 
was utilised in optimising a functioning protocol to study DNA methylation 
using immunofluorescence. Now such a protocol is available, it is possible to 
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implement it in future study designs. Experiments assimilating knowledge 
gained on zinc, iron, copper and calcium in regulating placental development 
with epigenetic regulation of trophoblast cell function may provide information 
valuable to placenta researchers. 
Finally, current methodologies for assessing and monitoring placental 
function are limited. The key to improving reproductive success is accurate, early 
diagnosis of disease including placental dysfunction. Thus, there is an inherent 
need to develop non-invasive methods that accurately determine the health of 
the placenta and pregnancy in real-time so that intervention strategies may be 
implemented in a time appropriate manner. Indeed, we have identified a number 
of potential micronutrients measured in circulation that may be useful in 
including in screening tools for predicting pregnancy outcome. In order for this 
idea to be pursued, assessment of micronutrient status should be undertaken in 
a much larger cohort of women and include high quality dietary data. 
Furthermore, it would be useful to include a more socioeconomically and 
ethnically diverse population. However, if proven useful, the inclusion of routine 
micronutrient screening in a clinical setting may be immensely valuable to 
decision-making and implementation of appropriate interventions for pregnant 
women who may be at risk of developing a pregnancy complication. 
8.4 Conclusions 
The work presented in this thesis has explored several key micronutrients, their 
interactions and their effects on pregnancy outcome. It offers a unique 
perspective into the role of maternal micronutrient status in pregnancy and 
demonstrates the complexities and multi-faceted nature of micronutrient 
interactions in pregnancy physiology. The work provides a basis for the 
advancement of research into how maternal nutrition might influence the 
epigenome of the placenta and the consequences this has to fetal growth in utero. 
Furthermore, the human cohort studies presented may be beneficial in the 
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development of early pregnancy screening tools that will allow a more accurate 
assessment of a woman’s risk of a pregnancy complication and thus allow early 
intervention strategies to be employed if required. 
Finally, to quote Jennifer Brea (TedSummit, June 2016) – “I don’t know” is 
a beautiful thing. “I don’t know” is where discovery starts. And if we can [be willing to 
say “I don’t know”] and approach the great vastness of all that we do not know, rather 
than fear uncertainty, maybe we can greet it with a sense of wonder.” What this thesis 
does not show directly but embodies in its entirety is the willingness to not only 
say “I don’t know” but to also say “I want to know”. 
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